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ABSTRACT 
 
CROSS-CUTTING NARRATIVES OF OPIOID USE DISORDER AMONG  
PREGNANT WOMEN AND MOTHERS:  
IMPLICATIONS FOR HUMANISTIC CARE 
SEPTEMBER 2019 
ALICE FIDDIAN-GREEN, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
M.P.H., UNIVERSITY OF MASSACHUSETTS AMHERST 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Aline C. Gubrium 
 
Opioid-related fatalities in the U.S. have increased drastically. Pregnant women and 
mothers with opioid use disorders (OUD) are a rapidly growing and vulnerable 
population. Using a critical narrative approach, this dissertation examines how the 
syndemic of trauma, substance use, and mental health conditions influences opioid use 
and treatment trajectories among pregnant women and mothers across the lifecourse. The 
goal of this dissertation was to examine three discursive resources that shape the social 
construction of perinatal and maternal opioid use across all strata of social life: macro-
level (news media), meso-level (scientific), and micro-level (individual) narratives. 
Informed by 18-months of ethnographic observation, in-depth interviews, and mixed 
methods analysis of scientific research and news media coverage of perinatal and 
maternal OUD, this research brings together the voices of women in recovery, clinicians, 
social workers, policymakers, and the public. Building from what Sanders (2014) refers 
to as the “gendered double standard” faced by women with substance use disorders, in 
this dissertation I characterize the intersecting identities of female, pregnant/mother, and 
substance user as a gendered triple standard. Throughout this work I argue that being 
held to this gendered triple standard intensifies the stigma faced by pregnant women and 
mothers with OUD as they navigate the medical, legal, and social service institutions. 
Key findings from this research include: (1) a predominating focus on “fetal victimhood” 
(Knight, 2015), which overlooks the needs of pregnant women and mothers with OUD 
that run concurrent to ensuring a healthy pregnancy and birth; (2) approaches to 
addressing the opioid “crisis” that elide key at-risk populations (e.g. People of Color, 
active substance users, and polysubstance users); (3) “folk” pharmacokinetic knowledge 
and practices utilized by pregnant women and mothers that function as both facilitators 
and barriers to treatment engagement; and (4) the traumas associated with institutional 
policies and procedures specific to the management of opioid use (e.g., practices 
associated with civil commitment to treatment, loss of custody, and intergenerational 
family separation via the criminal justice and/or foster care systems). Informed by key 
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findings, this dissertation concludes with five specific recommendations for research and 
practice. 
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CHAPTER 1 
 
INTRODUCTION  
 
A Starting Point 
 
Thanksgiving 2015 
I spent most of the drive frustrated that I had waited until the Wednesday before 
Thanksgiving to make the trek to New Jersey. The traffic was nearly stand still, and what 
should have been a four hour drive took close to seven. In the first few years after Sean 
died we would spend at least one of the major family holidays at his parents’ house. It felt 
important to me for Ev to be surrounded by the pictures and memories. Watching how 
happy he and his grandmother always were to spend time together— baking cookies, 
visiting the deer at the park, cuddling on the couch— was confirmation. Being there 
during those early years felt comforting. I suppose it was knowing that everyone was 
connected by a shared loss, even though it affected us each so differently.  
It had been barely two years before that Thanksgiving that I had finally explained 
to Ev that his dad had died from a heroin overdose at the age of 27 in 2004, at what was 
retrospectively the beginning of what is now referred to as the “opioid crisis.” In all 
those years I kept waiting for Ev to ask for some explanation of how or why his dad died, 
but he never did. It began to feel like he never would. The culture of openness around 
opioid-related deaths that has become at times numbingly ever present these days, did 
not exist at that time. I remember finally deciding to tell Ev when we were driving 
somewhere. I had read in some parenting book that facing the same direction and not 
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holding eye contact was the best way to talk about emotional topics. I don’t know if any 
of that mattered. All I remember was the long silence after I told him, and the only word 
he responded with:“why?”  
 
1999 
The first time I went to New Jersey to meet Sean’s parents, he showed me a 
framed picture of them from the 1970s. Nancy is wearing a long black leather jacket, and 
has a red bandana tied under her chin. Paul has a huge smile. He’s wearing a navy 
sailor’s coat, holding a carton of Marlboro Reds under one arm with a lit cigarette in his 
mouth, his other arm around Nancy. When I met Paul, he still that had beautiful and 
thick dark hair that he had in the photo. Even now I can still see him combing it with the 
tiny barber’s comb that he would pull out of his back pocket absentmindedly, alternately 
smoothing his hair with the comb and his palm, multiple times a day. I knew that picture 
had been taken shortly after Paul and Nancy were married. At some point over the years, 
I learned that picture was taken after Paul had gotten out of rehab for heroin use. The 
big smile was not just for his beautiful wife, but also for his release, for going home, for 
his smokes; for his freedom, I suppose.  
 
1997 
 There was a group of us taking the ferry from the island to the mainland, and I 
ended up in a seat across from Sean’s best friend. We didn’t know each other that well 
then, but at some point during the ride he told me he was worried about a friend. There 
was something in the story about a family and heroin; I think the friend had recently gone 
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to rehab. It all seemed so removed to me that I honestly didn’t pay close attention to the 
details. I didn’t remember that conversation until the year or so after Sean’s funeral. I 
still don’t know what might have been different if I had known that our mutual friend was 
talking about Sean— that he first tried heroin with his father when he was fourteen or so, 
that he was injecting by the age of 16, that he had been in rehab at least once by the time 
he was 19. All the things I didn’t know. 
 
2000 
I remember Sean telling me two things when I got pregnant: one— that he was 
increasingly worried about his father, and believed that this first grandchild would be the 
reason for him to finally get on methadone (it was). Second, he wanted to be “different” 
than his father had been.  
 
2013 
We had recently moved to a small New England town— one of those places with a 
general store in the town center, and where generations of families still live. If you hike 
around in the woods you can find old stone markers identifying family graves, and hand 
carved signs pointing the distance to the liquor store and homes of locals for people that 
might be taking the back way to visit. I was completely anonymous, which I appreciated 
after living on a small island for close to ten years— a place where the desolate windy 
winters in particular were prime time for gossip. The ability to drive to a completely 
different town on a whim without giving a second of a thought to ferry schedules, wind 
direction, or tides was thrilling. It felt liberating to not have anyone know my history. 
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One summer afternoon after we had moved Ev and I went to a swimming hole, a secret 
spot that some local had decided I was trustworthy enough to give detailed verbal 
directions to. As Ev played around in the water with friends, I joined some of the moms 
that I recognized from school. The conversation shifted pretty quickly to talk of one of the 
women’s younger cousins, who from what I could gather, struggled with heroin 
addiction. I didn’t quite get all of the context, but from what I could pick up the cousin 
had children and there was tension around the parenting role the grandparents were 
taking on. What I remember most, though, is not saying a thing. Hearing the judging 
tone. Keeping quiet.  
 
Thanksgiving 2015 
Before that holiday I knew that Sean’s brother, who had struggled with heroin 
addiction throughout the 15 years that I had known him and was at that point working 
hard at his sobriety as a new father and husband, would more than likely be actively 
using when we got there. I talked to Ev about it. I tried to prepare him for what that 
might look like now that he was old enough to not write off Joe’s behavioral oddities as 
just that. When we finally got to the house Joe was attempting to detox himself in his 
bedroom. It would be his son’s first birthday two days after Thanksgiving. Although he 
had talked about checking into a treatment program, his wife wanted him to be there for 
the party. Her friends were coming, and her parents had sent a Mickey Mouse banner all 
the way from Peru for them to take pictures in front of.  
Joe spent Thanksgiving in his bedroom. The next morning, I watched him leave 
his room, take a shower, walk out the door, get in his truck and drive away. When I asked 
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his younger brother where he was going, he just shrugged. “Detoxing is the easy part” 
he told me, and walked off.  Hours after I had gone to sleep, I heard Joe come back 
home— singing loudly and knocking things over while his wife shushed him as she blew 
up balloons and hung streamers. He sounded so happy.  
The party started the next day at around 11. Joe was still high. He was dripping 
with sweat, and uncomfortably upbeat for a person who tends towards social anxiety and 
awkwardness. Watching it all was like stepping back in time. Seeing the expression on his 
wife’s face was like looking at myself all those years ago. I probably should have pulled 
her aside to say something— anything— but I didn’t. It was all I could do to make it 
through the 24 hours before we had to leave; looking into that mirror was too much. For 
the first time I could see an awareness in Ev that he hadn’t had before. I felt sick.  
We headed home the next morning. Although we did eventually talk about it, most 
of our ride home was silent. It was too raw. Too physically painful. Too heartbreaking. 
We have not gone back to New Jersey since then, and I’m not sure if we will again. The 
baby is four now, and Joe has not picked up in almost two years. 
This dissertation investigates opioid use disorder among pregnant and parenting 
women. Truth be told, I am not certain that I would have gravitated to this topic of my 
own volition. The spring following that Thanksgiving in New Jersey my advisor sent me 
the contact information for a potential research partner, a physician and addiction 
specialist working at an area behavioral health hospital as director of their opioid 
treatment programs. I expressed my thanks and promptly buried the contact information 
under a pile of work and other life obligations. I never actually considered the option of 
saying no to the topic of opioid use, but what I needed, consciously or not, before moving 
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forward with my research was the time to process my personal relationship to the topic. I 
can’t say that it was always easy. 
 As I have moved through this work over the past two-plus years, it stands out as 
rare to have spoken to someone who has not been directly affected in some way by this 
topic. Over dinner one night, the two research assistants working with me realized they 
each had a cousin die from likely the same batch of heroin— within the same week, 
within miles of each other. I hadn’t realized until that moment that their motivation to 
work on this project came from their own process of seeking answers. As I learned 
throughout this research process, this was not uncommon among other professionals 
working in the field of substance use and treatment. Layered into this dissertation 
research is my internal process of looking starkly at my own stigma around addiction, 
and the complexities inherent to loving a person who struggled with a substance use and 
mental health comorbidity. Because there were many moments of Sean being a loving 
father; of Sean as a talented carpenter, fisherman, and gardener; and of Sean’s own father 
being a patient, caring, and present “Pop-Pop.” So no, I don’t think this research topic 
“chose me.” Rather, it was inevitable for me to choose it. Honestly, there are still 
moments— even writing at this exact instant, that I struggle to move past the secrets and 
silences that remain driven by the stigma that shrouds substance use and addiction.  As a 
participant told me one day: “No. I don’t think we can ever get rid of the stigma. No 
matter what. Sure, with our families maybe. But if someone at work finds out? Not a 
chance. Not even a chance.”  
 
Culture of Storytelling 
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 We exist in a “culture of storytelling” (MacIntyre, 1984, p. 216). As a form of 
narrative, storytelling “gives shape to human experience…[and is] arguably the one 
symbolic practice that is universal” (Lindloff & Taylor, 2011, p.181). My choice to begin 
this dissertation with a personal narrative is threefold. First, sharing a personal narrative 
functions as a reflexive entry point by positioning myself in relationship to this topic. 
Second, as part of my personal set of research ethics, I made a conscious choice to make 
myself as vulnerable as I asked participants to me with me. Lastly, beginning this 
dissertation with a personal story centers the importance of a narrative approach. 
Narratives are particularly relevant to the investigation of a topic as complex as substance 
use, particularly among marginalized populations (e.g. women and mothers) that tend to 
be reticent about participating in social science research for myriad reasons linked to 
stigma and fear of punitive consequences. The goal of this dissertation was to examine 
three discursive resources that shape cultural narratives of perinatal and maternal opioid 
use in the United States (U.S.) across all strata of social life: macro-level (news media), 
meso-level (scientific), and micro-level (individual) narratives (Loseke, 2007). The three 
narrative layers are not hierarchical, nor are they separate; rather, they intersect to 
influence each other continuously. 
Macro-level narratives refer to stories that produce cultural identities and establish 
symbolic boundaries. Macro-level narratives produce the master narratives (McKim, 
2017) of perinatal and maternal OUD that are imbedded into the social imaginary (i.e. 
shared cultural notions of defining characteristics of people with OUD, and responses to 
manage OUD). These master narratives consist of “imagined characteristics of 
disembodied types of people that simplify a complex world” (Loseke, 2007, p. 661). As 
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descriptive stories of events, public media narratives function as macro-level narratives 
by streamlining the complexities of pregnant women and mothers who use opioids into 
monolithic notions and characteristics.  
Meso-level media narratives influence social perceptions and public health policy 
around maternal opioid use disorders by: identifying and drawing attention to policy 
priorities; framing the issue; and by framing the issue, shaping public attitudes towards 
risk and management of maternal opioid use disorder (Lancaster, et al., 2011; Schiavo, 
2014). Meso-level narratives are those that produce institutional and/or organizational 
identities, thereby determining and defining imagined targets of policy and law. These 
evidence-based narratives directly inform service provision and policy development for 
specific populations (Loseke, 2007). The scientific literature on opioid use disorder and 
treatment produces meso-level narratives by defining the characteristics and needs of 
pregnant women and mothers with opioid use disorders as they engage with institutions  
that manage their opioid use disorders (e.g. medical, legal, and social services).  
Lastly, micro-level narratives are stories of personal experience and identity. 
These narratives refer to both inter- and intra-personal experience that prompt “self-
understandings of unique, embodied selves about their selves” (Loseke, 2007, p. 662). In 
this dissertation, micro-level narratives refer to individual stories of opioid use and 
treatment among pregnant women and mothers, as well as individual stories from the 
perspective of service providers and those who work directly with this population. 
Under the umbrella of the dominant public health research paradigm, narratives of 
health are most typically conceptualized as individual stories (i.e. illness narratives 
elicited from interviews) that convey subjective experience of a health issue or event. 
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Under this paradigm, scientific literature stands in contrast to individual stories; as 
representations of objectivity and truth, they are not considered to serve a narrative 
function. Media narratives are similarly absent from this paradigm, despite their 
pervasion through all sectors of society. In this dissertation I argue that this dominant 
public health research paradigm is limited, given that macro-, meso-,  and micro-level 
narratives co-exist, reinforce, and influence each other, each fulfilling a distinct role. 
Each narrative layer is socially constructed, and “arise[s] from and exist[s] within the 
larger culture” (Sharf, Harter, Yamasaki, & Haidet, 2011, p.38).  
“[P]ersonal stories cannot escape the constraint of institutional interests, nor are 
they separate from cultural values, beliefs, or expectations” (Sharf, Harter, Yamasaki, & 
Haidet, 2011, p.38) and vice versa. For example, the analysis of macro-level (public 
media) narratives presented in Chapter 3 of this dissertation illustrate that pregnant 
women and mothers with opioid use disorders are represented in public discourse in two 
primary ways: either as negligent parents causing direct harm to their children, or as 
earning redemptive potential (i.e. getting on the “straight and narrow”) via treatment or 
incarceration. Central to these macro-level narratives are “victims of the crisis”: infants, 
children, and the state (i.e. increased financial burdens to the medical and social service 
systems). Notably absent from the list of victims, however, are pregnant women and 
mothers. The narrative impact of this type of reporting is to overlook the needs of women 
as independent from child bearing and parenting. Furthermore, this type of representation 
produces a master narrative of women who “can't be left alone because I don't trust 
myself” (Seelye, 2016) and who “can't function as mothers” (Achenbach, 2016). This 
narrative identity of women as needing to be managed then drives the demand for 
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programming that incorporates a “healthy dose of benign paternalism and, in some cases, 
involuntary care through civil commitment” (Satel, 2017).  
Micro-level narratives, presented in Chapters 4 and 5 of the dissertation, illustrate 
that paternalistic approachs to treatment can also be a significant source of trauma, which 
negatively shapes women’s opioid-use trajectories. Straddling these examples are 
scientific definitions that define substance use disorders as a form of brain disease 
(National Institute on Drug Abuse [NIDA], 2019). This categorization importantly 
contradicts perceptions that addiction is a moral failing and character defect. 
Simultaneously, the narrative identity of people with substance use disorders as having 
some level of brain disfunction reinforces paternalistic treatment practices that can 
overlook the autonomous needs and experiences of the women that receive treatment. As 
one example, micro-level narratives presented in Chapter 4 describe that a consequence 
of a brain disease model of opioid use disorder is that women who maintain their 
recovery without pharmacotherapies can be excluded from programs offered under 
standard treatment protocols. As a result, this leaves many women without necessary 
supports to maintain long-term recovery. 
The goal of this dissertation was to examine the three discursive resources (e.g. 
macro, meso, and micro-level narratives), assessing the ways in which they speak to, 
interact, resist, silence, and bolster each other. In presenting an overview of perinatal and 
maternal opioid use and treatment in the U.S. I begin Chapter 1 by reviewing and 
analyzing the meso-level (scientific) narratives around opioid use disorder in the form of 
a review of the state of the field (i.e., literature review), as is consistent with the field of 
public health. My review of the scientific literature has, thus, a two-fold purpose: 1) to 
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present a standard literature review, and 2) to analyze how this literature shapes cultural 
narratives on perinatal and maternal opioid use and treatment. Ultimately, the meso-level 
review also serves as a touchstone for analyzing the macro-level (public media) and 
micro-level (individual) narratives presented in subsequent data chapters. Rather than just 
focusing on the “what’s” of the scientific literature (i.e. as objectivity, fact, and truth), the 
goal of this research is to additionally illuminate the “how’s” of this literature—how the 
discursive three resources, analyzed separately and vis a vis one another, are discursively 
marshaled to impact pregnant women and mothers with opioid use disorders.  
 
Meso-Level (Scientific) Narratives  
 
Perinatal and Maternal Opioid Use in the U.S.: Scope and Risk Factors 
Opioid use and opioid-related fatalities in the U.S. have increased drastically. 
Between 1999-2017 over 400,000 people in the U.S. died from an opioid overdose; it is 
currently estimated that every day 130 Americans die from an opioid-related fatality.  
There are three notable spikes in opioid-related fatalities during these time periods: the 
first, from 1999-2009, wherein the bulk of overdoses were attributed to prescription 
opioids; the second, from 2010-2012, wherein most overdose deaths were attributed to 
heroin; and the third from 2013-2017 (and continuing beyond the time of this writing) 
where the bulk of opioid-related fatalities involve synthetic opioids, particularly illicitly 
manufactured fentanyl (Centers for Disease Control and Prevention [CDC], 2019) 
Women and mothers in the U.S. with opioid use disorders are a rapidly growing 
and vulnerable population. Between 1999 and 2015, mortality rates from prescription 
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opioid overdoses among women increased by 471% as compared to 218% for men; 
mortality rates for heroin overdoses among women during that same period were double 
that of men (U.S. Department of Health and Human Services [USDHHS], 2016). 
Concomitantly, rates of perinatal opioid use and neonatal opioid withdrawal syndrome 
more than quadrupled between 1999-2014; it is estimated that every 15 minutes an infant 
is born experiencing opioid-related withdrawals as a result of opioid exposure in utero. 
(CDC, 2018).  
Scientific and biomedical discourse around opioid use primarily centers around 
the diagnosis of opioid use disorder (OUD). According to the most current Diagnostic 
and Statistical Manual of Mental Disorders 5th Edition (DSM-V), OUD refers to patterns 
of opioid use that interfere with multiple aspects of life, such as the ability to maintain 
employment and positive social relationships; it is classified as either mild, moderate, or 
severe (Substance Abuse and Mental Health Services Administration [SAMHSA], 2017). 
As currently defined by the National Institute on Drug Abuse (NIDA, 2019), drug 
addiction is a “chronic, relapsing disorder characterized by compulsive drug seeking and 
use despite adverse consequences. It is considered a brain disorder because it involves 
functional changes to brain circuits involved in reward, stress, and self-control, and those 
changes may last a long time after a person has stopped taking drugs” (NIDA, 2019, 
para.1). A biomedical model of addiction represents an important departure from a moral 
model of addiction, which points to notions of moral frailty as the true root of addiction 
(Leshner, 1997; Musto, 1999).  
The notion of addiction as a chronic medical condition (versus moral failing) is 
not new to the scientific literature. Maddux and Desmond (1981) initially identified the 
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concept of substance use disorders as a lifetime condition (then identified as a “career”, a 
term that has since been replaced with the more appropriate “chronic”). In 1997, Hser, 
Anglin, Grella, Longshore, and Prendergast published the framework for a “career” 
model of substance use disorders, drawing from prior studies conducted by Hser and 
Anglin (Anglin & Hser, 1990; Anglin, Hser, & Grella, 1997; Hser, Anglin, & Powers, 
1993; Hser, Yamaguchi, Chen & Anglin, 1995). In the same year, Leshner (as affiliated 
with NIDA) published the article “Addiction is a Brain Disease, and it Matters” 
in Science (1997), propelling the notion of addiction as a chronic condition into 
mainstream cultural discourse on substance use.  
According to a brain disease model of addiction, although the initial decision to 
experiment with a substance may be voluntary, over time “a person's ability to exert self-
control can become seriously impaired; this impairment in self-control is the hallmark of 
addiction” (NIDA, 2019). Furthermore, “brain imaging studies of people with addiction 
show physical changes in areas of the brain that are critical to judgment, decision-
making, learning and memory, and behavior control. These changes help explain the 
compulsive nature of addiction” (NIDA, 2019). Known risk factors for the development 
of OUD consist of biology and genetics; environmental factors, including trauma, 
parental and peer influence, and exposure to a substance, in terms of age of first 
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initiation, route of administration; and the physiological effects of the substance (CDC, 
2016; NIDA, 2019; SAMHSA, 2015; see Figure 1).  
Some of the critiques harbored at the brain disease model of addiction center on 
conflicting ideologies of risk, particularly the silencing of structural factors that 
contribute to addiction, as well as minimizing concepts such as brain plasticity (i.e. 
capability of the brain to change and reorganize), existing evidence of people who might 
“age out” of problematic substance use patterns, and those individuals who use opioids 
but do not meet the criteria for diagnosis (Hall, Carter, & Forlini, 2015). Guided by a 
brain disease model, 
current research goals in 
the U.S. specific to OUD 
primarily center on 
investigations related to 
neuroscience, epigenetics, 
pharmaceutical 
development, and 
prescription monitoring programs (NIDA, 2018). With this focus the risk of somatic 
reductionism (Lock, 2015) looms large, wherein the focus on biology and molecular 
processes overshadow the larger political-economic processes that shape “the 
environment” and other “risk factors” (Cadet, 2014; Leatherman & Hoke, 2016). Take, 
for example, the above model of risk factors associated with substance use disorders. Up 
until 2016, these factors included three factors: genetics, trauma (including exposure to 
parental or caregiver substance use), and age at first exposure (Cadet, 2016; MDPH, 
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2016; NIDA, 2016; SAMHSA, 2016). However, when looking at the newly updated 
model of factors that contribute to substance use disorders (Figure 1), we no longer see 
direct reference to trauma, and the model now largely appears to center on the substance 
used (i.e. the “drug” in question). 
The scientific literature identifies important sex differences as related to women 
with opioid and other substance use disorders. Women with opioid use disorders have 
higher rates of mental health comorbidities (e.g. depression, anxiety, post-traumatic stress 
disorder [PTSD]), poor self-concept, lifetime adversity (e.g. sexual trauma, intimate 
partner violence IPV), socioeconomic vulnerability, and housing insecurity as compared 
to men (Crandall et al., 2003; Evans, Grella, & Upchurch, 2017; Kremer & Arora, 2015; 
USDHHS, 2016). Additionally, women enroll in treatment programs in rates lower than 
men and are more prone to “telescoping,” which refers to a more rapid onset of substance 
dependence and associated psychological and social consequences (Evans, Grella, & 
Upchurch, 2017; Holscher et al., 2010; Sanders, 2014; USDHHS, 2016). 
According to the Substance Use and Mental Health Services Administration 
(SAMHSA), trauma is an “almost universal experience” (2014, p.2) shared by women 
and mothers with mental health and substance use disorders. In the scientific literature, 
trauma refers to adverse childhood and lifetime experiences, including direct and indirect 
exposure to physical, sexual, and emotional violence, as well as the traumas associated 
with war, combat, and natural disasters (SAMHSA, 2014). There are two main 
hypotheses explaining the link between trauma, mental health conditions, and substance 
use disorders. The self-medication hypothesis (Breslau et al., 2003) theorizes that 
substances are misused to relieve the psychosocial suffering that stems from exposure to 
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trauma. An additional theory hypothesizes that substance use leads to high-risk 
behaviors, which in turn increases the risk of exposure to trauma (Hassan et. al., 2017). 
Both hypotheses correlate with the extant psychological literature on trauma-avoidant 
behavior wherein substance use simultaneously originates from and perpetuates negative 
affect, exacerbating long-term mental health and other biopsychosocial outcomes 
(Blakely et al., 2019).  
Trauma discourse primarily reference narratives of Adverse Childhood 
Experiences (ACEs), drawing heavily from the landmark “ACE” study (Felitti et. al., 
1998) that identified a dose-response relationship between exposure to adverse childhood 
experiences and negative health outcomes over the lifecourse, including increased risk 
behaviors across multiple categories (e.g. propensity towards substance use, risk of 
sexually transmitted infections, and teen pregnancy); likelihood of having depression, 
anxiety, or other mental health conditions; emotional, social, and cognitive impairment; 
and increased risk for heart disease and early death (CDC, 2016; Felitti et al., 1998). 
Findings from the ACE study were essential in shifting the field of substance use research 
towards an inclusion of both trauma and social factors, in addition to brain biology and 
genetics (Felitti, 2003). Since the advent of the ACE study (Felitti et al., 1998), research 
findings consistently support a positive association between adverse childhood and 
lifetime experiences and substance use disorders (Douglas et. al., 2010; Evans, Grella, & 
Upchurch, 2017; Heffernan et. al., 2000; Khoury et. al., 2011; Stein et. al., 2017).  
Findings based on data from the 2016 National Survey of Children’s Health 
identify that 45% of children under the age of 18 living in the US have experienced at 
least one ACE—the most common of which is economic insecurity—followed by 
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parental divorce/separation. Living with a parent with an alcohol or other substance use 
disorder is the third most prevalent ACE in 45 states. One in ten US children have 
experienced three or more ACEs, and exposure to ACEs increases with age (Child 
Trends, 2018). Based on crimes reported to law enforcement, an estimated two million 
adolescents have been the victims of sexual assault, over 30% of who were under the age 
of nine (U.S Department of Justice [USDOJ, 2016]). Close to 90% of all juvenile 
survivors of sexual assault are female; males are more likely to be survivors of physical 
assault, and become perpetrators of physical and sexual violence themselves (USDOJ, 
2016).  
Exposure to childhood adversity (childhood sexual trauma in particular) among 
women is likely to be internalized as self-criticism, poor self-concept, social exclusion, 
depression, and anxiety (Evans, Grella, Upchurch, 2017; Leadbeater, Kuperminc, Blatt, 
& Hertzogg, 1999; Mendle, Leve, van Ryzin, & Natsuaki, 2014). In contrast, men are 
more likely to express outwardly aggressive externalizing behaviors (Evans, Grella, 
Upchurch, 2017; Lewis, McElroy, Harlaar, & Runyan, 2015). Additionally, whereas for 
men externalizing behaviors decrease with age, this internalizing effect for women 
increases with age. For women, exposure to childhood sexual abuse increases overall risk 
for polyvictimization (i.e. increased exposure to other childhood and lifetime adverse 
experiences; Lewis, McElroy, Harlaar, & Runyan, 2015).  
For pregnant women and mothers, opioid use disorder can present a unique set of 
adverse outcomes, including poor birth outcomes, postpartum depression, and removal of 
child(ren) by social services (Tsai & Doan, 2015; Wilder, Lewis, & Windhusen, 2015), as 
well as the deleterious impacts of maternal opioid use on “maternal-infant bonding, 
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exacerbation of psychiatric symptoms, disrupted social support systems, and inhibition of 
educational and career prospects” (Holbrook, 2015, p. 372). Neonatal opioid withdrawal 
syndrome (NOWS) occurs in 50% of infants exposed to opioids (including opioid 
treatment pharmacotherapies) in utero. Symptoms of NOWS appear soon after delivery 
and can include gastric discomfort, weight loss, dehydration, fever, and central and 
autonomic nervous system distress. Severity of NOWS symptoms are not dependent on 
maternal doses of opioids. Furthermore, despite popular assumptions to the contrary, 
symptoms of chemical withdrawal experienced by infants with NOWS do not equate to 
being “born addicted.” Current treatment protocols for newborns with NOWS require 
hospitalization, observation, sensory stimulation, low-dose feeds, skin-to-skin contact, 
breastfeeding, and the use of pharmacotherapies to address side effects as necessary 
(Crandall, Crosby, & Carlson, 2004; Kremer & Aurora, 2015; Tsai & Doan, 2016).  
In addition to experiencing a range of economic and social vulnerabilities that 
accompany chaotic substance use, pregnant women and mothers with opioid use disorder 
often receive inadequate health care, and experience heightened feelings of shame and 
other internalized self-depreciating thoughts and feelings (Evans, Grella, Upchurch, 
2017; Holbrook, 2015; Lupton, 2012; Sanders, 2014). Additionally, women attempting to 
achieve or sustain recovery face multiple stressors associated with the myriad of 
mandates to maintain or regain custody, such as clinical visits for medications for opioid 
use disorder, psychotherapy, meetings with social workers, potential court or legal 
appointments, and attendance at peer support groups, such as Narcotics Anonymous 
(NA) or Alcoholics Anonymous (AA; Holbrook, 2015; Kremer & Aurora, 2015).  
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Although policies that have responded to increasing rates of perinatal opioid use 
disorder and neonatal opioid withdrawal syndrome have importantly prioritized treatment 
access for pregnant women, in the first year postpartum many of these programs and 
supports taper. Mothers with opioid use disorder are most likely to die from a fatal opioid 
overdose during the “4th trimester” (i.e. the first year postpartum) (Schiff et al., 2018). 
Furthermore, national data identifies homicide and suicide among all women to be the 
highest in the first year postpartum (Palladino, Singh, Campbell, Flynn, & Gold, 2012), 
contributing significantly to high U.S. rates of maternal mortality. Because of parental 
substance use, the demand for foster care placements has spiked nationally (MADHHS 
2018), disrupting families and contributing to intergenerational patterns and a negative 
feedback loop of substance misuse and trauma.   
In response to some of the barriers identified in the scientific literature, hospitals 
have increasingly invested in programming that promotes maternal-infant bonding to 
improve neonatal outcomes during this critical time by supporting shared rooming, skin-
to-skin contact, and breastfeeding (Tsai & Doan, 2016). Some hospitals enlist volunteer 
“cuddlers” to comfort newborns through their physical symptoms, and give parents and 
caregivers a break. Initial data points to reduced hospital stays as a result of these 
approaches to treatment (Kraynek, Patterson, & Westbrook, 2012; Sullivan, 2016). For 
mothers, the immediate post-partum period is a critical time in which to reassess 
treatment and social support, to screen for postpartum depression, and encourage 
breastfeeding to enhance maternal-infant bonding (Kremer & Aurora, 2015; Roussos-
Ross, Behnke, & Warner, 2012). 
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Moral Economies of Treatment 
Under the brain disease model, OUD is categorized as a chronic health condition 
commonly equated to other chronic illnesses, such as Type 2 diabetes. Health experts 
largely view sustained engagement with medications for opioid use disorder (MOUD) as 
the “gold standard of care” that improves health and psychosocial outcomes for people 
with OUD. Use of MOUD has been shown to lower rates of relapse and death, and 
improve quality of life and social engagement (Holbrook, 2015; Hser, Evans, Grella, 
Ling & Anglin, 2014; Wilder & Windhusen, 2015; Wilder, Lewis, & Windhusen, 2015; 
Volkow, 2018). However, more than 80% of individuals living with OUD do not receive 
treatment. Treatment rates are lower for women versus men (SAMHSA, 2017), and 
within six months of giving birth treatment retention drops significantly and overdose 
rates spike dramatically (Wilder, Lewis, & Windhusen, 2015). A poorly understood 
challenge remains why many women and mothers do not remain engaged with 
medications for opioid use disorder long enough to achieve sustained benefits (Schiff et. 
al., 2018). 
Medications for opioid use disorders include methadone, buprenorphine 
(suboxoneâ or “sub”), and naltrexone (vivitrolâ; naltrexone is contraindicated in 
pregnancy, however). There are a dearth of studies that comparatively assess the efficacy 
of MOUD. Additionally, there are no studies which explore patient predictors of 
comparative MOUD success (Blanco & Volkow, 2019; Nunes, Krupitsky, Ling, Zummo, 
Memisoglu, Silverman, & Gastfriend, 2015).  
Methadone is a long-acting agonist opioid that has been used in the treatment and 
management of OUD for approximately 50 years (Novick, Salsitz, Joseph & Kreek, 
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2015). An appropriately titrated individual dosage will prevent withdrawal symptoms; 
block the euphoric effects of any additional opioids; reduce cravings for a period of 24 
hours; and reduce the risk of infectious disease (i.e. HIV or HCV from injection drug 
use), death, and criminal activity (Novick, Salsitz, Joseph & Kreek, 2015). When 
compared to untreated perinatal OUD, perinatal use of methadone yields optimal 
maternal and neonatal health outcomes (Jones, Finnegan, & Kaltenbach, 2012; Krans et 
al., 2016). Among all treatment modalities, methadone has the most comprehensive data 
supporting its efficacy, (reduced morbidity, mortality and increased treatment retention); 
this is due in large part to the extent of time it has been prescribed. 
A series of studies conducted at Rockefeller University in the 1960s established 
methadone maintenance treatment as a successful and viable treatment for OUD (Hansen 
& Roberts, 2016). Although research findings from the Rockefeller studies identified the 
multiple positive health outcomes of which one was crime reduction, policy support 
focused almost solely on crime reduction. The main critiques of this program model point 
to the use of Methadone as a distinct way of policing communities of color under the 
guise of protection (Hansen & Roberts, 2016). Additionally, the choice to locate 
methadone clinics in low income communities in response to protests from more affluent 
communities and wherein “methadone maintenance is dispensed in a clinical setting that 
is distinct from mainstream medicine and has the trappings of the arm of law 
enforcement” (Hansen & Roberts, 2016, p.92) has been widely critiqued over time 
(Musto, 1999). 
The main critiques of methadone are specific to its safety profile and potential for 
abuse, overdose, and diversion to unregulated markets (Holbrook, 2015; Novick, Salsitz, 
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Joseph & Kreek, 2015). Methadone distribution is highly regulated and monitored. The 
majority of individuals receiving methadone are required to receive a supervised daily 
dose from a licensed clinic. Program oversight is monitored by the Food and Drug 
Administration (FDA), and from its inception, these regulations have had a greater focus 
on diversion prevention than patient outcomes (Novick, Salsitz, Joseph, & Kreek, 2015). 
The structure of daily clinical visits can be crucial for many individuals, particularly in 
the early stages of recovery. At the same time, daily visits pose significant barriers for 
low-income patients, including difficulties accessing transportation, childcare, and time 
off from work (Hansen & Roberts, 2012; Holbrook, 2015; Jones, Finnegan, & 
Kaltenbach, 2012; Novick, Salsitz, Joseph & Kreek, 2015). The stigma associated with 
OUD and MOUD overall can be difficult to avoid with daily clinical visits to a “marked” 
location (i.e. a “methadone clinic”), poses an additionally significant barrier for pregnant 
and parenting women that is further compounded for single mothers, individuals with 
limited flexibility and agency in their work setting, and those with limited social support 
systems (Proctor et al., 2015; Sanders, 2014; Timko et al., 2016). More difficult to 
address is the lore associated with the use of methadone that is a common narrative 
shared among users and their families and networks, including that it causes liver cancer, 
bone and tooth decay, and that one is simply substituting “one drug for another” 
(Narcotics Anonymous, 2016; Personal communication, 2016; 2018). 
In 2000 the Drug Abuse Treatment Act classified buprenorphine as a Schedule III 
Drug (as per the DEA, a drug with low to moderate risk of dependence), allowing it to be 
prescribed in office based settings (Hansen & Roberts, 2016; Novick, Salsitz, Joseph & 
Kreek, 2015). As an office-based therapy, buprenorphine addresses many of the critiques 
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harbored towards methadone— most specifically that it circumvents the structural 
barriers of accessibility, as well as the stigma associated with daily clinical visits, by 
being folded into traditional treatment practices (Martin & Finlayson, 2015; Novick, 
Salsitz, Joseph & Kreek, 2015; Timko, Schultz, Cucciare, Vittorio, & Garrison-Diehn, 
2016). One critique of the introduction of buprenorphine is that as the demographic of 
opioid addiction increasingly shifted towards a middle income, White population with 
higher levels of education, so did the demand for less stigmatizing treatment approaches 
(Hansen & Roberts, 2016). 
As a partial agonist, buprenorphine will displace other opioids bound to the opioid 
receptor in the brain and therefore has a “plateau” effect—once a certain dosage is 
reached, there are no additional opioid effects. For individuals with higher opioid 
tolerances, dosages may be insufficient to prevent cravings, thus resulting in decreased 
adherence (Krans et al., 2016). The addition of naloxone to buprenorphine, an agonist 
that can cause withdrawal if injected, means the risk of overdose with buprenorphine is 
lower than with methadone (Martin & Finlayson, 2015; Novick, Salsitz, Joseph & Kreek, 
2015; Timko, Schultz, Cucciare, Vittorio, & Garrison-Diehn, 2016). Instead of focusing 
on an increased safety profile and the importance of expanding treatment options, 
lobbying efforts advocating for the scheduling of buprenorphine focused on providing 
treatment to individuals who would have a lower propensity for criminality, misuse or 
diversion, and therefore be better candidates for buprenorphine and an office based model 
(Hansen & Roberts, 2016; Holbrook, 2015; Netherland & Hansen, 2016). The substantial 
increase in opioid use has resulted in an upsurge of buprenorphine being diverted and 
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sold within informal, unregulated markets. Buprenorphine retention remains a challenge 
(Blanco & Volkow, 2019).  
The least amount of data exists for naltrexone, and its associated outcomes. 
Although naltrexone is not recommended for pregnant women, it can be used by women 
and mothers following the perinatal period. Naltrexone is administered as an injectable 
dose that lasts for 28 to 30 days. Patients are required to be abstinent from opioid for 
seven days prior to naltrexone initiation, which presents a notable barrier to treatment 
initiation. As such, it is most commonly used in institutional settings, particularly in 
criminal justice facilities (Blanco & Volkow, 2019).  
The official position of the American College of Obstetricians and Gynecologists 
(ACOG) is that OUD is a chronic condition which requires routine care and maintenance, 
and that women with OUD seeking prenatal care should not face criminal or civil 
penalties including loss of custody (ACOG 2016). For pregnant women who are actively 
using opioids, initiation to MOUD is considered crucial— not only does it increase the 
likelihood a mother will remain engaged in long-term treatment, prenatal care, and 
parenting in the postpartum period, it also prevents fetal stress in utero by ensuring a 
regulated and unadulterated dose of opioids (Holbrook, 2015; Kremer & Aurora, 2015; 
Roussos-Ross, Behnke, & Warner, 2012; Terplan, 2015). Complete withdrawal from 
opioids during pregnancy can be highly dangerous, resulting in miscarriage, preterm 
birth, low birth weight, and stillbirth (Kremer & Aurora, 2015). If a woman chooses to 
opt out of MOUD, the recommended course of action is a medically supervised 
withdrawal during the second trimester of pregnancy, when it poses the lowest risk of 
complications. This process is costly, and requires a lengthy hospital stay; women who 
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undergo the procedure have high rates of relapse (Kremer & Aurora, 2015; Martin & 
Finlayson, 2015).  
It is standard for methadone treatment programs to mandate group and individual 
behavioral therapy, linking attendance to medication access. Initially, this was not a 
requisite for individuals maintained on buprenorphine and naltrexone therapy in office-
based settings. For individuals receiving these therapies in publicly funded clinics or 
institutional settings, mandated group or individual behavioral therapy can be mandated 
(Timko, Schultz, Cucciare, Vittorio, & Garrison-Diehn, 2016; Wilder, Lewis, & 
Windhusen, 2015). Gender-responsive treatment programming addresses differing risk 
factors associated with OUD that are more likely to be associated with women versus 
men, such as exposure to sexual and emotional trauma, co-occurring mental health 
comorbidities, and socioeconomic vulnerability (Campbell & Ettorre, 2011; Hannah-
Moffet, 1998; SAMHSA, 2014; Sanders, 2014).  
Addressing trauma is a central component of gender-responsive health care 
delivery, which demands multi-sectorial approaches that extend beyond the clinic 
(SAMHSA, 2014). Given the high prevalence of sexual and emotional trauma among 
women with OUD, and the associated the biopsychosocial impacts of trauma, access to 
and availability of trauma-informed training and practices have increased in recent years. 
The four key assumptions of a trauma-informed approach include the “4-R’s”: realize 
(prevalence and associated factors), recognize (manifestations of), respond 
(institutionally and systematically through the implementation of trauma-informed 
principles and practices), and resist re-traumatization (via organizational practices and 
policies (SAMHSA, 2014). According to SAMHSA guidelines, the six guiding principles 
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of a trauma-informed approach include: ensuring physical and psychological safety of all; 
trustworthiness and transparency between clients, family, and staff; the importance of 
peer support and shared lived experience; collaboration and power-sharing, promoting 
empowerment, voice, and choice making through shared decision making, advocacy, and 
goal setting; and being responsive to “cultural, historical, and gender issues” (SAMHSA, 
2014, p. 11). 
Many people in treatment and recovery seek out support in the form of 12-step or 
other peer support models. However, reliance on 12-step programs (i.e. Narcotics 
Anonymous, or NA, and Alcoholics Anonymous, or AA) remains controversial in the 
scientific literature given their grounding in moralistic notions of addiction and lack of 
consistent evidence (Ferri, Amato, & Davoli, 2006; Kaskutas, 2009; Sanders, 2014). 
Additionally, although this program model has been generalized and “feminized” and 
tailored to women, its foundation retains a male-dominant focus (Sanders, 2014). Gender-
responsive programs center around relational theory, and as such put considerable focus 
on relationship dynamics between women, romantic partners, children, and family 
(Hackett, 2013). Critiques of gender-responsive programming include the 
homogenization of women and their needs, which can obscure intersections of race, sex, 
class, and gender. Additionally, gender-responsive programming can put strong emphasis 
on “responsibilizing” (Hannah-Moffet, 1998, p.11) of the individual. While this approach 
can provide useful skills and tools at the individual level (e.g. job skills, parenting 
classes), it does not account for structural barriers to treatment and recovery, and 
displaces responsibility away from the institutional or community level. 
  27 
Within 12-step programs, great importance is placed on building a relationship 
with a “sponsor” for people that are “working the steps” of their recovery process 
(Sanders, 2014). While the peer support model typically highlighted in 12-step programs 
shows evidence of being beneficial for both mentors and mentees (Tracy & Wallace, 
2016), less is known about the impacts of developing relationships with program 
participants who might similarly be in early stages of recovery. Depending on what stage 
of recovery an individual is in, they may not be equipped to provide adequate emotional 
support. Breaking ties with networks of active substance users (i.e. “avoiding people, 
places, and things” that may trigger a person to relapse or use a substance) is the most 
standard recommendation, particularly in the early stages of recovery. However, doing so 
often means losing crucial emotional support that may have supplanted family networks 
over the course of an individuals’ substance use trajectory (Bourgeois, 2009; Sanders, 
2014).  
Strict definitions of sobriety that exclude MOUD pharmacotherapies underlie 
many 12-step programs and can be detrimental to an individuals’ recovery, paradoxically 
contributing to the stigma and shame the programs seek to redress (Narcotics 
Anonymous, 2016). According to Narcotics Anonymous (2016), the sole prerequisite for 
program attendance is the intent to be substance free (including from MOUD). However, 
program participation (i.e. sharing in the group setting) requires attendees to be substance 
free (including what NA refers to as “drug replacement programs” such as methadone, 
buprenorphine, or naltrexone). While use of MOUDs does not preclude program 
attendance, NA dictates “encourage those members to participate only by listening and 
by talking with members after the meeting or during break” (Narcotics Anonymous, 
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2016). According to NA, this policy is not meant to alienate, but prevents “confusion” 
among program attendees.  
In the field of maternal and child health, the perinatal period is often considered a 
“window of opportunity” (Daley, Argeriou, & McCarty 1998, p. 240) for intervening in a 
multitude of health conditions among populations that might otherwise remain outside of 
the health care system, as is often the case with women who are active substance users. In 
pregnancy, women become a captive audience and routine prenatal visits present a 
unique opportunity to develop relationships with a clinic or hospital and health care 
providers, and to address health concerns. However, this notion is neither simple nor 
straightforward in the context of substance use. Interactions between care providers and 
women with OUD can be fraught with tension, judgement, and miscommunication, 
exacerbated by legitimate fears of punitive interventions that can divide mothers from 
their children and families (Holbrook, 2015; Lupton, 2012; Sanders, 2014; Terplan, 
Kennedy-Hendricks, & Chisolm 2015). Additionally, while routine prenatal visits do 
indeed present an opportunity, the singular focus on this point in time remains 
mechanistic and shortsighted (Wilder, Lewis, & Windhusen, 2015). In reality, 
stigmatizing public discourse inhibits care-seeking among this population. Many women 
attempt detoxification before initiating prenatal care, and some avoid care altogether due 
to fears of provider-stigma, mandatory reporting to social services and loss of custody. 
While considering OUD as a chronic condition has created space for a treatment 
versus punitive-based focus, this “trope of chronicity” (Garcia, 2010, p. 12) has reshaped 
moral notions of addiction by positioning MOUD as the sole option, particularly for 
women whose maternal status is contingent on treatment enrollment and adherence. The 
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“trope of chronicity” that defines the institutional classification of addiction can 
contribute to a collective sense of hopelessness by framing relapse as an inevitability and 
a failure, exacerbated by the use of “morally charged” language such as regression and 
recidivism (Garcia, 2010, p. 10). Furthermore, biomedical conceptions of addiction as a 
chronic, relapsing brain disease can run counter to the abstinence-based model instituted 
across the myriad of managing institutions that mothers interact with, fear, or avoid on a 
daily basis, e.g. medical, legal, and social service entities (Holbrook 2015; Terplan, 
Kennedy-Hendricks, & Chisolm, 2015). For example, as observed during data collection 
for this project, many direct-care staff making decisions about a woman’s maternal status 
remain aligned with a moral model of addiction and were strictly unforgiving of relapse. 
And though the definition of abstinence within some institutions increasingly includes the 
use of MOUD, failure to adhere to treatment protocols had multiple punitive 
implications, such as court-mandated stipulations for maintaining custody and accessing 
government-funded housing.  
 
Theoretical Frameworks Shaping Meso-Level (Scientific) Narratives of  
Opioid Use Disorder (OUD) 
This research is primarily a call for a robust critical public health agenda. 
Particularly with regard to the worldwide increase in deaths and diseases of “despair” 
(e.g., substance-related fatalities, suicide, and depression), a more nuanced understanding 
of the lived experience of people impacted by opioid use is imperative to advancing 
culturally resonant and justice-based solutions to yield optimal health. Embodiment refers 
to how people biologically incorporate their world across the lifecourse, and furthers the 
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notion that an assessment of individual biology cannot be divorced from a political 
economic lens that considers history, place, culture, and systems and processes of power 
that constrain or facilitate agency (Geronimus, 2006; Krieger, 2005; Krieger, 2012; 
Leatherman & Goodman, 2011). The internalizing effect (Mendle, Leve, van Ryzin, & 
Natsuaki, 2014) experienced by women who have been exposed to childhood adversity 
(childhood sexual trauma in particular) is a relationship best encapsulated by renowned 
social epidemiologist Nancy Krieger, who notes that  “bodies tell stories about—and 
cannot be studied divorced from—the conditions of our existence” (Krieger, 2005, 
p.350).   
Krieger (2005) invites us to consider three core claims of embodiment:  
(1) Bodies tell stories about—and cannot be studied divorced from—the 
conditions of our existence;  
(2) Bodies tell stories that often—but not always—match people’s stated 
accounts; and 
(3) Bodies tell stories that people cannot or will not tell, either because they are 
unable, forbidden, or choose not to tell. (p.350)   
While embodiment has largely been applied in public health as a framework to examine 
the impact of racism and disparate patterns of racial inequities (Krieger 2001; 2012), it 
provides relevant context for understanding perinatal and maternal opioid use. An 
embodied approach stands in contrast to a disembodied approach, wherein research 
endeavors center on “faulty” genes and addressing “problematic” or “risky” behaviors, an 
approach strongly aligned with the brain disease model of addiction, and which can be 
limited in its conception of the factors associated with OUD. 
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In this chapter, I present theories from critical medical anthropology and public 
health that shape meso-level (scientific) narratives of perinatal and maternal OUD. 
Considered together as a critical public health approach, a merging of these theoretical 
frameworks carry potential to bolster current public health approaches. Considering these 
frameworks together can link the “chasms” between social and biological sciences by 
connecting “structures of inequality, constrained agency, and pathways to embodiment 
within ethnographically grounded local contexts, lived experience realities, and local 
biologies” (Leatherman & Hoke, 2016, p. 10).   
Public health efforts call for primary prevention efforts to mitigate overall 
“upstream,” or underlying, factors (i.e. preventing childhood exposure to parental 
substance use other traumas, and the social determinants of health for example). 
However, the bulk of prevention efforts that address maternal OUD are secondary (i.e. 
universal drug screens in pregnancy) and tertiary (i.e. individually tailored behavioral 
therapy, monitoring, and prescription of MOUD). A political economic analysis of health 
and wellbeing is integral to an upstream public health approach by showcasing the 
“social processes, although full of complexity and contradiction, [that] are key to a 
deeper understanding” of illness and lived experience (Goodman & Leatherman, 1998, p. 
20) and which are deeply intertwined with health.  Below, I present a lifecourse syndemic 
framework, which links biology, trauma, substance use, mental health comorbidities, and 
political economic factors across the lifecourse of women and mothers (Leatherman & 
Goodman, 2011; Leatherman & Thomas, 2001).  
 
The Political Economy of Perinatal and Maternal OUD 
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Stigma is socially constructed and can result in limited social networks, stress, 
and dehumanization and discrimination, vastly impacting health and quality of life; 
education of both stigmatized and stigmatizer(s) has the potential to mitigate the 
withdrawal and secrecy that is most typical course of action for members of a stigmatized 
group (Sanders, 2014). More than any population, pregnant and parenting women who 
use substances experience high rates of social stigma (Campbell & Ettorre, 2011; Evans, 
Grella, Upchurch, 2017; Holbrook, 2015; Lupton, 2012). Concepts of morality and illness 
are intertwined with stigma, and can be traced throughout the evolution of society and the 
public health profession. Kremer and Aurora (2015) present a framework of stigma and 
illness for perinatal and postpartum OUD that is derived from the moral and social panic 
observed by Alonzo (1995) in his work with HIV+ individuals. According to Alonzo, an 
illness is likely to be stigmatized over the course of time if it fits the following six 
criteria: (1) if it is associated with what is considered deviant behavior, (2) if it is seen as 
solely an individuals’ responsibility, (3) if it represents what is considered to be “morally 
sanctionable behavior,” (4) if it is perceived as contagious to the community at-large, (5) 
if it is associated with a death that is both undesirable and unaesthetic, and lastly (6) if it 
is not well understood by both society and health care providers (Kremer & Aurora, 
2015).   
At first glance point four— the threat of contagion—might be considered 
inapplicable given that addiction is not biologically infectious. However, with opioid-
related fatalities occurring at epidemic proportions that are often portrayed in the media 
as haphazardly disrupting lives and families, and the reality that injection drug use carries 
a very real threat of transmission of infectious diseases such as HIV or HCV, this point 
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fits with the remainder of this model of stigma and (select) illnesses as intertwined. Given 
this model, it is useful to consider the history of drug policy, drug treatment policies, and 
the role of the media and messaging and how they influence and perpetuate stigma 
among women and mothers with OUD.   
Current approaches to the management of OUD represent a departure from the 
War on Drugs approach from the 1970s that favored criminalization over treatment, and 
drove the flagrant and dramatic rise of the incarceration of People of Color in the U.S 
(National Research Council, 2014). The War on Drugs was launched by the Nixon 
Administration in 1970. In an interview conducted in the 1990s, John Erlichman, 
President Nixon’s domestic policy advisor at the time, clarified the motives underlying 
the War on Drugs and its associated policies at that time: 
The Nixon campaign in 1968, and the Nixon White House after that, had two 
enemies: the antiwar left and black people. You understand what I’m saying? We 
knew we couldn’t make it illegal to be either against the war or blacks, but by 
getting the public to associate the hippies with marijuana and blacks with heroin, 
and then criminalizing both heavily, we could disrupt those communities. We 
could arrest their leaders, raid their homes, break up their meetings, and vilify 
them night after night on the evening news. Did we know we were lying about the 
drugs? Of course we did. (Baum, 2016, para. 2) 
 
As part of a series of legislation passed under the War on Drugs, the 
Comprehensive Drug Abuse and Prevention and Control Act of 1970 sought to lower 
rates of substance use and the violence associated with unregulated markets, allowing law 
enforcement to conduct “no knock” searches, which primarily targeted low-income 
Communities of Color. In response to the “crack epidemic” of the mid-1980s to 1990s, 
then President Reagan signed the Anti-Drug Abuse Prevention Act into law in 1986, 
creating funding for drug treatment, abstinence-based substance use education programs, 
and increased construction of prisons. Mandatory minimum sentencing for drug 
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possession was central to the Anti-Drug Abuse Prevention Act, a policy that has been 
widely critiqued for promoting racial disparities in sentencing, and discriminant 
surveillance of low-income Communities of Color (Netherland & Hansen, 2016; Musto, 
1999).  
In a special report presented to Congress in 1997, the U.S. Sentencing 
Commission reported that while 90% of people convicted in federal court for crack 
cocaine distribution were Black, the majority of crack cocaine users were White (Musto, 
1999). People who admitted to using crack cocaine at the time were 52% White, 38% 
Black, and 10% Hispanic. Yet data from the U.S. Sentencing Commission from that time 
shows that 79% of 5,669 sentenced crack offenders were Black, 10% were Hispanic, and 
only 10% were White, lending credence to the contention that mandatory minimum 
sentencing laws were racially biased and fundamentally flawed (Musto, 1999). The 
majority of incarcerated individuals are currently Men of Color serving time for non-
violent drug offences; women are the most rapidly increasing incarcerated population in 
the U.S. (National Research Council, 2014). 
Policies around perinatal and postpartum OUD are guided by the Child Abuse 
Prevention and Treatment Act (CAPTA), which was enacted in 1974 and reauthorized in 
2010.  Under this legislation, healthcare providers are required to report newborn 
exposure to prenatal substance use, including medications for opioid use disorders 
(Children’s Bureau, 2015). Because trust and rapport between pregnant women with 
OUD and their caregivers or care giving institutions are the keystones to successful 
treatment and optimal outcomes for parents and child(ren), this requirement poses a 
fundamental conflict for providers attempting to develop a long-term relationship with a 
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patient that yields successful outcomes (Jones, Finnegan, & Kaltenbach, 2012; Kremer & 
Arora, 2015, Terplan, 2015).  
The legal requirements of the Child Abuse Prevention and Treatment Act run 
directly counter to current prenatal care practice guidelines set forth by the American 
College of Obstetricians and Gynecologists that do not support punitive approaches to 
perinatal substance use (American College of Obstetricians and Gynecologists, 2016). 
According to the Guttmacher Institute (2019), the current status of state policies on 
substance use in pregnancy as of May 2019 are listed below:  
• 23 states plus D.C. classify substance use in pregnancy as child abuse 
• 25 states plus D.C. require reporting of suspected substance use in pregnancy 
• 8 states mandate testing when substance use in pregnancy is suspected 
• 3 states consider substance use in pregnancy as grounds for civil commitment to 
treatment 
Regarding substance use treatment programs for pregnant women: 
• 19 states have targeted treatment programs  
• 17 states plus D.C. give pregnant women priority access to treatment programs 
• Only 10 states specifically protect women from discrimination from publicly 
funded treatment programs 
Current policy efforts and public discourse around OUD have rapidly shifted from 
punitive-based legal interventions that focus on individual responsibility to a call for 
compassionate treatment efforts that instead draws from a whitewashed narrative that 
depicts “good kids” addicted because of the over prescription of legitimized medicine 
(Netherland & Hansen, 2016). As a stark contrast to legislative efforts during the U.S. 
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“crack epidemic” the Substance Use Disorder Prevention that Promotes Opioid Recovery 
and Treatment (SUPPORT) Act was passed in October 2018 with nearly unanimous, 
bipartisan support—a notable feat during the current combative political landscape in the 
U.S. In addition to providing funds for expanded access to MOUDs and lifting insurance 
restrictions, the SUPPORT Act specifically earmarks increased funds for the treatment of 
pregnant and postpartum women with OUD (Library of Congress, 2018). It should come 
as no surprise, then, to read researchers Julie Netherland and Helena Hansen (2016) refer 
to the opioid “crisis” as the “war on drugs that wasn’t” (p. 664). 
Ironically, racism initially had a protective effect on rates of prescription opioid 
fatalities among African-American and Latinx populations. Perceptions among providers 
that Patients of Color were more likely to sell or abuse narcotics resulted in lower opioid 
prescriptions for African- American and Latinx patients (Netherland & Hansen, 2016; 
Terplan, Kennedy-Hicks, & Chisolm, 2015).  Public attention has focused almost 
exclusively on rates of opioid related fatalities among Whites, even though notable 
increases can be seen across all races/ethnicities. For example, an article from the 
Washington Post in July 2016 covering the Democratic National Convention reports that:  
The issue has become a bipartisan one, with many on both sides agreeing that the 
focus must be on treating people with addiction, not on putting them in prison. 
However, several Republican presidential contenders last year stopped short of 
advocating that approach to other drug laws, most notably those involving 
marijuana and cocaine, which disproportionately affect African Americans. 
Opiate abuse predominately affects whites. (Zezima, 2016, p. A05; emphasis 
mine) 
 
Despite substantial increases in opioid-related fatalities across all races and ethnicities, 
news reports primarily remain focused on opioid use and opioid-related deaths among 
White, middle-income, rural Americans. Simultaneously, African-American and Latinx 
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women with OUD remain more likely than their White counterparts to be incarcerated, 
separated from children, and less likely to have access to long-term addiction treatment 
and/or counseling (Acevedo, Garnick, Ritter, Horgan & Lundgren, 2015; Hansen & 
Roberts, 2012). 
 
The Lifecourse Syndemic Framework 
Syndemic theory is an innovative contribution from medical anthropology that is 
increasingly taken up in the field of public health and applied to the analysis of both 
communicable and non-communicable disease patterns (Mendenhall, Kohrt, Norris, 
Ndeteti, & Prabhakaran, 2017; Singer, Bulled, Ostrach, & Mendenhall, 2017; Tsai, 
Mendenhall, Trostle, & Kawachi, 2017). The word syndemics is derived from the Greek 
words synergos (more than two) and demos (people) (Singer, 2009). Syndemics are 
distinct from epidemics (e.g. a flu outbreak), pandemics (i.e. a global epidemic such as 
Ebola) and endemic patterns of disease (e.g. malaria, Type 2 diabetes) (Friis, 2010). 
Syndemics are a complex system theory that assess “the concentration and deleterious 
interaction of two or more diseases or other health conditions in a population, especially 
as a consequence of social inequality and the unjust exercise of power” and represent a 
bridge between a political economic framework and embodiment studies (Singer, 2009, 
p. xv). It is important to note that syndemics are not synonymous with co- or multi-
morbidities; rather, the framework indicates a symbiotic interaction, and a focus on the 
“product of interactions” (Singer, 2009, p.37) within a larger political economic 
framework. Central to syndemics is the influence of violence, a factor that “transverses” 
all “spheres of life and livelihoods” (Mendenhall, 2014, p.304), and a call for 
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multidisciplinary solutions that examine power, violence, and the interplay between 
structure and agency. Structural violence refers to the inequitable distribution of power 
enmeshed into the political economic framework of society that drives divergent patterns 
of health and wellbeing (Farmer, 1996). Structural violence is an important component to 
bring to the forefront, as it makes central the role of social position and social stigma in 
shaping differential access to the goods and services that promote, and alternatively 
disenfranchise, wellbeing. 
Syndemic theory was first established in the public health literature with the 
publication of findings about the SAVA syndemic, which examined the interactions 
between substance abuse, violence, and AIDS, and provided the first evidence of 
interlinked epidemics analyzed syndemically and labelled as such (Singer, 2009). 
Analysis of the SAVA syndemic included an examination of the role of interpersonal and 
structural violence on childhood trauma, self-esteem, and levels of social support, and 
their collective impact on sexual practice (particularly in regards to sex work and lack of 
prophylaxis) and needle sharing as both pertained to the spread of HIV/AIDS (Singer, 
1994). Mendenhall subsequently documented the VIDDA syndemic, which utilized a 
syndemic framework to emphasize and illustrate that the prevalence of Type 2 Diabetes 
among female Mexican immigrants is not an endpoint, but rather part of a larger cycle of 
violence, immigration, depression, diabetes, and abuse that required addressing all factors 
to make marked progress towards improving health outcomes among this population 
(Mendenhall, 2012; 2014). 
Although the pattern of opioid use and opioid-related fatalities in the U.S is 
currently referred to as an “epidemic” and most recently a “crisis,” this research applies a 
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syndemic framework that more accurately encapsulates the “hydras of ill health” 
(Worthman & Korht, 2005, p. 863) that constitute, contribute to, and exacerbate OUD 
among pregnant women and mothers. As an upstream model of health, the application of 
a syndemic framework in the context of perinatal and maternal OUD represents an 
important contribution to current biomedical approaches. A syndemic framework can 
drive the development of integrated, evidence-based policies, programs, and service 
delivery models to achieve optimal health outcomes (Singer, Bulled, Ostrach, 
Mendenhall, 2017; Mendenhall et al., 2017).  
Syndemics provides an important framework to understand how the confluence of 
historical, social, and structural factors collide into the expression of health in the present 
moment. However, focusing on the expression and treatment of a health outcome (i.e. 
OUD) remains a limited approach. A lifecourse-informed approach to health draws from 
both sociology and developmental psychology literature, and is particularly relevant for 
an examination of opioid and other substance use disorders, which are most often 
experienced longitudinally throughout one’s lifetime. Lifecourse-informed approaches 
are additionally relevant for the analysis of reproductive and maternal and child health, 
allowing for important linkages to intergenerational patterns of health, wellbeing, and 
social adversity (Elder, 1998; Elder, Johnson, & Crosnoe, 2003; Lu & Halfon, 2003; Pies 
& Kotelchuk, 2014).  
A lifecourse approach to reproductive and maternal and child health includes five 
key concepts that are important to consider in the context of OUD among pregnant and 
parenting women: (1) embodiment; (2) developmental influences of both risk and 
protective factors (i.e. single, multiple, and cumulative factors that can pose risk or 
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function as sources of resiliency); (3) extended developmental time frames (i.e. 
incorporating a historical analysis at the personal, social, and structural levels); (4) 
multiple determinants of health outcomes (that include social and structural factors, and 
their interactions); and (5) the “representation of health as functional trajectories” (Russ, 
Larson, Tullis, & Halfon, 2014, p. 504) that are comprised of transitions and critical 
turning points (Russ, Larson, Tullis, & Halfon, 2014), including protective as well as risk 
factors. Key concepts of a lifecourse model include trajectories (i.e. longitudinal patterns 
across the life course that consist of a series of transitions or turning points) and “critical 
turning points” (Hser, Longshore, & Anglin, 2007). The concept of “critical turning 
points” is derived from the lifecourse approach literature and refers to singular and 
cumulative events within an individual’s lifecourse that “redirect” OUD trajectories, both 
positively and negatively. Although becoming a parent is identified as one such critical 
turning point for women, there is a dearth of research that examine the confluence of 
individual, social, and structural factors that constitute critical turning points in opioid use 
trajectories among pregnant and parenting women (Evans,  Li, Grella, Brecht, & Hser, 
2013; Hser, Longshore, & Anglin, 2007; Hser, Evans, Grella, Ling, & Anglin, 2015; 
Jessup et. al., 2014; Reitan, 2018; Teruya & Hser, 2010).  My conceptualization of a 
syndemic lifecourse model of maternal OUD is conceptualized below (Figure 2), and 
includes the clustering and interactions between substance use, mental health 
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comorbidities (e.g. 
PTSD, anxiety, 
depression), and 
violence (structural, 
institutional, and 
interpersonal) that 
occurs throughout the 
lifecourse.  
Significance of the Inquiry and Guiding Research Questions 
The scientific literature consistently identifies higher rates of adverse childhood 
and adult experiences (i.e. sexual and emotional trauma), chronic pain, mental health 
comorbidities, socioeconomic vulnerability, and social stigma among pregnant women 
and mothers with OUD. However, despite substantial increases in funding for individual-
level prevention efforts, such as increased access to MOUD (e.g. Methadone, 
Buprenorphine, naltrexone) and Naloxone (to reverse overdoses), rates of treatment 
retention remain low, women continue to be less likely than men to seek treatment, and 
rates of OUD and opioid-related fatalities continue to rise (Ashley, Marsden & Brady, 
2003; Crandall, Crosby, Gregory, & Carlson, 2003).  
Critical ethnographic research has contributed rich scientific data around the 
threads of violence—structural, symbolic, and every day (Bourgeois 2009; Farmer 1996; 
Scheper-Hughes 1993)—that are interwoven throughout the lives of women with opioid 
and other substances use disorders in the U.S. In particular, Angela Garcia’s (2010) book, 
The Pastoral Clinic: Addiction and Dispossession Along the Rio Grande, examines the 
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violence of intergenerational material, cultural, and geographic dispossession among 
heroin users in the Espanola Valley of New Mexico. Kelly Knight’s (2015) Addicted. 
Pregnant. Poor contains visceral depictions of the structural vulnerability and violence 
inherent to the concurrent temporalities (i.e. biomedical and legal stipulations that 
conflict with the lived experience of sex work and exposure to violence and vulnerability) 
navigated by pregnant and addicted women living and working in low-rent hotels (Knight 
2015). Alison McKim’s (2017) book, Addicted to Rehab: Race, Gender, and Drugs in the 
Era of Mass Incarceration, highlights structural violence as it plays out across divergent 
treatment provided in private versus public substance use treatment programs, and the 
racially stratified policing of addicted women through the medical and criminal justice 
systems. Despite this rich ethnographic work, more qualitative research is needed that 
specifically focuses on opioid use trajectories and treatment patterns among pregnant and 
parenting women (Ashley, Marsden & Brady, 2003; Holbrook, 2015; Martin & 
Finlayson, 2015; Terplan, Kennedy-Hicks & Chisholm, 2015; Torchalla, Linden, 
Strehlau, Neilson & Krausz, 2015).  
My dissertation research responds to the call from Nancy Campbell and Elizabeth 
Ettore to “gender addiction” (2011) by bringing a critical feminist lens to the fore to 
examine the “epistemologies of ignorance” (Tuana, 2006) around notions of “risk” that 
remain “resistant to acknowledging the…power differentials that structure the lives of 
drug-using women” (Campbell & Ettore, 2011, p. 1). Assessing how the role of power 
shapes dominant discourse, and ultimately medical and policy practices, is crucial when 
analyzing OUD among pregnant and parenting women. Building from what Sanders 
(2014) refers to as the “gendered double standard” faced by women with substance use 
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disorders, in this dissertation I characterize the intersecting identities of female, 
pregnant/mother, and substance users as a gendered triple standard. Being held to this 
gendered triple standard intensifies the stigma faced by pregnant and parenting women 
with OUD as they navigate the public health, medical, social service, and legal 
institutions. Furthermore, there is a continued stratification of this gendered triple 
standard along lines of race and ethnicity.  
Although there is a trend away from punitive towards treatment-based approaches 
to OUD, pregnant and parenting women with OUD remain one of the most stigmatized 
groups in society, routinely judged as being unfit to parent and uncaring of their 
child(ren) (Terplan, Kennedy-Hendricks, & Chisolm, 2015). Messaging and discourse 
surrounding OUD in pregnancy shape conceptions of who is deserving of empathy and 
care, with pregnant women expected to adhere to “reproductive asceticism” (Ettorre, 
2009, p. 246) by controlling and managing their bodies according to medical dictates, 
inscribing the notion of “pregnancy as an ethical practice” (Lupton, 2012, p. 4) and 
pregnant woman as having a moral obligation to keep themselves and their growing child 
healthy. According to the collective discourse, pregnant and parenting women with OUD 
not only are harming themselves, but also their reproductive potential, threatening their 
socially prescribed “purpose.” In this way, “motherhood at the margins of social and 
economic life is also fraught with potential failure” (Brown & Bloom, 2009, p. 314). 
This research seeks to locate when and how pregnant and parenting women are 
made either legible or illegible (i.e. are they included or erased?) via the three discursive 
resources that shape cultural narratives and perceptions of perinatal and maternal OUD in 
the U.S. This dissertation examines how gender-specific programming and trauma-
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informed approaches are brought to the fore in an effort to prevent “fetal victimhood” 
(Knight, 2015), while often erasing women who are no longer pregnant, whose children 
are no longer “cute” babies, and those who may have lost custody of their child(ren), 
perhaps permanently. This analysis includes not only the heightened exposure among 
women to physical and sexual violence, but the ways in which policies themselves can 
enact forms of violence on women with OUD. Similarly, this dissertation research 
investigates the gendered intersections between mental health and substance use among 
women. 
Questions guiding this inquiry include: (1) how the broader cultural narrative of 
OUD as originating from access to prescription opioids aligns with micro/individual and 
meso/scientific narratives; (2) how race, racism, and People of Color are featured in the 
context of a “crisis” that is primarily associated with Whiteness; and (3) how the notion 
of a gendered triple standard influences the experiences of opioid use and treatment 
among pregnant women and mothers, and how this notion is further stratified along lines 
of race, place, and poverty. 
Organization of the Dissertation 
As a comprehensive narrative assessment of perinatal and maternal OUD, the specific 
aims of this dissertation are to:  
1) Describe the macro-level (public media), meso-level (scientific), and micro-level 
(individual; (i.e. in-depth interviews) narratives of perinatal and maternal OUD; 
2) Compare each narrative level (e.g. macro, meso, and micro), assessing how they 
confirm, contradict, silence, and position themselves in relation to one another; 
and  
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3) Analyze the intersection of the three discursive resources to inform programmatic 
and policy responses to address OUD among pregnant women and mothers.  
Chapter 1 began by introducing the three discursive resources analyzed throughout 
this dissertation, and continued in presenting meso-level (scientific) narratives of 
perinatal and maternal OUD, as well as the framework shaping these narratives. Chapter 
2 consists of the methodology for the dissertation, beginning by advocating for narrative 
research as an essential component to a critical public health agenda, and ending with a 
discussion of data collection and analyses procedures utilized for data collected for this 
dissertation. Chapters 3, 4, and 5 present the substantive findings from the dissertation 
research. Chapter 3 presents the macro-level (public media) narratives of pregnant 
women and mothers with OUD. Chapters 4 and 5 present micro-level (individual) 
narratives from pregnant women and mothers with OUD, as well as professional 
stakeholders working with this population. Chapter 6 consists of a concluding analysis 
and recommendations for research and practice. 
Chapter 3, “Macro-Level Media Narratives Of Opioid Use Disorder Among 
Pregnant Women And Mothers,” presents analytic findings from a content and discourse 
analysis of meso-level (public media) narratives of perinatal and maternal OUD. This 
chapter illustrates the near absence of media coverage of women with OUD that existed 
until the emergence of a growing concern for neonates and infants impacted by rising 
rates of neonatal opioid withdrawal. Additionally, Chapter 3 illustrates how policy and 
programmatic responses to the current opioid “crisis” both differ and align with historical 
media coverage of crack and methamphetamine use, and the ways in which race and 
socioeconomic status intersects with these representations.  
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Chapter 4, “Micro-Narratives of the Biomedical Management of Perinatal and 
Maternal Opioid Use Disorder,” details the lived experiences of treatment engagement, 
and barriers and facilitators to the holistic care and treatment of perinatal and maternal 
OUD. This chapter begins with a discussion of formal and informal biomedical treatment 
perceptions and practices, examining differences in medication preference, the challenges 
inherent to managing substance use and mental health comorbidities, and exploring what 
drives women to “get off the clinic” and disengage with treatment. Next, this chapter 
explores the influence of the recovery movement and associated discourse on the 
provision and experience of care. Chapter 4 concludes by envisioning what an ethic of 
care and a justice-based approach to treatment for pregnant women and mothers with 
OUD might look like, first by investigating how relapse fits into current systems that treat 
and manage OUD, then by identifying informal systems of care, and finally, by 
examining the factors that yield supportive versus biased care.  
Chapter 5, “Micro-Level Narratives of Trauma Within The Context of the 
Biomedical Management of Maternal Opioid Use Disorder,” broadens current definitions 
of trauma within the substance misuse scholarship to include the violence of policies and 
practices within the legal, medical, and social service systems that pregnant women and 
mothers with OUD interact with on a routine basis. To illustrate, Chapter 5 identifies and 
discusses three forms of institutional violence as experienced by women in this project: 
1) civil commitment to treatment as a form of direct bodily violence, (2) loss of maternal 
status as visceral violence, and (3) institutional erasures as symbolic violence.  
To conclude, in chapter six I discuss the ways in which current strategies to 
address opioid use among pregnant and parenting women impact key at-risk populations 
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(e.g. Women of Color, polysubstance/non-opioid users, and active substance users). I 
then meditate on “spaces of the otherwise” (Povinelli, 2011) by highlighting resistance 
narratives from the women and mothers with OUD that participated in this project. 
Resistance narratives include the ways that women speak against interpersonal trauma 
narratives; they additionally encourage us to reconsider the act of leaving home, families, 
and children while actively using substances not as abandonment, but as a practice of 
protection and care. Chapter six closes with key implications and specific 
recommendations for the field of substance use treatment for pregnant women and 
mothers, grounded in findings from an examination of the intersections of each of the 
three narrative levels presented throughout this dissertation research. 
 
A Closing Note on Language 
 Throughout the dissertation, I refer to “opioids,” “opioid use,” and the “opioid 
crisis” broadly, primarily for the sake of clarity. When used in this manner, I am using an 
umbrella term that encompasses the use of heroin, fentanyl, and non-medical use of 
prescription opioids (e.g. oxycodone [OxyContin®, Percocet®] and hydrocodone 
[Vicodin®]). I am acutely aware that reference to “opioids,” “heroin,” “Fentanyl,” “non-
medical use of prescription opioids,” and “accidental overdose” can be a strategic 
application of racist, sexist, and classist discourses. When I am analyzing these elements 
(i.e. issues of race, class, sex, and gender roles) that are key to a critical understanding of 
the current state of opioid use and misuse in the United States, I will pointedly distinguish 
between the type of opioid used and how demographic and use patterns are used 
strategically to categorize and deploy narratives that simultaneously prioritize and ignore 
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particular social groups in a response that is not derived from science, but which drives 
current responses to the opioid crisis.    
Throughout research that took me to multiple presentations, conferences, 
meetings, and symposia, and in and out of various clinical and community-based 
treatment settings, pregnant and parenting people that identify as transgender, queer, or 
non-binary (or anywhere across the LGBTQIA+ spectrum) were a noticeably absent 
population both in body and reference. For me, this stands out as a critical finding that is 
essential to explore in future research, but one which was regrettably beyond the scope of 
this dissertation research.  
A related and final note is about the use of the term “pregnant and parenting 
women.” I am similarly aware that people who identify as men can be mothers, and that 
not all people identify with the gender labels man or woman. In this research, “pregnant 
and parenting women” specifically constitutes cis-gendered women who personally 
identify with the term “pregnant woman or mother.” I alternately use the terminology 
“pregnant women and mothers with opioid use disorders” and “women with perinatal or 
maternal opioid use disorders” throughout this dissertation. The intention of this phrasing 
is to acknowledge that many of the mothers interviewed in this project had lost custody 
of their children, some temporarily and some permanently. While this loss of custody 
strips mothers of their maternal status and rights in the eyes of the state, it is essential to 
continue to recognize them as mothers. Because they are.   
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CHAPTER 2 
METHODOLOGY AND CONTEXT 
 
Chapter Overview 
On telling her mother that she was working on this project, one of the student 
research assistants working with me relayed that her mother’s first response was a 
comment about the association between the over-prescription of opioids and OUD. 
Having already transcribed the life history interviews I had conducted with mothers with 
OUD, the research assistant responded to her mother by reporting some of the standout 
patterns from the data: that a traumatic event was likely to precede problematic opioid 
use, that many participants had a prior history of problematic alcohol or other substance 
use before misusing opioids, and that few participants were ever legitimately prescribed 
opioids. Regardless, the message about the link between OUD and prescription opioids 
remains firmly entrenched, with a particular focus on blaming pharmaceutical companies. 
This is the focus of recent non-fiction bestsellers, including: Dreamland: The True Tale 
of America’s Opiate Epidemic (Quinones, 2015), Drug Dealer, MD: How Doctors Were 
Duped, How Patients Got Hooked, and Why It’s So Hard to Quit (Lembke, 2016), 
Dopesick: Dealers, Doctors, and the Drug Company that Addicted America (Macy, 
2018), American Overdose: the Opioid Tragedy in Three Acts (McGreal, 2018), Pain 
Killer: An Empire of Deceit and the Origins of America’s Opioid Epidemic (Meier, 
2018), and Cherry (Walker, 2018).  
At least in 2018, the sustained focus on “Big Pharma” obscures an immediate 
reality that the current “opioid crisis” is about heroin and fentanyl, and no longer 
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prescribed opioids. This also means that factors such as exposure to myriad traumas are 
often overlooked. This is not to say that prescription-monitoring programs and critical 
assessments around the liberal use of opioids as a first response to the management of 
pain are not essential. Take for example, Kirsten1 and Kathleen, both patients of Dr. O, a 
local physician who lost his license for running a rogue pain clinic in Springfield, MA, 
one of the locations of this project. Because the clinic could be reimbursed at higher rates 
for cortisone shots versus standard maintenance and medication prescription visits, Dr. 
O’s patients received a cortisone injection each time they wanted to refill a prescription. 
Kirsten was getting monthly cortisone injections and was forced out of the practice when 
she asked to stop the injections and be weaned off pain medications. In her words:  
you're only supposed to get [cortisone shots] four times a year, and you were 
getting them every month. You wouldn't get a prescription unless you got the 
injection. Your appointment would be at eight in the morning and you'd still be 
sitting in his office at 2pm waiting in the waiting room to have your appointment. 
He'd prescribe you fentanyl lollipops and Ativan for before the injection to keep 
you sedated.  
 
Because they hurt, I asked? “They're awful, awful. Yeah it was pretty bad,” Kirsten 
confirmed. Within six months of entering Dr. O’s care, Kirsten was “on 30 milligrams of 
Percocet’s four times a day plus my choice of fentanyl patches, morphine, oxycontin, or 
methadone for long term. Every time I saw him I would switch it up… because I wasn't 
getting high enough [and] I wanted to try something different.” In 2009, Dr. O entered 
into a “Voluntary Agreement Not to Practice” with the Massachusetts Board of Medicine 
(Mass.gov, 2017). A quick Google search identifies the Springfield practice as 
permanently closed, and Dr. O as a currently licensed by the New York State Board of 
Medicine and practicing in that state instead.   
 
1 Pseudonyms used for all participant and organization names 
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While this example is undoubtedly distressing and unfortunately not an outlier, 
restricting access to prescription opioids is not a silver bullet solution for addressing the 
rising rates of OUD and opioid-related fatalities. Of note are the limited number of 
studies that draw definitive links between the medically advised use of prescription 
opioids and OUD. Further, findings are mixed as to the efficacy of prescription-drug 
monitoring programs on rates of opioid fatalities (Finley, Garcia, Rosen, McGeary, Pugh, 
& Potter, 2017). A rising wave of media focus has increasingly turned to focus on 
individuals who rely on opioid maintenance therapy to manage chronic and/or terminally 
induced pain without developing OUD, and who are now facing barriers to accessing 
medication and suffering from unmanaged pain as a result. Public perceptions of this 
emergent “crisis” are best illustrated by a New York Post Op-Ed, entitled “The Insane 
Crackdown on Pain Medication” (McCaughey, May 2018).  
Importantly, a myopic focus on over prescription of pain meds overlooks rising 
rates of “deaths of despair” (i.e. an overall decline in psychosocial health, as evidenced 
by increased rates of trauma, suicide, substance use, and substance use related 
morbidities; Auerbach & Miller, 2018) and the myriad factors that influence substance 
use trajectories outside of access to prescription opioids. In the case of Kirsten, during her 
life history interview she detailed living with her aunt and uncle at age 12 while her 
mother was in a treatment program for alcoholism. Near the end of her interview, she 
added that her mother struggled with cocaine use throughout Kirsten’s childhood. Kirsten 
remembered being 12 years old, “sitting in our living room and [my mom] sleeping and 
her nose just starting to run with blood.” Kirsten’s own problematic cocaine and alcohol 
use began at age 15, long before she entered the pain clinic and became addicted to 
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opioids. While her story is unique, as are all of those of women I interviewed in this 
study, every story is united by the experiences of interpersonal and structural trauma, 
which preceded problematic opioid use patterns. The contextual details of each woman’s 
story, however, are lost in a near singular focus on the crude etiology of the problem—
mode of substance acquisition— as well as in public health strategies that narrowly focus 
on increased access to medication as the solution. 
 In this chapter, I review the methodological context and approach used in the 
study. Specifically, I advocate for a narrative research approach to promote a critical 
public health agenda. I begin by theoretically grounding my narrative research approach 
to examine various inquiry paradigms as they shape my methodology. Next, I detail the 
data collection and procedures and analytical approach I have used for the three 
discursive resources (macro [public media], meso [scientific], and micro [individual]) 
included in this dissertation. The chapter concludes with reflections on ethical 
considerations in narrative research, and questions to consider for a justice-based research 
approach. 
 
How Does Theory Inform Practice? 
Methods that overlook lived experience, local knowledge and subjectivities do not 
push the field of public health closer towards a more nuanced understanding of critical 
moments across the substance use continuum. As a contrast, engaged, narrative 
approaches are useful for getting at participants’ own understanding of substance use, 
thereby enriching understanding of the complexities of OUD. To illustrate the point, 
consider treatment recommendations that often determine medical pharmacotherapy by 
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mode of consumption: methadone (daily clinical visits at a methadone clinic) for needle 
injection of heroin (illicit), and buprenorphine (take home dosages, prescriptions written 
in the privacy of a physicians’ office) for pill consumption of OxyContin (licit) 
(Holbrook, 2015; Krans et al., 2016). Findings from multivariate logistic regression 
analyses that assess predictors of methadone versus buprenorphine use among 
approximately 800 pregnant women mirror trends from the general population: women 
being treated with buprenorphine are more likely to be older, married, have higher SES 
and education, and a history of licit opioid use, contrasted to women receiving methadone 
who are more likely to have co-occurring Hepatitis C infection, a partner with a history of 
substance use, loss of custody of child(ren), history of illicit opioid use, and concomitant 
use of cocaine, marijuana, and benzodiazepines (Krans et al., 2016). It is this data that 
painted differing profiles of the licit versus illicit opioid user, which was then used as a 
basis to determine which medication aligns with which profile.  
Assuming trends in data mirror “objective truth,” the differentiation between 
prescribing methadone versus buprenorphine to injection or prescription opioid users was 
at face value a valid policy. However, a deeper look at the data behind this logic reveals 
this: historically, methadone has been primarily funded by public sources (i.e. Medicaid), 
whereas buprenorphine (until recently) has been funded by private sources (Holbrook, 
2015; Hser, 2015). Admittedly, this trend is shifting towards broadened and 
individualized treatment protocols, but this practice was standard until relatively recently, 
and remains important to investigate. There remain a dearth of studies that comparatively 
assess MOUD efficacy; additionally, there are no studies which explore patient predictors 
of comparative MOUD success (Blanco & Volkow, 2019; Holbrook, 2015; Nunes, 
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Krupitsky, Ling, Zummo, Memisoglu, Silverman, & Gastfriend, 2015). This point should 
compel researchers and practitioners to consider the implications of policies that are 
based on public perceptions of morality versus science, particularly in the case of 
perinatal and maternal OUD. Furthermore, limiting treatment options based on such 
findings is not in keeping with core ethical tenets of public health practice: active 
promotion of beneficence (and avoidance of maleficence), autonomy, and social justice 
(Bensley & Brookins-Fisher, 2009).  
 
Research Paradigms in Public Health 
The historical practice of limiting treatment protocols for opioid 
pharmacotherapies are just one example in which the social nature of “truth” as 
ascertained through a positivist/post-positivist lens can be unintentionally misguided and 
harmful. As an important compliment, a humanistic research paradigm can enrich 
findings to develop effective and just public health interventions. To achieve this goal, it 
is crucial to choose methods that can elicit interpretations of, and experiences with, 
perinatal and maternal OUD, as well as the range of contingencies that influence opioid 
use practices. Humanistic methods present an important opportunity to make meaning out 
of these transitional moments, and can guide research and intervention in a health 
positive direction. 
 A paradigm “represents a worldview that defines, for its holder, the nature of the 
‘world,’ the individual's place in it, and the range of possible relationships to that world 
and its parts” (Guba & Lincoln, 1994, p.107). As such, inquiry paradigms are the 
umbrella which encompass the ontological (i.e. what is the nature of reality and what can 
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be known about it), epistemological (i.e. what is the relationship between researcher and 
participant, or what can be known?), and methodological (i.e. what research application 
should be used to address both ontological and epistemological questions?) foundations 
of any researcher’s motivations (Creswell, 2007; Guba & Lincoln, 2005). Following the 
identification of a research paradigm, strategies “of inquiry put paradigms of 
interpretation into motion” (Denzin & Lincoln, 2011, p. 36). Three research paradigms 
are pertinent to the selection of methods with which to examine maternal OUD: 
positivist/post-positivist, constructivist, and critical.   
The positivist paradigm emerged as social scientists sought to replicate 
biological/biomedical science research in social contexts. Using this framework, social 
reality was conceived as singular, a priori (determined by theory, not observation), and 
objective. As such, quantification was paramount, with a goal of identifying cause and 
effect as determined by deductive theories—either confirmed or produced—and 
researchers sought to maintain a strict separation between themselves and their “subjects” 
(purposeful word choice, given the paradigm). Ultimately, the focus of the positivist 
approach in social sciences is to predict and control behavior, as well as to test and 
generate hypotheses. Under this paradigm, methodologies are likely to be quantitative 
(Denzin & Lincoln, 2005; Lindloff & Taylor, 2011; Zoller & Dutta, 2008).  
Whereas a positivist paradigm perceives truth or reality as something to be 
“captured” and understood through study, a post-positivist paradigm posits that 
reality/truth can be never be completely “captured,” but can be approximated. Contrasted 
to positivism, which seeks to verify, post-positivist methods seek to falsify (Guba & 
Lincoln, 2005). Within this paradigm, identification and prediction of the causal patterns 
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of phenomena under study remain the goal, while acknowledging that “reality” and 
“truth” can only ever be approximated. As such, multiple methods are used to achieve 
triangulation in an attempt to capture this approximation (Denzin & Lincoln, 2005; 
Lindloff & Taylor, 2011). While post-positivist researchers may use qualitative methods, 
they are typically used to inform subsequent quantitative methodologies and are held up 
to the same criteria as quantitative data in a quest for validity (Charmaz, 2014; Denzin & 
Lincoln, 2005; Lindloff & Taylor, 2011; Zoller & Dutta, 2008). 
Positivist/post-positivist methods have contributed much to the field of public 
health. For example, in the context of OUD, positivist/post-positivist methods have 
identified a cause and effect relationships of opioids on individual biology (e.g. opioid 
use can inhibit the uptake of dopamine, becoming more pronounced over time), as well as 
critical associations between exposures such as trauma on substance use uptake and 
treatment outcomes. What these methods cannot tell us, however, are the nuanced factors 
that are intertwined with decision-making, action, and experience. Under the 
positivist/post-positivist paradigm, in the quest for replicability, uniformity, prediction, 
and generalizability, outliers are primarily excluded since they are considered to be 
unrepresentative, weak correlates (Buchanan, 1992). Yet by discounting outliers we are 
thus confirming a belief in the lack of complexity of lived experience (Buchanan, 1992; 
Charmaz, 2014). Positivist/post-positivist methods therefore remain limited in their 
ability to elicit a “deeper understanding of circumstances that help to explain why and 
how people make the decisions that they do” (Ulin, Robinson, & Tolley, 2005, p. 17). 
The goal of constructivist research is to “illuminate how humans use cultural 
symbol systems to create and share meanings for their existence and activities” (Lindloff 
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& Taylor, 2011, p.9), while relying heavily on the use of narratives to provide “thick” 
descriptions of context, phenomena, and both individual and collective perceptions 
(Geertz, 1985; Lindloff & Taylor, 2011; Schwandt, 1994; Zoller & Dutta, 2008). 
Constructivist research assumes an interdependence between researcher and subject, with 
findings produced as the result of a dialogic process between investigator and interlocutor 
(i.e. the co-construction of knowledge). As such, an understanding of the phenomena 
under inquiry is equally as important as understanding the context of research 
participants. (Schwandt, 1994). In understanding this context, the researcher is called 
upon to simultaneously and critically assess the positionality and biases they bring to the 
research dynamic that directly influence this co-construction of knowledge. 
A goal of constructivist research is to promote “conversation amongst a plurality 
of voices, without assuming there is common ground prior to the conversation” (Baert & 
Rubio, 2007, p. 71), and by comparing and contrasting findings through dialogue (Guba 
& Lincoln, 1994, p.111). This “ethic of dialogue” seeks to “transform biases” (Lindloff & 
Taylor, 2011, p. 36). This is particularly important when seeking to untangle social 
constructions of reality that have become “cumulatively embedded in formal institutions” 
over time (Lindloff & Taylor, 2011, p. 45), as is the hallmark of structural and 
institutional violence. 
At their root, critical theories seek to examine systems of power, pinpointing and 
questioning how those systems reinforce inequities (Delgado & Stefanic, 2012; Lindloff 
& Taylor, 2011). As with a constructivist paradigm, reality is understood to be subjective, 
yet simultaneously shaped by a broad range of social and political economic factors that 
have over time become “crystallized (reified) into a series of structures that are now 
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(inappropriately) taken as ‘real’…, a historical and virtual reality” (Guba & Lincoln, 
1994, p. 110). The goal then, is for critical research to promote “equitable participation in 
health discourse and practice, and advocate for change in problematic social structures 
and relationships of power” (Zoller & Dutta, 2008, p. 15).   
 As with constructivist methodologies, the critical researcher and participant are 
assumed to be linked, and directly influenced by the values and assumptions that both 
bring to the co-construction of knowledge and experience (Guba & Lincoln, 2005; 
Lindloff & Taylor, 2011). In keeping with this paradigm, dialogic methods are used, 
wherein knowledge is co-created through an interactive process between participant(s) 
and researcher(s). A goal of this dialogic interaction is to identify how “structures might 
be changed, and comprehending the actions required to effect change” (Guba & Lincoln, 
1994, p.110). Evaluation criteria for critical research focuses more on praxis—taking that 
“transformative intellectual” knowing into action that yields social change (Freire, 1970; 
Guba & Lincoln, 1994, p.110).   
Narrative health promotion refers to a broad methodological approach that 
expands beyond a personal tale; it encompasses storytelling, narrative data (e.g. text, 
newspapers, and scientific reports), and narrative analysis (Riessman, 2008). The 
“narrative turn” was shaped by critiques of positivism/post-positivism, the increasing 
popularity of memoirs, an increase in identity movements (i.e. liberation movements led 
by historically marginalized populations), and an increased cultural acceptance of 
“therapeutic culture” (Riessman, 2008). Storytelling methods are wide ranging and can 
include: autobiography, biography, ethnography, interviews, life histories, oral histories, 
testimonios (Chase, 2005; Creswell, 2007), and digital stories.  
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It is through the narrative process of “retrospective meaning making” (Lindloff & 
Taylor, 2011, p. 181) that individuals identify turning points and transitions, make 
meaning out of those moments, and then use that meaning to formulate next steps 
(McAdams, Josselson, & Lieblich, 2001). Of note is that by nature, narrative is a dialogic 
process that is shaped, and is shaped by, interaction with story listeners. Engaging in the 
process of storytelling and listening “enables people to make their experiences intelligible 
to each other” (Lindloff & Taylor, 2011, p. 181). The process of constructing a coherent 
narrative (written or otherwise) has been noted to give individuals a sense of control over 
their health or experience that enables them to create goals for the future, resulting in 
improved overall health (Pennebaker & Seagal, 1999; Pennebaker, 2000; Sharf & 
Vanderford, 2003). Notable benefits of the process of creating personal narratives include 
an increased sense of self-efficacy and social support (Bosticco & Thompson, 2008; 
Pennebaker, 1993), positive impacts on physical and mental health, and helping to reduce 
illness-related symptoms and improve physical functioning (Hinyard & Kreuter, 2007; 
Leukefeld, Godlaski, Clark, Brown, & Hays, 2002).  
 
Intersecting Narratives of Health: A Humanistic Perspective 
This research seeks to examine the macro (public media)-, meso (scientific)-, and 
micro (individual)- level narratives around OUD that are continuously operating in 
conjunction with each other, reinforcing or resisting each other in ways that affect 
collective notions of optimal health (Sharf, Harter, Yamasaki, & Haidet, 2011). Drawing 
from both critical and constructivist perspectives, this research employs a humanistic lens 
to investigate the three intersecting narratives of perinatal and maternal OUD (macro, 
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meso, and micro). Research goals when employing a humanistic lens in health are 
fivefold: (1) the processes underlying peoples’ motivations; (2) the engaged process of 
sense-making, or the social construction of reality; (3) sensitization, foregrounding the 
multiple factors that influence health as a means to promote empathy and understanding; 
(4) critique— questioning and confronting social norms and the status quo; and (5) 
mobilization and social change (Buchanan, 1998; Riessman, 2008).  
Humanistic perspectives (Buchanan, 1992) recognize that people are experts of 
their own experience and prioritize dialogue about perception and experience as the best 
way to support, promote, and achieve agency and well-being. As such, a humanistic 
perspective functions as a “site of discourse” (Denzin & Lincoln, 2005, p.6) by 
questioning strict reliance on “evidence-based” modalities and approaches and looking to 
both the humanities and social sciences to prompt critical conversations and research 
questions that integrate democracy, globalization, identity, and justice (Denzin & 
Lincoln, 2005). The broad goal of this type of research is dialogue, not only between 
researchers, community members, and participants, but also a larger, inclusive public 
discussion that is not simply seeking perpetual confirmation, but rather promoting new 
thoughts, ideas, and action (Buchanan, 1998). The end goal is to promote justice-based 
discourse, programs, and interventions. As such, the role of a narrative researcher 
becomes that of a bricoleur, someone who can recognize the components of their own 
identity, how those relate to the intersectionalities of participants, and see research as a 
power-laden endeavor, informing the process of creating a bricolage— a “pieced together 
set of representations that are fitted to the specifics of a complex situation,” which 
connect the parts to a larger whole (Denzin & Lincoln, 2005, p.5).   
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Macro, meso, and micro-level narratives pervade all aspects of population-based 
healthcare and public health—from individual sense-making about health and wellness to 
patient-provider communication, health messaging, the development and use of health 
literacy materials, the conveyance of social norms, social and political advocacy, and 
community mobilization efforts (Charon, 2006; Harter, Japp, & Beck, 2005; Schiavo, 
2007; Yamasaki, Geist-Martin, & Sharf, 2016). Narrative health promotion can currently 
be viewed as having two perspectives with distinct foci: (1) message-based approaches to 
health communication, or the creation and use of effective messaging to achieve 
behavioral change (i.e. “how can we get more pregnant women to utilize MOUD”) and 
(2) process-based approaches to health communication, which focus on how meanings of 
health are “constituted, interpreted, and circulated” (Dutta & Zoller, 2008, p.4) (i.e. “what 
are perceptions of maternal OUD and how do these relate to locally situated cultural 
norms and structural constraints?"). It is this second, process-based approach with which 
this research is aligned.  
 
Data Collection  
Data collected for this dissertation consisted of three discursive resources that 
shape cultural narratives of perinatal and maternal OUD: (1) macro-level (public media) 
narratives, which included reports of the “opioid crisis,” including a historical analysis of 
national media coverage of maternal opioid use from 2005-2018; (2) meso-level 
(scientific) narratives, which included peer-reviewed scientific reports of OUD among 
pregnant women and women from 2000-2018; and (3) micro-level (ethnographic, 
individual-level data) narratives, including: life history interviews with mothers in 
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recovery; in-depth interviews with physicians, clinicians, social workers, and staff at 
community-based organizations; sociodemographic surveys from mothers; and 
participant observation field notes written in and around two digital storytelling projects 
with mothers in recovery, as well as local and regional policy and public health meetings 
convened around treatment strategies for perinatal and maternal OUD.   
 
Macro-Level (News Media) Narratives 
 A goal of the media analysis was to compare historically print based news 
coverage of OUD among pregnant and parenting women across politically divergent 
news sources. The rationale for print versus cable news sources was to allow for a 
historical analysis, made possible via the institutional archives at the University of 
Massachusetts Amherst. Sources included in the media analysis were determined by self-
reported political ideology: The New York Times (liberal), the Washington Post (liberal), 
the Wall Street Journal (conservative-leaning), the Christian Science Monitor (centrist), 
and the Economist (“radical centrist”). 
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At the time of this writing the most recently available data identifies three notable 
waves in opioid-related 
fatalities from 1999-
2017. The first, from 
1999-2009, wherein the 
bulk of overdoses were 
attributed to 
prescription opioids; 
the second, from 2010-
2012, wherein most 
overdose deaths were attributed to heroin; and the third from 2013-2017 (and continuing 
beyond the time of this writing) where the bulk of opioid-related fatalities involve 
synthetic opioids, particularly illicitly manufactured fentanyl (Figure 3; CDC, 2019).  
 The original time parameter for the search was 2000-2018. Rates between 1999 
and 2000 showed little variation, and collecting news reports into 2018 allowed for the 
most current analysis possible. Using the database LexisNexis Uni, the initial search 
included all articles from The New York Times, the Washington Post, the Wall Street 
Journal, the Christian Science Monitor, and the Economist from 2000-2018. Search 
terms included: (women OR mothers OR children OR neonatal abstinence syndrome OR 
neonatal withdrawal syndrome) AND (heroin OR opioids OR opiates OR fentanyl OR 
methadone OR suboxone OR buprenorphine). This initial search yielded 5,738 articles. 
Figure 3. Three Waves of the Opioid Epidemic: 1999-2017 (CDC, 2019) 
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Non-probability convenience sampling was used to reduce the final sample size. 
Based on available population-level data, three spikes in overall opioid-related fatalities 
were identified: 2006, 
2011, and 2017 (Figure 4). 
Based on best practice 
methodology for media 
analyses, the year 
preceding and following 
each spike was included, to 
incorporate comprehensive 
social context (Macnamara, 
2005). The final time parameters for the search were: (1) January 1, 2005- December 31, 
2007, (2) January 1, 2010- December 31, 2012), and (3) July 1, 2015- June 30, 2018). 
Using these restricted time parameters yielded 3,885 articles. 
 Abstracts of the 3,885 articles were reviewed to ensure that content centered on 
pregnant and parenting women with opioid use disorder. Exclusion criteria included 
articles that were about women who were neither pregnant nor parenting, articles that 
were film or book reviews, articles that were not about the United States, and articles that 
discussed pregnant and parenting women using non-opioids (e.g. cocaine or 
methamphetamines). All duplicate articles were removed (i.e. if the same article was 
listed from a print source and a web-based source). After applying exclusion and 
inclusion criteria the final sample included 121 public media articles. 
 
Figure 4. Three Peaks in the Opioid Epidemic: 1999-2017 (CDC, 2019) 
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Meso-Level (Scientific) Narratives 
 At the meso-level, I examined the peer-reviewed, scientific literature on opioid 
use disorder and treatment among pregnant women and mothers. Although there are data 
that specifically examine and define perinatal and postpartum OUD, maternal OUD is not 
a standardized category. Therefore, the scientific literature for this analysis includes 
reports on perinatal and postpartum OUD, as well as OUD among women broadly.   
Using the databases PubMed and PsychINFO, I included peer-reviewed journal 
articles on OUD among women (perinatal, postpartum, maternal, and women broadly), 
with a restricted publication date range of January 1, 2000 through December 31, 2018. 
The start date of 2000 aligns with the rationale for media narratives. To assess temporal 
trends, I separated the 18-year period into three search periods of six years each: (1) 
January 1, 2000 to December 31, 2005, (2) January 1, 2006 to December 31, 2011, and 
(3) January 1, 2012 to December 31, 2018. Search terms included “(women OR pregnant) 
AND (opioids OR heroin OR fentanyl).” To ensure a comprehensive final sample, the 
following additional search terms were used to identify additional articles: “(women OR 
pregnant) AND (opioids OR heroin OR fentanyl) AND trauma,” “(women OR pregnant) 
AND (opioids OR heroin OR fentanyl) AND childhood adversity,” “women OR 
pregnant) AND (opioids OR heroin 
OR fentanyl) AND mental health,” 
“(women OR pregnant) AND 
(opioids OR heroin OR fentanyl) 
AND (methadone OR buprenorphine 
OR naltrexone OR medication-
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assisted treatment).” The initial search from January 1, 2000 to December 31, 2006 
yielded 892 articles; January 1, 2006 to December 31, 2011 yielded 1,235; and January 1, 
2012 to December 31, 2018 yielded 1,990; for a total initial sample of 4,117 articles. 
After applying inclusion and exclusion criteria (see Figure 5), my final sample consisted 
of 197 peer-reviewed journal 
articles (37 from January 1, 
2000 to December 31, 2005; 64 
from January 1, 2006 to 
December 31, 2011; and 96 
from January 1, 2012 to 
December 31, 2018; see Figure 
6). Incarcerated populations and 
veterans were excluded given 
their population-specific risks 
and needs.  
 
Micro-Level (Individual) Narratives 
Situating the Project Locally 
Rates of opioid related fatalities in Massachusetts (MA) are substantially higher 
than overall U.S. rates (Figure 7). Massachusetts has instituted considerably progressive 
opioid-related policies, including expanding access to naloxone (opioid overdose reversal 
pharmacotherapy) via first responders, prioritizing treatment access for pregnant women, 
and integrating rooming-in programs for newborns and mothers within a clinical setting 
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to reduce symptoms associated with neonatal opioid withdrawal syndrome (MA 
Department of Public Health, 2018). MA additionally has created nationally recognized 
systems and processes to prepare women for the inevitability of having a report filed with 
the Department of 
Children and Family 
(DCF) upon birth and 
delivery, as per Child 
Abuse Prevention and 
Treatment Act 
legislation 
(DCF, 2019). 
Massachusetts is one 
of the few states that has seen a reduction in fatal opioid overdoses in the past year (MA 
Department of Public Health, 2018).  
 This project was conducted across two counties in the Western region of MA: 
Franklin and Hampden. Out of the 14 counties in MA, both Franklin County and 
Hampden Counties rank high in poverty rates (12th and 14th respectively). Classified as 
rural, Franklin County is one of the least populated counties in MA (approximately 
70,000 residents as of 2017). Franklin County is predominantly white; 91% of the 
population is non-Hispanic White, 4% Latinx, 1.5% Black or African American. 
Approximately 10% of the population lives below the poverty line. From 2013-2017 the 
per capita income in Franklin County was $33,000, 93% of people older than 25 had a 
high school diploma and 37% had a Bachelor’s degree or higher. Interviews and 
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ethnographic data collected in Franklin County included the city of Greenfield and towns 
of Orange and Turners Falls, all of which have some of the highest poverty rates in the 32 
cities, towns, and villages (census-designated places, or CDPs) that constitute Franklin 
County. Per capita incomes in Greenfield, Orange, and Turners Falls are $30,000, 
$23,000, and $22,000 respectively.  
In contrast, Hampden County is classified as a small urban region (estimated 
population in 2017 was 470,000). Hampden County is more racially diverse that Franklin 
County, with approximately 63% of the population non-Hispanic white, 25% Latinx, and 
11% Black or African American. Twenty-five percent of households speak a language 
other than English. Approximately 17% of the population lives below the poverty line. 
From 2013-2017, the per capita income was $28,000, 85% of people older than 25 had a 
high school diploma, and 27% had a Bachelor’s degree or higher (U.S. Census Bureau, 
2018). Interviews and ethnographic data were conducted in Chicopee, Holyoke and 
Springfield, which rank as cities, towns, and villages (census-designated places, or CDPs) 
with the poorest economic profiles in Hampden County. Per capita incomes and percent 
population living in poverty for Chicopee, Holyoke and Springfield is $26,000 (14% in 
poverty), $23,000 (29% in poverty), and $20,000 (29% in poverty) respectively (U.S. 
Census Bureau, 2018). Hampden County ranks in the top quartile of most racially 
segregated metropolitan areas in the U.S. (Partners for a Healthier Community, 2016). 
As a research endeavor that is taking a critical public health perspective, the 
decision to conduct this project in both Franklin and Hampden Counties was specifically 
driven by their distinct demographic profiles, as well as my own observations during my 
preliminary data collection, during which much of the discourse centered on whiteness, 
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rurality, and poverty. The graph below (Figure 8) draws attention to the notable 
difference in opioid-related fatalities in these racially divergent counties. Yet more often 
than not, opioid discourse in MA continues to center whiteness. Figure 8 presents raw 
counts. However, an embodied approach requires us to consider body counts, to truly 
make “bodies count” (Krieger & 
Smith, 2004, p.92).  
The “opioid epidemic 
doesn’t discriminate” was a 
phrase that constantly echoed 
throughout this project, repeated 
across the media, in state reports, 
on websites, in interviews, at 
meetings and conferences, and in 
my personal social media newsfeed and conversations. As I argue in my dissertation, our 
public health responses to OUD remain discriminate. The phrase “the opioid epidemic 
doesn’t discriminate” is closely aligned with notions of colorblind liberalism, which 
promotes a collective sense that race is not “a central factor in determining the life 
chances of Americans” (Bonilla-Silva & Dietrich, 2011, p. 190). Racism remains 
embedded in U.S. society. Colorblind liberalism functions to deny the existence of White 
privilege and perpetuates silencing of the institutional nature of racism (Peterson, 
Gubrium, & Fiddian-Green, 2018) that directly influences perinatal and maternal OUD 
outcomes. A perfect example is the counter chant of “All Lives Matter” that arose in 
direct response to the Black Lives Matter movement. The cultural perception was that 
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somehow a public movement highlighting the structural and interpersonal violence 
experienced by People of Color on a daily basis in the U.S implied that White lives were 
no longer of import. Which is not the case. Every death of course matters; every life 
matters. A critical 
public health 
endeavor must then 
examine and ensure 
that this is indeed 
the case. Figure 9 
provides a 
breakdown of 
opioid fatalities in 
MA by race and ethnicity, providing the overall U.S rate as a point of comparison. Of 
note is the dramatic rise in opioid-related fatalities among Latinx populations in 
Massachusetts. Although this data ends in 2016, in Massachusetts opioid-related fatalities 
for 2018 have levelled; among Latinx and African-American populations they continue to 
rise, and rates among Latinx populations are nearly identical to those among Whites.  
Ethnographic Data Collection 
The ethnographic data in this dissertation builds on findings from my preliminary 
research, which consisted of me co-facilitating two digital storytelling projects in 
Greenfield with mothers in recovery from OUD. In one workshop, digital storytelling 
participants were volunteers from Moms Supporting Moms, an organization of peer 
mentors (women with lived experience of perinatal substance use, self-identified as being 
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in recovery) who provided support to newly pregnant women with OUD as they 
navigated the health, legal, and social service systems (Paterno, Fiddian-Green, & 
Gubrium, 2018). In the second workshop, participants were women self-identified as 
being in recovery from OUD, who had children under the age of 12 months. Although I 
was familiar with the scientific literature on this population, prior to participating in the 
two digital storytelling workshops I was not familiar with the lived experience of 
pregnant women and mothers with OUD. Participating in the preliminary data collection 
activities therefore provided important insight that helped me develop interview questions 
and to preemptively identify potential ethical concerns. 
 In this project, I employed an ethnographic approach. I wrote field notes during 
public meetings, symposia, lectures, and conferences convened around perinatal and 
postpartum opioid use disorder from March 2017 through September 2018, as well as 
during the two (preliminary research) digital storytelling projects. In addition, I wrote 
field notes after each interview. Guided by Emerson, Fretz, & Shaw (1995), my field 
notes aimed to capture the depth of events and identify and detail the processes observed, 
from the perspective of both the researcher as well as characterizations of participants 
themselves, when applicable. My field notes also captured participant explanations and 
theories of events; elements related to interview locations (e.g. homes, clinical sites, 
recovery centers, residential recovery facilities), as well as context not captured in 
verbatim renditions of interview transcript. Finally, given the humanistic framework of 
my dissertation, field notes were used to identify structural and social impediments that 
both facilitate and constrain agency (Silverman, 2005).   
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In-Depth Interviews 
A total of 30 semi-structured, in-depth interviews were conducted with twenty 
(n=20) women with a history of opioid use and other substance use disorders and 
treatment, and ten (n=10) medical, public health, and social service professional 
stakeholders affiliated with organizations that develop policies and provide services to 
pregnant and parenting women with a history of opioid use and misuse. Basic 
sociodemographic information was collected from women in treatment/recovery 
to characterize the sample. All interview participants were compensated $20 cash, which 
constituted an hourly living wage in the region. Some professional stakeholders declined 
compensation. All participants were asked to give permission to record interviews; one 
interviewee declined. The remaining 29 interviews were audio recorded, and transcribed 
verbatim by a trained research team member. Interviews were conducted in a range of 
locations throughout Western MA, where participants were most comfortable doing so, 
including: professional and clinical offices, women-only residential recovery facilities, 
participants’ homes, and coffee shops. Because I conducted all of the interviews alone, I 
instituted a practice of texting my time, location, and expected time of completion to a 
colleague or friend, and texting again once I was in my car and finished. All study 
protocols were approved by the Institutional Review Board (IRB) of the University of 
Massachusetts Amherst. 
Women in recovery were recruited from contacts made during my preliminary 
research phase, via word-of-mouth, and through snowball sampling. Because the role of 
digital storytelling co-facilitator requires close listening to participants, each DST 
workshop allowed for relationship building and the development of trust with Katie, who 
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later assisted with word-of-mouth participant recruitment in Franklin County. 
Additionally, Katie agreed to pilot test the interview guide. To do this, I interviewed her 
using a draft interview guide I had developed. At the conclusion of the interview, we 
discussed potential limitations of the draft interview guide, and collaboratively made 
minor revisions to incorporate for the final interview guide. Work on a third DST project 
(though focused on perinatal depression and not OUD) during the active data collection 
phase resulted in relationship building with LaTonya, a staff member at a community-
based organization in Springfield (Hampden County), who further assisted with 
recruitment by connecting me to Kathleen, a recovery coach (i.e. peer mentor) who then 
introduced me to some of her clients. In each instance, participants or staff members 
involved with the DST workshops functioned as “gate-keepers” for their respective 
communities—gaining their trust was integral to participant recruitment. Each gate-
keeper then shared flyers and contact information with potential participants, who  
contacted me. Remaining women were recruited via word-of-mouth from subsequent 
interviewees. Eight of the twenty women interviewed lived in Franklin County, and 12 of 
the eight women interviewed lived in Hampden County at the time of their interview.  
  
Interview Procedures for Women. Inclusion criteria for women included: (1) 
self-identified opioid and other substance use and treatment, (2) pregnant and/or had 
given birth to at least one child under the age of 10, and (3) age 18 or older. Prior to 
beginning the interviews, each of the 20 women completed brief sociodemographic 
surveys to characterize the sample. Questions were asked about age, marital status, 
annual income, education, number of children, and custody status (Appendix A). 
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Interviews with mothers in recovery began with an open-ended life history question 
(Atkinson, Kuroe, & Kitahara, 2006) prompting participants to reflect on key life 
experiences (i.e. critical turning points) in seven-year intervals (i.e. 0-7, 8-14, etc. until 
their current age). Guided by arts-based qualitative data collection as an asset-based 
approach to conducting research with marginalized populations (Frankowski, Leader, & 
Duncan, 2009; Stelter, 2010), I offered paper and colored pencils to participants during 
this question. A few participants created their own life history timeline, but most opted to 
collaboratively complete the timeline, preferring that I sketched out the timeline and 
added key events and dates as they spoke. I followed the open-ended life history question 
with semi-structured questions, wherein I asked participants more pointed questions 
about their experiences with treatment (e.g. barriers and facilitators to entry, and 
perceptions of opioid treatment pharmacotherapies); their experiences with pregnancy, 
childbirth, and parenting and interactions with health care, legal/criminal, and social 
service systems; their definition of recovery; and their understanding of addiction (i.e. 
“why some people become addicted and others do not?”). Each interview purposefully 
ended on a positive note, asking women about future goals and existing resources in their 
lives.  
  
Interview Procedures for Professional Stakeholders. For professional 
stakeholders, inclusion criteria included: (1) program administrators or program staff 
employed by organization that provide (or support organizations that provide) treatment 
and services to women with OUD and (2) age 18 or older. Program providers, clinicians, 
and policy makers were recruited via word-of-mouth through professional networks and 
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contacts developed during the ethnographic data collection phase. Four of the 
professional stakeholders worked at organizations in Hampden County, one worked at an 
organization in Franklin County, and the remaining four worked at the regional and 
national level.  
Professional stakeholders were asked semi-structured questions about their 
current job title and responsibilities, length of time and experience working in the field of 
substance use treatment, and what drew them to the field. Subsequent questions asked for 
their general observations of pregnant and parenting women with OUD (e.g. 
characteristics, specific needs, and barriers to treatment and recovery). As with the 
mothers in recovery, professional stakeholders were also asked to provide a definition of 
recovery, and to describe their understanding of addiction (i.e. “why do some people 
become addicted and others do not?”). Interview guides for women and professional 
stakeholders can be found in Appendices A and B. 
 
Data Analysis 
Narrative inquiry approaches data analysis through five lenses that are 
simultaneously distinct and intertwined. First, as a process of retrospective sensemaking, 
all narratives should be considered as a “distinct form of discourse” (Chase, 2005, p.656). 
Analysis should therefore focus not simply on chronology, but rather on how a story is 
told, and to and for whom—looking closely at the unique point of view presented. 
Second, narratives can be considered a strategic form of action, wherein a narrator (or 
narrative level) “shapes, constructs, and performs the self, experience, and reality” 
(Chase, 2005, p. 657). Focusing on the voice of each narrative actor or level requires 
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researchers to examine the social position of the narrator (Gubrium & Holstein, 2002). 
Third, narratives are distinctly unique, and simultaneously shaped by the political, social, 
and historical realities that frame them. Similarly, the fourth lens focuses on narratives as 
“socially situated interactive performances” (Chase, 2005, p. 657), which are co-
produced by a range of actors, including researchers and facilitators. Fifth, researchers 
should consider themselves as narrators as they form interpretations of situations, 
contexts, and findings, and package and present (perform) them to a range of audiences; 
this raises important questions about voice, representation, and interpretive authority 
(Chase, 2005, p. 658; Gubrium, Krause, & Jernigan, 2014).  
My analytical strategy for each of the three discursive resources in the dissertation 
(macro, meso, and micro) was to examine narrative content, context, and discourse (Gee, 
1999; Morse & Field, 1995; Riessman, 2008). Content analysis of each discursive 
resource focused on local cultural paradigms of OUD found in the data, focusing on the 
“told”—on what is said, “rather than on aspects of the ‘telling’” [i.e., the how’s] 
(Riessman, 2008, p.54). My content analysis focused on the social construction of 
identity [i.e., what types of identities are produced] at both the individual and group level. 
Contextual analysis focused on the perceptions and structural circumstances (i.e., 
historical, political, economic) that shape identity, practice, and experience (Morse & 
Field, 1995). Content and context analysis was guided by constructivist grounded theory, 
a continually iterative approach that broadly involves simultaneous data collection and 
analysis; code development from data, not predetermined hypothesis or logic; using 
“constant comparison” throughout each stage of research to compare and contrast 
categories; memo-writing to identify and define thematic categories and any connections 
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between them, as well as identifying gaps; and theoretical sampling, or, sampling for 
construction of theory, not generalizability (Charmaz, 2014; Glaser & Strauss, 1967; 
Lindloff & Taylor, 2011). 
Discourse analysis focuses on the “how’s” of storytelling. My discourse analysis 
was guided by Gee’s (1999) seven discursive building tasks, with specific questions 
asked in each task:  
1) Significance: how is language being used to make certain events significant or 
not?  
2) Activities: how is language being used to put activities into practice?  
3) Identities: how is language used to enact certain identities?  
4) Relationships: how is language used to enact certain kinds of relationships?   
5) Politics: how is language used to convey and give meaning to the distribution of 
social goods, as well as the values and status linked to those goods?  
6) Connections: how is language used to form connections, disconnections, and 
make things relevant or irrelevant?   
7) Sign systems and knowledge production: how is language used to privilege 
certain systems of knowledge (i.e., authoritative forms) over others (i.e., 
subjugated forms)?  
Using discourse analysis, I focused on how phenomena were articulated in the three 
discursive resources to consider the range of ways that values, beliefs, cultural norms, 
and themes of dissonance shape the narrative data. 
My step-by-step data analysis procedure for the macro-level (public media),and 
micro-level (individual) narratives consisted of the following: a) three research team 
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members (myself, one graduate research assistant, and one undergraduate research 
assistant) independently reviewed all interview transcripts, and media reports, using 
theoretical memo-writing to identify, refine, and develop themes as they evolved from the 
open/in vivo coding processes; b) each researcher then inductively composed a list of 
thematic (content) codes derived directly from the data that reflected emerging patterns 
and themes; c) collectively and iteratively, the research team reviewed and revised our 
independent coding schemes to reach consensus on the final codes, using the constant-
comparative method to compare initial codes to reduce the data and identify the 
categories and codes that comprised the codebook; and d) finally, the team collectively 
dimensionalized the final coding schema (i.e. defined the properties and characteristics of 
each category). I followed these same steps independently to analyze the the meso-level 
(scientific) narratives. 
 All qualitative data (interviews and news media articles) were systematically 
organized and coded using NVivo (12.0). Meso-level (scientific) narratives were 
systematically entered into Microsoft XL and organized by three time periods: 2000-
2005, 2006-2011, and 2012-2018. To optimize the credibility, dependability, and 
transferability of findings, we sought to minimize discrepancies between participants' 
views and the researchers' interpretations and seek thematic saturation (Creswell, 2007; 
Ulin, Robinson, & Tolley, 2005). Findings were iteratively triangulated across the three 
narrative levels throughout the data analysis process, assessing the “display of multiple, 
refracted realities simultaneously” (Denzin & Lincoln, 1994, p.8). Data triangulation 
consisted of reviewing data across all three narrative levels, assessing commonalities, 
discrepancies, and gaps in the data. 
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Macro-Level (News Media) Narratives 
A total of 121 articles met the inclusion criteria and were included in the final 
analysis sample 
(N=121). Figure 
10 illustrates the 
distribution of 
the sample by 
political 
ideology of 
news sources. 
For the first time period (2005-2007), 15 articles were included and were from liberal 
(n=14) and conservative sources (n=1); there were no centrist news reports for this time 
period. For the second time period (2010-2012), 21 articles were included for analysis. 
Sources were as following: liberal (n=17), centrist (n=2), and conservative (n=2). For the 
third time period (2015-2018), 85 articles were included for analysis. This sub-sample 
included the following: 
liberal (n=66), centrist (n=7), 
and conservative (n=12) (see 
Figure 11). The intent of my 
analysis was a comparative 
analysis across news sources 
by political ideology. However, given the small sample of media reports from both 
Figure 10. Final Sample of News Media Articles by Time Period and Political Ideology (Blue 
represents liberal, orange centrist, and red conservative) 
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centrist and conservative sources in comparison to liberal sources, only a descriptive 
analysis of the differences was possible.  
 
Meso-Level (Scientific) Narratives 
In keeping with conventions of scientific writing in the field of public health, 
Chapter 1 consists of an analysis of the scientific literature on substance use broadly 
conceived, and more specifically, opioid use and opioid use disorder among pregnant 
women and mothers. For the purpose of this dissertation, the scientific literature specific 
to opioid use and opioid use disorders are not solely considered for the data they convey 
(i.e., the what’s), but for the function they fill at a specific narrative level (i.e., the how’s). 
Thus, the scientific narratives gathered for my analysis were additionally assessed for 
narrative content and context, as well as discursive strategies.  
Figure 12 illustrates 
time trends of sub-
populations of women with 
OUD in the U.S. across the 
scientific literature. The 
bulk of the literature 
focused on perinatal and 
postpartum OUD (74.6% of 
the entire sample). The overall time trend shows a dramatic increase from 2000-2018 of 
scientific reports that focused on perinatal and postpartum OUD. Scientific reports 
between 2000-2005 focus almost equally on pregnant and postpartum women (52%; 
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these categories are merged in reports, given the association between perinatal exposures 
and postpartum outcomes) and women and mothers (48%). By 2006-2011, this shifted to 
75% of reports on pregnant and postpartum women and 25% on women and mothers. In 
the period from 2012-2018 79.2% of reports focused on perinatal and postpartum OUD 
and 20.8% on women and mothers.  
Scientific reports on “women” presented findings on gender-specific risk factors 
for the development of OUD, as well as gender-specific-barriers to treatment entry and 
retention. These reports primarily focused on trauma (e.g. ACEs and intimate partner 
violence) and mental health comorbidities; a small number of these reports also focus on 
gender differences in sensitivity to pain. Scientific articles on “mothers and mothering” 
were nearly non-existent (2.5% of the overall sample). Three of the five total articles 
included in the analysis on mothering analyzed availability of childcare as a barrier to 
care: one identified parenting status among women enrolled in a methadone treatment 
program, a second reports on positive and negative experiences with the child protection 
system, and a third, the 
role of homelessness in 
families as a barrier to 
OUD treatment. 
Figure 13 
illustrates time trends of 
the content focus of 
scientific reports on 
perinatal and postpartum OUD. The three content areas of scientific reports on perinatal 
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and postpartum OUD include: (1) epidemiology of, and best practices for, perinatal and 
postpartum OUD (46.3% of the sub-sample [n=147]); (2) the epidemiology and 
management of NOWS as a function of maternal opioid use and socioemotional 
behaviors (31.3% of the sub-sample); and (3) gender-specific care (22.4% of the sub-
sample). The majority of articles on the epidemiology of, and best practices for, perinatal 
and postpartum OUD suggest treatment with MOUD (i.e. buprenorphine or methadone) 
in pregnancy as a best practice. Articles comparing maternal and neonatal outcomes 
between methadone and buprenorphine are a notable contribution of the literature; prior 
to this time period there was little data on overall treatment of OUD with buprenorphine. 
The distinguishing feature of articles on the epidemiology and management of NOWS 
was the narrative positioning of pregnant and postpartum women in the articles. The 
primary focus is on neonatal outcomes as a function of maternal dose and/or type of 
MOUD and maternal dose and/or type of opioid. These articles additionally assessed 
maternal strategies to reduce NOWS symptoms, such as breastfeeding and skin-to-skin 
contact in the postpartum period. Articles reporting on “gender-specific care” focused on 
strategies to address barriers to treatment entry and retention that are specific to pregnant 
women with OUD. 
 
Micro-Level (Individual) Narratives 
Micro-level narratives analyzed for this dissertation included: (1) 40 pages of 
ethnographic field notes written between March 2017 and September 2018, (2) transcripts 
of 29 of the 30 interviews (one participant did not give permission to be audio recorded), 
(3) 45 pages of interview field notes written after each interview, and  (4) 
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sociodemographic surveys completed by 20 mothers in recovery (Appendix C). The 
sample of mothers with OUD (n=20) was characterized using descriptive statistics. Age 
was included as a continuous variable, while marital status, education, race/ethnicity, 
employment status, number of children, and living situation were assessed as categorical 
variables.  
Descriptive characteristics of women interviewees are presented in Figure 14. 
Women interviewees were predominantly White, non-Hispanic (80%). The majority of 
women had either a high school degree (or equivalency) and some college (or vocational 
degree). Sixty percent of women were unemployed at the time of their interview, and 
90% of women interviewed had an annual household income of less than $20,000. Sixty-
five percent of women did not have custody of their children at the time of their 
interview. Sixty-percent of women identified heroin or fentanyl as their primary 
substance used prior to treatment; over 60% of those that used heroin or fentanyl were 
introduced to opioids via non-medically supervised/prescribed prescription opioids. Of 
the 16 women interviewed who were in treatment for OUD, 30% were enrolled in a 
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methadone 
program, 25% 
were prescribed 
buprenorphine, and 
31% were not 
taking any type of 
MOUD.  
Descriptive 
characteristics of 
professional 
stakeholder 
interviewees are 
presented in Figure 
15. The majority of 
professional 
stakeholders were 
White and female, 
with over five 
years of experience 
working in the 
substance use treatment field. Forty percent of professional stakeholders worked at the 
program staff or advanced administrative level, 20% were clinicians, 20% were staff 
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working in national or 
local government or 
policy, and 20% 
worked at a 
community-based 
organization offering 
services to women and 
mothers with OUD. 
 
 
Limitations 
The primary limitation in my macro-level (news media) analysis is the use of a 
non-random convenience sample and the exclusion of cable news and social media 
sources. Although the purpose of the media analysis was to focus on legitimate, 
“unbiased” sources of news reporting that policy makers might be most likely to review, 
an unavoidable reality of life in the 21st century is that public opinion is shaped by social 
media conversations and content. To address this limitation, I selected well-established 
news media sources, included a political spectrum within those sources, and purposefully 
selected time parameters that capture changing discourse and attitudes around risk factors 
and approaches to opioid use disorders among pregnant and parenting women.  
Two primary limitations of the individual, or micro-level narratives, was my use 
of convenience sampling procedures and the potential for self-reporting bias. Conducting 
this research in two geographically distant locations increased the diversity of the sample. 
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However, convenience sampling remains a limitation when working with marginalized 
populations. Although self-reporting bias is always a concern with stigmatized topics, 
gaining trust and receiving the input of gatekeepers was important in addressing this 
limitation. All women interviewed knew about my personal relationship to this topic; 
each of the gatekeepers shared that information with women, and women then shared that 
information between each other— each woman brought it up at the start of their 
interview. The combination of these factors increase my confidence in the limited impact 
of self-reporting bias evident in the interview data.  
The loudest critique of interpretive and social constructionist qualitative research 
remains that it does not stand up to the quantitative criteria of internal and external 
validity, reliability, objectivity, and that ultimately it is both subjective and biased.  The 
constructs of objectivity and bias are rooted in a positivist/post-positivist paradigm and 
the notion that a distinction and separation between researcher and participant is equal to 
objectivity, thus preventing bias from infiltrating findings. The role of researcher as co-
participant of the inquiry process is integral to qualitative research.  However, it is 
commonly construed as inherently biased by nature of proximity (Buchanan, 1992; 
Creswell, 2007; Lincoln & Denzin, 2011; Ulin, Robinson, & Tolley, 2005), as well as 
being biased toward verification that ultimately confirms the researcher’s subjective 
judgments (Flyvbjerg, 2001; 2006). However, if the goals of quantitative versus 
qualitative research are distinct, which I argue here, then it stands to reason that the 
criteria of quality are similarly distinct.   
Qualitative findings are typically not generalizable given their tendency towards 
smaller sample size (Creswell, 2007; Flyvbjerg, 2006), but is this the goal of such 
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research? No. By holding narrative (or more broadly, qualitative) methods to 
positivist/post-positivist standards of quality, we continue to overlook the differing goals 
held by each paradigm (Buchanan, 1992; 1998). The goal of applying humanistic 
methods is to gather “thick” descriptions that more deeply inform understandings of the 
social construction of reality within a given context. A humanistic research agenda 
recognizes that people are experts of their own experience, and prioritizes engaging with 
those individuals in dialogue about perception and experience to support, promote, and 
achieve agency and well-being (Buchanan, 1992). Furthermore, when assessing 
humanistic research methodologies, “quality cannot be determined by following 
prescribed formulas…[but rather] lies in the power of its language to display a picture of 
the world in which we discover something about ourselves and our common humanity” 
(Buchanan, 1992, p.133). 
I argue that the co-construction of knowledge inherent to narrative research is 
critical for a detailed and informed understanding of issues that are still not well 
understood— such as the intersections between substance use, mental health, and 
mothering. Why? Because adhering to the construct of confirmability implies a 
committed practice of reflexivity on the part of the researcher (Buchanan, 1992; 
Creswell, 2007; Lincoln & Denzin, 2011; Ulin, Robinson, & Tolley, 2005). This includes 
a realistic acknowledgement that individual bias undoubtedly impacts a researcher’s 
choice of not simply a paradigm, but also the questions we ask to get at our own research 
objectives that are important to us. In dismissing the concept of bias as inapplicable to 
positivist/post-positivist methodologies, quantitative research continues to overlook how 
a researcher's personal ethics and morals shape the focus of research, one's research 
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questions, and the data collection and analysis processes chosen in the first place 
(Flyvbjerg, 2006).  As Flyvbjerg (2001) argues, to make “social science matter” entails 
not only striving for social science to produce predictive theory, but also to focus 
research objectives and findings on issues of how social values are shaped by systems of 
power, and to become more adept at effectively communicating research findings to the 
public-at-large.   
 
Ethical Considerations  
Three considerations around research ethics and perinatal and maternal OUD 
arose from this project. The first ethical consideration was in relation to participant 
compensation. In this project I advocated to the IRB for the use of cash versus gift cards 
from a predetermined store or location. It is often assumed that cash compensation for 
people with substance use disorders will not be approved by an institutional review 
board. In my IRB protocol for this study I advocated and received approval for the use of 
cash compensation, drawing upon my prior research with marginalized women in which 
we identified that cash compensation was critically aligned with community-engaged 
research priorities to promote participant autonomy (Gubrium et al., 2016). Additionally, 
I advocated for cash compensation due to the overall limited access to transportation for 
all women who participated in this project, the majority of who relied on public 
transportation that is regionally documented to be limited in frequency and range 
(Partners for Healthier Communities, 2016). Lastly, much of the reason that cash 
compensation is avoided when conducting research people with substance use histories is 
related to stigma— specifically, the assumption that people will use the cash to buy 
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drugs. However, following this logic one can just as easily argue that participants can sell 
their gift cards, or alternatively purchase something with their gift cards, to subsequently 
sell for drugs. Yet, an IRB will readily approve the use of gift card compensation for this 
population.  
The second ethical consideration is related to my use of life history interviews. 
Although some interviews were conducted in institutional settings, I was not embedded 
in the power structure of those spaces. From work with women in treatment for OUD in 
another study, I have learned that women are often more comfortable sharing details with 
a non-clinical person, in part due to fears related to punitive consequences associated 
with relapse and concurrent opioid and MOUD use. However, the flip side of this is that 
although I shared clinical support resources with participants, I was not in a role where I 
had ongoing contact with each individual wherein I could assess their wellbeing beyond a 
follow-up text message(s) that I exchanged with each participant (which can present an 
additional layer of ethical considerations around boundary setting with participants). 
I believe in the value and contribution of conducting research outside of clinical 
settings in an effort to circumvent the influence of power dynamics on participant 
reporting. However, this also means that it was left to my individual discretion to either 
modify my questions or follow up with participants. For example, prior to interviewing 
Shaila in a residential recovery home, I had already witnessed her being excessively 
argumentative with other residents, and learned that she had set off the fire alarm the 
evening preceding our interview. At the start of the interview she told me that that at age 
20 her boyfriend died by suicide in front of her. From there she went on to recite a 
lengthy list of medications that she took for depression, bipolar disorder, OUD, and a 
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recent diagnosis of Hepatitis C “like lithium, gabapentin, thorazine, um Effoxor©, um 
what else…Suboxone©…I'm taking my Hep C medication. There's more, I'm trying to 
think. It's hard to think, [but] I think that's it.” From my fieldnotes written after the 
interview, I observed that she  
looks fragile, in part because as I am sitting close I notice her quivering- around 
the edges of her mouth, her hands, and just in general. I am guessing these are 
medication side effects, but I am not quite sure. While some of the women seem 
to sometimes disassociate when they are talking about their past, Shaila seems to 
feel it all.  
 
There were probing questions that I wanted to ask but chose not to. Even though I knew 
she had access to immediate support since she was housed in a residential treatment 
program, I proceeded cautiously, read her reactions carefully, and did not probe too 
deeply into her history for fear of triggering further trauma. 
The third ethical consideration relates to interview location in two distinct ways. 
Word-of- mouth recruitment can be imperative when working with difficult-to-reach 
populations, such as pregnant and parenting women with OUD, and it certainly was key 
to my ability to recruit participants. Much of my recruitment was done via text 
messaging. When Tanya responded and agreed to an interview, she sent me her address 
with no other context. When I showed up at a residential recovery facility (often referred 
to as a “halfway house”), I was surprised. Even more surprising when I showed up was 
that every woman in the house who had a child or children had already organized 
themselves to take turns speaking with me. I ended up going to the house two days in a 
row. Eight of my 20 interviews with mothers with OUD were conducted at that location. 
Although all women had used opioids, not all were being treated for OUD. Three of the 
women were being treated for alcohol use disorder, one of whom simultaneously had a 
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history of problematic cocaine and alcohol use. Ethically I did not feel like I could say no 
to those women, who appeared to have a lot of free, unstructured time. Because the 
consent form included the language “opioid or other substance use disorders,” including 
them did not run counter to project IRB approval. Importantly, these interviews 
contributed notable findings about the ways in which a near sole focus on opioids 
problematically obscures the needs of key populations (see Chapter 5 and Chapter 6).    
  A closing note on ethical considerations is about safety and perceptions of fear. I 
purposefully chose to interview participants where they were most comfortable (e.g., 
living room, car, coffee shop, community recovery space). My decision to do so was in 
large part related to transportation barriers and issues related to stigma and privacy given 
the topic of focus. When I showed up to Yadira’s apartment in Chicopee, it was in a 
section of the town that was visibly run down. The homes on the street were mostly 
unkempt, with a range of debris on the street and in people’s front yards. When I got to 
her house, I called Yadira and she came down the stairs to let me in, instructing me not to 
talk to the downstairs neighbor. When I got inside, the apartment was cluttered with 
clothes and toys and she immediately launched into telling me about how nosy the 
neighbor was, and how she just needed to “mind her own business.” Over the years, I 
have conducted interviews in a range of homes across Hampden county, and I have 
certainly been in neighborhoods that are different than those I have lived in, racially and 
economically speaking. I started to feel uncomfortable, and even slightly scared, during 
the interview, but I kept telling myself there was nothing happening that should have 
caused me to feel that way. I wrote off what might indeed have been an instinctive 
response, to my own internalized biases, and continued with the interview.  
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At some point during the interview, a police officer knocked on the door. My 
initial response was relief—that this was a signal to end the interview, that it might be an 
opportunity for me to leave. I could hear the officer telling Yadira that a neighbor had 
called because they had reported hearing strange noises. Yadira told the officer that 
everything was fine and he left the building. I stayed. The entire encounter lasted for no 
more than one minute. But after he left Yadira seemed on edge, wondering aloud what 
the sounds might be and why the neighbor had called. Perhaps ten minutes later, we 
could hear her roommate shouting from outside to let her in. I am not sure why he didn’t 
have a key, but as he came up the stairs I started asking myself why I was in this house 
with people I did not know, which led me to begin thinking of some of the precarious 
situations people had described as part of their substance using history. The roommate 
went in his room and shut the door, and I wrapped the interview up shortly thereafter and 
went home. 
I later recruited Yadira to participate in a clinic-based project that consisted of 
conducting focus groups with women in treatment for OUD. Over the five weeks she 
participated in that project I got to know Yadira better, as well as her sister and nephew. I 
know Yadira to be a sweet, considerate, smart, and hardworking mother. I have been to 
the outside of her house since then, though have not been invited inside again. We 
occasionally communicate via text message, and I would happily meet up with her again 
in the future. I am still not exactly certain what occurred when I was inside her house—
were my reactions a result of intuition or bias—or perhaps a combination of both? I can’t 
say with any definitive certainty, but will continue to reflect on this experience.  
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CHAPTER 3 
MACRO-LEVEL (NEWS MEDIA) NARRATIVES OF OPIOID USE DISORDER 
AMONG PREGNANT WOMEN AND MOTHERS 
 
Chapter Overview 
Starting in 2016 I began to notice increasing media reference to “cuddlers,” an 
innovative shift in hospital programming wherein volunteers offered their time by 
holding and soothing infants born with neonatal opioid withdrawal syndrome (NOWS) 
who were experiencing symptoms such as shaking and inconsolable, high pitched crying. 
After reading a few reports of the use of cuddlers in local hospitals and their role in 
reducing the severity of NOWS symptoms and length of stays in the Neonatal Intensive 
Care Unit, I decided that volunteering as a cuddler would provide important insight to 
this research. However, when I submitted my application to a local hospital serving 
“high-risk” populations, including infants with NOWS, I was told that the demand from 
potential cuddlers was so great they had stopped collecting names of potential volunteers. 
At that time, a cursory image search on Google generated dramatically divergent and 
racialized imagery of mothers who used crack versus opioids. The terms “crack baby,” 
“crack mom,” and “crack mother” yielded images of poverty, women smoking crack in 
derelict apartments (often while their children are in view), screaming babies, and 
assorted derogatory and racialized memes. Conversely, images associated with the search 
terms “opioid baby,” “opioid mom,” “opioid mother,” and “Oxytots” (as I had seen them 
referred to) yielded representations of “cuddlers,” smiling and healthy White families 
depicting success stories of overcoming addiction, and health education materials.  
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A robust scholarship has examined the cyclical nature of drug panics and the role 
of media in associating drug use with crime, moral deviance, and the “other,” a 
construction that has historically served to reinforce the dominant “logic of whiteness” 
(Peterson, Gubrium, & Fiddian-Green, 2018, p.2)  and entrench stratified racial 
boundaries (Goode & Ben Yehuda, 2009; Netherland & Hansen, 2016; Peterson, 
Gubrium, & Fiddian-Green, 2018). Media inflamed moral panics associated with drug 
scares simultaneously criminalize Black and Brown drug use while rendering innocent 
White drug use, regardless of actual use rates (Dearing & Rogers, 1996; Goode & Ben-
Yehuda, 2009; Musto, 1999). An examination of media coverage is essential to a 
complete understanding of the social construction of the current opioid “crisis” in the 
U.S.— after all, media stories are socially constructed narratives of events (Peterson, 
Gubrium, & Fiddian-Green, 2018). The media performs as a social “gatekeeper” at the 
macro-level of society by determining what constitutes a public priority, and providing 
the frame with which to orient beliefs and attitudes around a given issue, thereby shaping 
public notions of risk and directing policy efforts (Dearing & Rogers, 1996; Goode & 
Ben-Yehuda, 2009; Musto, 1999).  
This chapter presents an analysis of the macro-level (public media) narratives 
around opioid use among pregnant women and mothers in in the U.S from 2005-2018, 
illustrating the near absence of media coverage of women with OUD that existed until the 
emergence of a growing concern for neonates and infants impacted by rising rates of 
neonatal opioid withdrawal syndrome. In doing so media coverage predominantly centers 
on “fetal victimhood” (Knight, 2015) and erases the autonomous needs of women with 
OUD that run concurrent to ensuring a healthy pregnancy and birth outcomes. In this 
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chapter, I begin by examining historical media coverage of the crack and 
methamphetamine “epidemics” in the U.S. to inform a critical analysis of media coverage 
of the heroin “epidemic” cum “crisis” of the present, and the ways in which policy and 
programmatic responses to the current opioid “crisis” both differ and align with crack and 
methamphetamine epidemics of the past. Key findings from the media analysis presented 
in this chapter focus on diverging mediatized identities of pregnant women and mothers 
with OUD, and responses to address perinatal and maternal OUD that center on 
progressive social reform. The chapter concludes with an examination of the scant media 
coverage of the shifting racial demographics of the opioid “crisis,” and a cautionary call 
for sustained efforts that promote treatment of opioid use disorders over criminalization.  
 
Historical Media Coverage of Drug Epidemics in the U.S. 
 
Crack and the Culture of Poverty 
The historical roots of the unfit drug using mother can be traced to the racialized 
notion of social welfare recipients as costly and undeserving of federal support, a shift 
that mirrored the demographic transition of welfare recipients from post-war widows 
(1940s) to single-mothers (1960s), and the accompanying collective notion of poverty as 
synonymous with black and brownness, which in and of itself was socially constructed as 
a moral deficiency and character flaw (Duffy, 1990; Geary, 2015). The 1960s was 
witness to the publication of the Moynihan Report (1964) and Oscar Lewis’ seminal 
work, La Vida: A Puerto Rican Family in the Culture of Poverty (1968).  Although 
framed as a call for “equality of opportunity” (Geary, 2015, para. 36), Moynihan 
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correlated high poverty rates and welfare dependence among African-American families 
at that time to high rates of urbanization; unwed, divorced, or single mothers; females as 
household heads; and “illegitimate” children (Geary, 2015, para. 69). Similar to the 
Moynihan Report, Oscar Lewis’ popularization of the “culture of poverty” as a social 
theory explaining intergenerational poverty (Lewis, 1968) excluded structural dimensions 
of inequity as the determinant factor impacting individual agency and opportunity. 
There is no doubt that crack had significant impact on communities. As a cheaper, 
smokable form of cocaine, crack produces a short-lived, albeit “intense” high and is 
highly addictive. Although largely represented in the media (and therefore perceived as) a 
Black and Brown “inner-city problem,” crack use in the form of freebasing (smoking) 
cocaine was initially popular among wealthy investment bankers, Hollywood actors, and 
professional athletes in the 1970s. As the impacts of freebasing cocaine began to strain 
hospitals and police forces, the initial policy response was to expand treatment (Lyons & 
Rittner, 1998; Musto, 1999; Reinarman & Levine, 2004). Adding baking soda to cocaine 
resulted in the cheaper rock form of crack, which largely impacted low-income, Black 
and Brown communities in the Northeast and Mid-Atlantic regions in the 1980s— many 
of them women (Fryer, Heaton, Leavitt, & Murphy, 2006). Given its relatively low cost 
and the underground nature of selling illicit drugs, the business of selling crack became 
highly lucrative and subsequently violent. When “cocaine use became crack abuse, the 
problem became sociopolitical rather than medical” (Lyons & Rittner, 1998, p. 314) 
resulting in punitive approaches that drove the inequitable increase in the incarceration of 
Black and Brown people. As such, it can be argued that the greatest impacts of the crack 
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“epidemic” were more closely linked to “prohibition related violence” rather than use of 
the drug itself (Fryer, Heaton, Leavitt, & Murphy, 2006).  
Racially stratified media attention around the crack “epidemic” reached its height 
during Reagan’s tenure as President in the mid to late 1980s. Representation of “crack 
whores” and “crack babies” were used as fodder for the War on Drugs, legitimizing 
punitive, moralistic approaches to addressing substance use during pregnancy (Gubrium, 
2009; Lyons & Rittner, 1998; Terplan; Kennedy-Hicks, & Chisolm, 2015). Despite 
claims that crack use during pregnancy would propagate an “underclass of children 
whose cognitive and developmental disabilities would strain the country’s economic and 
social welfare system for years to come” (Terplan, Kennedy-Hendricks, & Chisolm, 
2015, p.1), a review of 36 longitudinal studies conducted with children who had been 
dubbed “crack babies” found this claim to be an unfounded (Frank, Augustyn, Knight, 
Pell, & Zuckerman, 2001). Robust evidence continues to link greater adverse birth 
outcomes from prenatal exposure to licit substances (e.g., alcohol and tobacco) versus 
illicit substances (e.g., opioids, methamphetamines, and cocaine) (Behnke & Smith, 
2013; Imer, 2012). However, media “demonization of drug-abusing parturient women 
[makes] better [media] copy than detailed elaborations of the germane issues” (Lyons & 
Rittner, 1998, p. 314), silencing and negating the impacts of poverty, racism, and the 
myriad structural factors that directly impact birth outcomes, including stress, access to 
nutritious food, housing, a livable wage, and quality health care.  
 
Enter Whiteness: Methamphetamine and Opioid Use 
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The scant scholarship that does examine whiteness in drug discourse identifies a 
historical pattern of a reinforced caste system of substance users that “positions whiteness 
as a ‘reference category’ [that] helps it to escape careful scrutiny or disappear altogether” 
(Linneman, 2015, p. 101), driving efforts that promote tolerance and treatment. It is this 
“normalized, ‘invisible weight’ of whiteness” (Linneman, 2015, p. 101) that casts black 
and brown-ness as deviant and in need of policing (Hansen, 2017; Netherland & Hansen, 
2016). The divergent social constructions of methamphetamine and opioid use in the 21st 
century highlight the strategic invisibility of whiteness in drug use discourse. Unlike the 
“pseudo-racialization” of methamphetamine use (Peterson, Gubrium, & Fiddian-Green, 
2018) that justified bootstrap ideologies and punitive measures, responses to the opioid 
“crisis” have largely called for decriminalization and progressive social reform 
(Linneman & Wall, 2013; Netherland & Hansen, 2016; Peterson, Gubrium, & Fiddian-
Green, 2018) 
Media coverage of methamphetamine use has primarily centered on the “white 
trash,” low income, rural drug user. This pseudo-racialization, or “othering,” of whiteness 
has long been deployed to “police the boundaries of whiteness and… ease the anxieties of 
White social position” (Peterson, Gubrium, & Fiddian-Green, 2018, p. 5). Anti-meth 
campaigns relied on visual representations that discursively situated meth users as 
“objects of disgust” (see Lupton, 2015) conflating the identities of meth user and “white 
trash” as a way to reconcile White drug users that threatened the dominant logic of 
whiteness (Linneman & Wall, 2013; Netherland & Hansen, 2016; Peterson, Gubrium, & 
Fiddian-Green, 2018). Two such examples, “Faces of Meth” and the “Montana Meth 
Project” represented meth users with rotting teeth, picked and bleeding skin, and as 
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emaciated sex workers (Linneman & Wall, 2013; Peterson, Gubrium, & Fiddian-Green, 
2018). The use of visual media narratives effectively cemented these associations, 
successfully casting White meth users as outsiders threatening the “supposed purity of 
hegemonic Whiteness” (Linneman & Wall, 2013, p. 318). What is similar in the social 
construction of methamphetamine and opioids is the White “face” of each crisis. How 
whiteness has been reconciled, however, represents a point of departure. 
In the 1960s and 70s, heroin users in the U.S. were primarily White males living 
in urban areas (Cicero, Ellis, Surratt & Kurtz, 2014). While racial differences in use 
patterns were slight (and positively skewed towards White males), media discourse 
problematized heroin use among low-income, urban African-American and Latino males, 
focusing largely on drug violence as justification for punitive approaches to addressing 
heroin use at the time. This was juxtaposed to a comparatively more sympathetic 
representation of the post-war White male heroin user (Netherland & Hansen, 2016). In 
the opioid “crisis” forty years later, as heroin become linked with Whiteness and “lack of 
oversight” on the part of the medical industry, the “discursive disappearance of Black and 
Brown drug users…was replaced with a concern for White, middle-class users” (Daniels, 
Netherland, Lyons 2018, p.330). Seemingly overnight, news reports focused on opioid 
use and opioid-related deaths predominated the media on drug use in America. 
Simultaneously, and also distinctly quickly, as the demographics shifted from Black and 
Brown to White heroin users, media representation and policy efforts shifted from 
punitive criminal justice interventions that focus on individual responsibility (blame), to a 
call for compassionate treatment efforts and decriminalization for “good kids” 
“suffering” from addiction through no real fault of their own, but rather as a consequence 
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of larger systemic factors like the over prescription of (previously) legitimized medicine 
(Netherland & Hansen, 2016).   
At the time of this writing, only three studies have critically examined media 
portrayals of whiteness in the context of the current opioid “crisis.” (Netherland & Hanse, 
2016; Hansen, 2017; Daniels, Netherland, & Lyons, 2018). One is a media content 
analysis of racial imagery in 100 articles reporting on “heroin” or “opioids” from 2001-
2011 (Netherland & Hansen, 2016). This study speaks to the racially coded reporting of 
Black, Brown, and White heroin and opioid use that portrays Whites as more 
sympathetic, agentless, and deserving of intervention, and Black and Brown users as 
criminals needing punitive and paternalistic interventions. Building from this study, the 
same team conducted a second study that examined the 20 most viewed visual news 
stories of from 2012-2016 using the terms “women” and “heroin” and Google as a search 
engine (Hansen, 2017). As Hansen (2017) notes in this study, the racial bifurcation of the 
opioid user is complicated by contrasting narratives of  “the suburban, middle class, yet 
vulnerable White woman whose prosthetic bolstering through pharmaceutical 
maintenance deserves national investments” and “competing narratives of unemployed 
rural White women whose addiction symbolically ‘blackens’ them” (Hansen, 2017, p. 
326). Findings from this study are largely aligned with prior work (Netherland & Hansen, 
2016), in which humanizing stories of “wasted whiteness” (Hansen, 2017, p. 328) center 
on addiction that stems from liberal prescribing practices of legitimized medicine, and an 
overall “lack of commentary on its impact on mothering and on the children of users” 
(Hansen, 2017, p. 327). Much of the focus on this scholarship is on racially divergent 
prescribing practices of MOUD across populations. 
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Building from this prior work on race, class, and opioids (see Netherland & 
Hanse, 2016; Hansen, 2017; Daniels, Netherland, & Lyons, 2018) my dissertation media 
analysis specifically examined the role of the gendered triple standard as pertains to the 
discourse and 
content of media 
reports on pregnant 
women and mothers 
and opioids from 
2005-2018. In 
keeping with trends 
of the overall 
sample, the bulk of media coverage on  pregnant women and mothers with OUD from 
2005-2018 was concentrated in 2015-2018 (70.2%), followed by 2010-2012 (17.4%) and 
2005-2007 (12.4%). In and of itself this was a notable finding around the historical 
invisibility of women with opioid use disorders in public media narratives. Overall 
coverage from centrist (Christian Science Monitor and the Economist) and conservatively 
leaning (the Wall St. Journal) historically newsprint media sources was minimal (19.8% 
of the total sample and 15.7% from 2015-2018; Figure 16), begging an investigation into 
what news sources centrist and conservative policy makers in particular draw from. The 
intent of this media analysis was to conduct a comparative analysis across ideologically 
divergent news sources. However, given the small sample of conservative and centrist 
news media sources (n= 24), the comparison of reporting differences by political 
ideology is limited to a descriptive analysis woven throughout each of the sections. 
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Figure 16. Final Sample of News Media Articles by Time Period and Political 
Ideology (N=121) 
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Inclusion of all media articles that met inclusion criteria allowed for a larger sample size 
(N=121) and therefore more robust analysis. 
 
Discourse Analysis: Mediatized Identities  
Mediatized (i.e., macro-level) narratives shape dominant discourse (McKim, 
2017) on perinatal and maternal OUD, which then become embedded into the social 
imaginary. These narratives influence social perceptions and public health policy around 
maternal OUD by identifying and drawing attention to policy priorities; framing the 
issue; and by framing the issue, shaping public attitudes towards risk and management of 
maternal opioid use disorder (Lancaster, et al., 2011; Schiavo, 2014). My analysis of 
macro-level discursive resources centered on the production of mediatized identities for 
pregnant women and mothers who use opioids, how these master narratives further 
shaped the thematic focus of news media coverage, and how collectively this focus 
perpetuates the social stigma faced by this population. 
A novel contribution from the dissertation media analysis was the finding that 
there was a slightly higher rate of disparaging versus sympathetic discursive 
representations of pregnant women and mothers with OUD (51.2% versus 45.5% of the 
total sample, respectively; Figure 17), which runs counter to scant existing research on 
comparative racialized media representations of Black, Brown, and White opioid users 
(Daniels, Netherland, & Lyons, 2018; Hansen, 2017; Netherland and Hansen (2016). As 
with overall temporal trends, the majority of the sub-sample of articles that represent 
pregnant women and mothers with OUD sympathetically were published between 2015-
2018 (76.4%), and 10.9% in the period from 2010-2012, and 12.7% from 2005-2007. 
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Articles that represent pregnant women and mothers with OUD disparagingly follow a 
similar trend: 74.2% of this sub-sample were from 2015-2018, 16.1% were from 2010-
2012, and 9.7% were from 2005-2007. Of note are differences in sympathetic versus 
disparaging 
descriptions 
in media 
reports by 
political 
ideology of news source. Conservative and centrist news sources combined had a higher 
proportion of articles that described women sympathetically as opposed to disparagingly 
when compared to liberal news sources: 24% versus 76%, and 14% versus 86%, 
respectively.   
Overall, mediatized representations of pregnant women and mothers with OUD 
predominantly depict White women, a narrative that aligns with broader social notions of 
the “face of the opioid crisis” as White and middle class (Hansen, 2017). References to 
non-White opioid users, coded or not, were rare in this analysis. By coding, I mean that 
when non-White race is not directly mentioned, it is referenced through the use of names 
in reports that are akin to police blotters that list names and criminal charges, and are 
lacking in circumstantial context. For example, the case of “Blanca Rosa Reyes, 24, of 
Silver Spring on charges of second-degree murder, child abuse and neglect in the death of 
[her two year old son] Matthew Navarrete-Reyes” (Zauzmer & Koh, 2015), who we can 
infer to be Latina by reading her full name as well as her son’s hyphenated last name. 
This type of coverage on the criminogenic effects of Black and Brown opioid users aligns 
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with established historical patterns (Hansen, 2017; Peterson, Gubrium, & Fiddian-Green, 
2018), but again, were rare in this analysis. 
 
Fetal Victimhood and Disparaging Portrayals  
Aligning with intersectional notions of a triple gendered standard experienced by 
pregnant women and mothers with opioid use disorders, the majority of discursive 
depictions of pregnant women and mothers who use opioids in the sample cast women as 
negligent, causing direct harm to infants and children (75.8%). This long cemented trope 
of “fetal victimhood” (Knight, 2015) erases the needs of women as autonomous from 
childbearing and rearing, and was marked by the absence of contextual factors (i.e. 
exposure to trauma and other structural factors) that were featured in sympathetic media 
narratives of women with redemptive potential who were on the “straight and narrow.” 
Media headlines such as the New York Times report on “Children in Torment” (Herbert, 
2006) and the Wall St. Journal’s coverage on “Children of the Opioid Crisis; Left Behind 
by Addict Parents Tens of Thousands of Youngsters Flood the Nation's Foster-Care 
System; Grandparents Become Moms and Dads Again” (Whalen, 2016) abound, 
regardless of political ideology. Furthermore, notions of fetal victimhood are distinctly 
divergent from narratives of “crack babies” that propagated fears of low-income Children 
of Color that would burden present and future social service and medical systems and 
society as a whole. 
Historically, media coverage on substance use has relied on the 
anthropomorphization of drugs to reinforce the myth that using a drug once will 
instantaneously cause addiction (Goode & Ben-Yehuda, 2009). Yet this tactic erases the 
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myriad of factors that shape potential for addiction beyond a single dose, such as trauma, 
underlying mental health conditions, and structural factors (Linneman & Wall, 2013; 
Musto, 1999; Netherland & Hansen, 2016; Peterson, Gubrium, & Fiddian-Green, 2018). 
In the context of mediatized identities of pregnant women and mothers with OUD, 
opioids were anthropomorphized in a way that furthered a brain disease model of 
addiction to encompass its impacts on the parenting capabilities of women. The 
Washington Post describes opioids as “termite rot, eating at the foundation of a 
community… [a] cultural self-destruction that is particularly pernicious when women 
with children can't function as mothers” (Achenbach, 2016). Coupled with this notion of 
impaired parenting, are reports such as a New York Times article on a study using brain 
scans to understand how opioids “blunt a person's natural parenting instincts. Compared 
with the brains of healthy people, the brains of people with opioid dependence didn't 
produce strong responses to the cute baby pictures” (de la Cruz, 2016). 
A phrase consistently heard throughout this project was that “addiction doesn’t 
discriminate.” Yet the collective response does just that, particularly in regard to 
overlooking the needs of women as distinct from children. Take this article from the New 
York Times in 2017 that stated:  
Addiction is an indiscriminate disease. You want to blame the weakness inside a 
person. But like a tree, it extends its gnarled branches in many directions: toward 
the children it hurts, toward the state it burdens and toward the victims it 
consumes. (Basile, 2017) 
 
This contradictory statement encapsulates popular notions of fetal victimhood — that 
addiction is an internal weakness and its “victims” include only children and the state. 
Notably absent in the list of victims is, of course, the mother, who was presumably not 
  106 
“strong” enough to overcome her addiction and provide the maternal care she should 
(Basile, 2017). 
 It is important to consider the political impacts of media coverage that 
regurgitates narratives of fetal victimhood, particularly under a socially conservative 
administration. In his first State of the Union Address in January 2018, President Trump 
told a story of an Albuquerque, New Mexico police officer who came upon a pregnant 
women who was “homeless and preparing to inject heroin.” In Trump’s words, when the 
officer approached the woman and warned her “she was going to harm her unborn child, 
she began to weep. She told him she did not know where to turn, but badly wanted a safe 
home for her baby.” In the State of the Union version of the story as reported in the New 
York Times, the officer “felt God speak to him,” compelling he and his wife to adopt the 
child after she was born, naming her Hope (Weiner, 2018). 
One day prior to the 2018 State of the Union Address, then Attorney General Jeff 
Sessions announced a newly developed “Joint Criminal Opioid Darknet Enforcement” 
team to disrupt illicit online sales of opioids. Refencing rising rates of opioid-related 
fatalities, Sessions was quoted in the Washington Post as saying: 
These are not just numbers. These are moms, dads, daughters, spouses, friends 
and neighbors… They include a man and a woman who overdosed and died at 
home. Their helpless five-month old daughter was home alone with them. She 
starved to death in her bassinet over the course of three days. (Horwitz, 2018) 
 
Although Sessions draws from the “addiction doesn’t discriminate” discourse, his 
concluding statements underscored that this notion did not extend to pregnant or 
parenting mothers (and fathers in this example). Moralistic addiction rhetoric such as this 
is troublesome, particularly from a conservative administration under which fetal 
victimhood has been used to bolster anti-choice efforts to overturn Roe v. Wade. 
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Additionally, as of January 2019, substance use in pregnancy is categorized as child 
abuse in 23 states and the District of Columbia and is grounds for civil commitment in 
three (Guttmacher Institute, 2019). 
More than three-quarter of the articles on perinatal and maternal OUD that 
centered on reports of fetal victimhood wrote stories of child negligence and harm, 
aligning with the historical pattern of the pseudo-racialization of White 
methamphetamine users as a way to reconcile those individuals that fall outside of the 
dominant logic of whiteness. In all of these media reports mothers were cast as morally 
deficient, and included disturbing and graphic descriptions of child neglect and abuse that 
dehumanize pregnant women and mothers with OUD. Across political ideology these 
articles described women as nameless appendages of the “cancer” that is the opioid 
problem, with “tendrils that are going everywhere” (Turkewitz, 2017), ensnaring mothers 
who “run out on drug runs” after birth (Whalen, 2017) and who “find drugs more 
important than their kids” (Hoffman, 2017). For example, there was the story of the 
parents found dead in a vehicle parked on the side of the road [with] three surviving 
children, all under the age of six” left in the backseat (Ugwu, 2017); reports of women 
sentenced to jail who “induce labor so they can get back out and do more heroin" (Craig 
& Lewis, 2017); the story of a 7-year old who explained to their school principal how to 
“properly shoot heroin – something [they] learned from watching it happen at home” 
(Zezima, 2018); and a collection of articles reporting on the poisoning or fatal ingestion 
of opioids by children.  
While all news sources included similarly disturbing stories of fetal victimhood, 
the Christian Science Monitor (as a centrist news source) and Wall St. Journal (as a 
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conservative news source) tended to be slightly less sensationalist than the ideologically 
liberal news sources. For example, the Christian Science Monitor reported about a child 
who told police officers, “I see my mom passed out like that all the time” (Khadaroo, 
2016) and the Wall St. Journal described children who “watch their mothers and fathers 
overdose and die on the bathroom floor… live without electricity, food, or heat… and 
learn to steal and forage to meet their basic needs” (Whalen, 2016). Particularly in their 
reports prior to 2015, both the New York Times and Washington Post included grossly 
graphic descriptions of events. In 2011, the Washington Post described a “situation…as 
disturbing as it was cruel: three girls, trapped in a bedroom tainted with urine and feces, a 
piece of drywall nailed across the door. The people responsible, police say, were their 
parents.” (White & Buske, 2011). Most disturbing was a New York Times article from 
2006 about two toddlers left unattended in a bath. The author detailed how the children 
were:  
[U]nable to escape as the water burned and blistered their feet and ankles and kept 
on rising. One of the boys struggled to save himself by standing on his toes, but to 
no avail. Authorities said that when the boys were found, they were lying face up 
in the water on the bathroom floor, their bodies all but completely scorched. They 
had burned to death. (Herbert, 2006)  
 
Would it have been possible for the New York Times author to know with certainty that 
“one of the boys struggled to save himself by standing on his toes, but to no avail,” or 
was this simply the use of creative license by a potentially aspiring crime writer? It is 
important to question the utility of this kind of reporting, and what impact it has on the 
political and social stigma faced by mothers with OUD.   
The time period from 2015-2018 saw an increase in reports of “opiate fatigue” 
among front-line workers interacting regularly with pregnant women and mothers with 
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OUD (i.e. reports of increasing frustrations among first responders or judges). Perhaps 
due to the dramatic increase in opioid related fatalities as of 2016 that have far exceeded 
death rates from any prior drug “epidemic,” media reports from 2016 forward began to 
touch on increasing frustrations with “enabling these people amid a surge in drug-related 
foster care cases, property crimes and emergency room visits” (Craig & Lewis, 2017; 
emphasis mine). In a Washington Post article titled “Communities in Anguish Over 
Reviving Opioid Addicts,” a conservative Kentucky Sheriff who opposed the use of 
Naloxone by his deputies recounted, "I've had three babies born in my jail in 18 months, 
and the last one was born in the toilet.” The article concluded the article with a “solution” 
that perfectly encapsulates notions of fetal victimhood: “the judges, to save the babies, 
sentence the mothers to jail” (Craig & Lewis, 2017).  
The pinnacle of “opiate fatigue” (Achenbach, 2016) is perhaps best represented 
by a Christian Science Monitor report on the increase in viral videos of parental 
overdoses, such as “another case of a child standing helplessly by an adult unconscious 
from a drug overdose…filmed by an onlooker in a supermarket” (Tan, 2016; emphasis 
mine). A concerning pattern in media reports was the use of viral videos by local law 
enforcement as “potential wake up calls [that] outweigh individual privacy concerns” 
(Ugwu, 2017) that reinforce harmful stigmas that perpetuate barriers to care for this 
population. The use of viral videos relates to increased “compassion fatigue” among front 
line workers (e.g. first responders, emergency room staff) and its impacts on the 
provision of care. As an example, in a New York Times article law enforcement officials 
were quoted arguing that access to mediations for opioid use disorders (MOUD; e.g. 
methadone and buprenorphine) and naloxone (Narcan ©) “continues the cycle of 
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dependence and has created a black market that fuels crime” (Macy, 2016). Drawing 
from a moral model of addiction and further reinforcing the stigma associated with 
MOUD was the headline chosen by the New York Times for this article: “Addicted to a 
Treatment for Addiction” (Macy, 2016). 
The emergency room was another place where “opioid fatigue” was reported to 
impact care. The New York Times article, “Injecting Drugs Can Ruin a Heart- How Many 
Second Chances Should a User Get?” (Goodnough, 2018) focused on the increase in 
emergency room visits among mothers for sepsis and endocarditis, both of which are 
serious health conditions that result from bacteria introduced to the blood stream from 
repeated needle injection. In this article Jerika Whitefield, 28, was described as a young 
mother saved by open-heart surgery to treat her endocarditis that resulted from injecting 
heroin. Her stepfather reported that the attending physician told him: “once someone’s 
been shooting up, you go through all this money and surgery and they go right back to 
shooting up again, so it’s not worth it.” That this article was published in 2018 speaks 
volumes to the continued work needed to address stigma in the medical setting. 
The few disparaging reports of mothers who were neither pregnant nor 
postpartum primarily described them as either destitute sex workers who were estranged 
from their children, or serial heroin users involved in some criminal act. There was an 
implied racial bifurcation to these types of media reports. Women engaged in sex work 
were coded as non-White through the use of their names, such as the New York Times 
who described “Sooki, mother of “five children, all of them in foster care…[who tells the 
reporter] ‘I've been selling my body since I was a teenager’” and “Takeesha…dressed in 
a red camisole and shiny red thigh-high boots” (Kilgannon, 2012). In contrast, the women 
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engaged in criminal activities unrelated to sex work were coded as White. As one 
example, the Washington Post story of the “blond bandit” who “admitted that she 
committed a carjacking, robbed two banks and attempted to rob a third in November, and 
was part of a group that distributed more than 700 grams of heroin across the Washington 
area” (Jouvenal, 2012). In keeping with findings from the work of Hansen (2017) and 
Netherland and Hansen (2016), the story of the  “blond bandit” includes sympathetic 
discursive context. Unlike the sex workers who were portrayed as stuck in their role 
without any contextual explanation for their circumstance,  the “blond bandit” was 
reported as remorseful, quoting her lawyer, who stated: "she knows she has to pay a debt 
and wants to pay that debt. She doesn't want to see anybody else hurt" (Jouvenal, 2012).  
 
On the “Straight and Narrow”: Sympathetic Portrayals  
The largest proportion of sympathetic mediatized portrayals of pregnant women 
and mothers with OUD focused on the importance of pregnancy; loss, or fearing loss of, 
custody; and incarceration as critical to their success in maintaining treatment and 
recovery, i.e. being on the “straight and narrow” (58.2%). Articles wherein women were 
portrayed sympathetically yet were not on the “straight and narrow” via treatment or the 
criminal justice system (41.8%) utilized humanizing narratives centered on tragedy, guilt, 
and redemptive potential. Central to sympathetic representations of pregnant women and 
mothers was a categorization of addiction as a chronic illness, a classification which 
crossed political ideology of news sources. In 2016, the Christian Science Monitor called 
for an “approach to reversing the crisis [that] may help lead to a broader cultural shift—
from a crackdown approach that stigmatizes users, to greater compassion” (Khadaroo, 
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2016). Similarly, in 2016 the New York Times wrote: “we should think of drugs not 
primarily through the criminal justice lens, but as a public health crisis” (Kristof, 2016). 
A few months later, the Wall St. Journal also reported on the importance of a “public 
health approach” to the opioid “crisis,” noting it to be an opportunity to develop 
“enlightened systems of care” (Satel, 2017). 
Overall descriptions of women on the “straight and narrow” were sympathetic and 
emotive. For example, a New York Times story on mothers in recovery from OUD 
provided humanizing context for Elizabeth’s experience as a new mother, in spite of the 
revelation that she had waited until the end of her third trimester of pregnancy to stop 
actively using heroin and enter treatment. In the article, Elizabeth was depicted sweetly, 
speaking to her daughter in a “soft singsong murmur” while she anxiously cleaned and 
organized her home for an impending visit from the state Department of Children and 
Families. She was later described caringly giving her baby a massage, a skill she was 
noted to have learned in the treatment facility she entered during pregnancy. 
 She poured sunflower oil into her hands and began to rub them over her 
daughter’s chubby thighs. The oil glistened on the baby’s soft, fresh skin. “She’s 
so ticklish. We’re going to do the legs and the feet. You ready? Is Mommy doing 
it right?” Her daughter cooed, then grinned. It was the first time I had seen her 
smile. (Egan, 2018) 
 
Woven throughout redemptive narratives were references to violence and childhood 
trauma. In the New York Times story of Samantha Coleman, her substance use was linked 
to a violent relationship, as well as an entrenched family history of “her mother, aunts, 
uncles, grandparents and great-grandparents [who] had all landed in court before… 
facing charges associated with child welfare, drugs and domestic violence” (Schonbek, 
2017). 
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 In keeping with a brain disease model of addiction, in which opioid use can 
impair a woman’s maternal capabilities and instincts (de la Cruz, 2016), sympathetic 
reports of women who were on the “straight and narrow” referenced the need for 
paternalistic interventions, such as loss of custody or incarceration, to help women stay 
the course. Loss of custody was portrayed in multiple articles as a “rock bottom" (Kamp 
& Campo-Flores, 2016) that was key to getting on the “straight and narrow” via 
mandated treatment structures dictated by family treatment court. In the Christian 
Science Monitor, a mother was quoted telling the reporter: "If my judge didn't make the 
decision to send me to treatment, I would have went to prison and I wouldn't have 
changed nothing about myself" (Gass, 2018).  It is this type of reporting of agentless 
women that reinforced the need for programming that incorporated what the Wall St. 
Journal described as a “healthy dose of benign paternalism and, in some cases, 
involuntary care through civil commitment” (Satel, 2017).  
Much like the pseudo-racialization of methamphetamine use, these articles 
referenced  illicitly versus licitly accessed opioids to denote lower socioeconomic status. 
“This type” of woman was described as having a history of incarceration, limited family 
support, and “fathers of their babies [who are] out of the picture.” However, women with 
OUD “destined to go through their pregnancies in a shelter, jail or even on the street, 
fending for themselves as they had often done before” were portrayed as “tough, sassy, 
[and] vulnerable” (Seelye, 2016), granting them a sympathetic reasoning and compassion 
not extended to women with crack or methamphetamine use disorders. For example, in 
describing a mandated residential treatment program for mothers, the Washington Post 
(2016) described  
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Nine women [who] live in the little house by the railroad tracks. It's early fall, and 
they're sharing three bedrooms and a single bathroom. They rise each day at 6 
a.m., brush their teeth, eat breakfast together and then get into a van to ride a half-
mile to all-day group therapy. At dusk they'll be back, typically sitting on the 
porch, smoking cigarettes and watching the trains go by. The conductor will blow 
the horn. The women will wave, cigarettes brightening with the motion. It's a nice 
little ritual, and routines like this — "repetition and reward," as the counselors 
say— are encouraged for people in recovery from heroin and opioid addiction. 
These women dream of returning to normal life. Several have children but lack 
custody of them. In the grip of addiction, they traded away what they loved most 
in life for transient jolts of euphoria. In the war against self-destruction, victories 
tend to be small, incremental and fragile. (Achenbach, 2016) 
 
Some of the sympathetic portrayals of women reported on women who were not 
able to get on, or stick to, the “straight and narrow.” The narrative of these articles 
revolved around an overall lack of culpability and awareness around the addictive 
potential of prescription opioids. In a New York Times magazine feature from 2018, 
Alicia is a young mother who was described hiding her Percocet addiction from her 
family. Yet the article also signaled her social worth via the description of her job 
“working as a day care teacher and also assisting families of children with autism” (Egan, 
2018). A Christian Science Monitor article (Khadaroo, 2016) described the case of Susan 
Davis, whose substance misuse was reported to begin with a painkiller prescription to 
treat a sports injury. In reference to her first oxycontin prescription Ms. Davis is quoted 
as saying "I had no idea it could be so addictive…they give it out like it's candy." Davis 
goes on to say that "this disease doesn't discriminate. It doesn't matter if you're wealthy or 
poor or educated or not." Immediately contradicting this statement, however, the authors 
explained that Ms. Davis was indeed educated, clarifying that she currently holds “a 
master's degree” (Khadaroo, 2016), again signaling her redemptive potential.  
 
Content Analysis: Topical Media Coverage 
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In addition to discursive representations of pregnant women and mothers 
conveyed via macro-level (public media) narratives, the thematic content conveyed in 
each article was critical to my analysis. Thematic content was informed by discursive 
portrayals of pregnant women and mothers with OUD and centered on three main topics: 
(1) impacts of perinatal/maternal opioid use on demographic and social trends (76% of 
total sample), (2) public health programs and medical management of OUD (54.5% of 
total sample), and (3) critical factors that influence opioid uptake among pregnant women 
and mothers (36.4% of total sample; Figure 18). Over 90% of reports on social and 
demographic trends, 87.9% of media coverage on public health care was from, and 
76.2% of reports on 
factors influencing 
opioid uptake were all 
published in 2015-
2018. These temporal 
trends were in keeping 
with overall findings, wherein the bulk of media reports were concentrated in 2015-2018. 
Articles on social and demographic trends predominantly focused on the 
economic burdens of neonatal opioid withdrawal syndrome (NOWS) and shifting 
demographics, such as lowering life expectancies among Whites and an increase in 
grandparent-headed households concurrent to increasing rates of parental loss of custody. 
Additionally, articles called for criminal justice reform and innovative treatment 
approaches that prioritize treatment over the criminalization of substance use disorders. 
Conservative and centrist news sources (25% of coverage) primarily reported on the 
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economic strains on social service and medical systems, as well as the economic 
implications of increased grandparent headed households. Liberal news sources (75% of 
coverage) focused more on emotional dynamics, i.e. how grandparent caregivers coped 
with and adapted to parenting their grandchildren.   
Articles on factors influencing opioid use uptake primarily pointed to reckless 
prescribing practices, and called for restricting access to prescription opioids as a key 
component of efforts to curb OUD and opioid-related fatalities. Fifteen articles across the 
total sample identified the role of trauma as a factor influencing opioid use trajectories; 
10 of which were published in 2015-2018. Only four articles (three of which were from 
2015-2018) reported on mental health comorbidities as a risk factor for OUD; none were 
from conservative or centrist news sources. Of the articles that reported on trauma as a 
risk factor, 40% were from conservative and centrist news sources and 60% from liberal 
sources.  
 
“It Used to be so Mayberry”: The “Tragic Unraveling” of Quaint, Rural America 
Distinct from the crack and methamphetamine epidemics, which both contributed 
to the rise in the number of incarcerated women in the U.S., is a narrative of opioid use 
that centers on the tragic and economic decline of rural America; this narrative 
discursively positions people with OUD as citizens of worth and value. A prime example 
is the strategic transition from labeling opioid-related fatalities as a “crisis” rather than an 
“epidemic.” The Merriam-Webster dictionary defines an epidemic as “an outbreak of 
disease that spreads quickly and affects many individuals at the same time.” In contrast, a 
crisis refers to “a situation that has reached a critical phase… especially one with the 
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distinct possibility of a highly undesirable outcome” (Merriam-Webster, 2019). Based 
on this definition, it should be argued that all drug epidemics have been crises, not just 
the opioid “crisis.” 
Wherein war-like language was historically used to justify a War on Drugs 
approach to manage “White trash” methamphetamine users and Black and Brown heroin 
and crack users (Hansen, 2017; Peterson, Gubrium, & Fiddian-Green, 2018), in the case 
of opioids this same type of language was used to convey an overall unease and fear 
around a “tragic” unraveling of White, rural America. This fear of the changing 
demographics of “quaint, rural America” centered on a narrative of overlooked White, 
rural poverty. In one Washington Post article, opioids were anthropomorphized as 
“weapons of mass destruction,” categorizing opioid addiction as a “serial killer” 
responsible (Achenbach, 2016) for a “Zombie Apocalypse” in “quaint, rural America.” In 
this article women were described as “trying to survive an epidemic of self-destruction in 
small-town and rural America,” reporting that  
Death rates have risen sharply among Whites, particularly women, particularly 
those with a high school education or less – the White working class that played a 
key role in the November election. Last year, overall life expectancy in the United 
States fell for the first time since 1993, when HIV was rampant. Today there is no 
emergent virus running amok. Instead, Americans are dying from a rash of 
pathologies, sicknesses and addictions that experts call "diseases of despair.”  
 
The Wall St. Journal similarly deployed crisis language in their report that opioid-related 
problems among pregnant women and infants in the U.S. were “rising at a faster rate in 
rural communities than in urban settings, underscoring the terrible toll the addiction crisis 
is taking on small towns” (Whalen, 2016).  
The majority of news reports in my analysis referred to “rural” opioid use, cuing a 
whiteness that was contrasted to “urban” black and brownness (Hansen, 2017; Netherland 
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& Hanse, 2016). In these reports rural towns which “used to be so Mayberry” (a New 
York Times article title referencing the fictitious community that was the setting for the 
Andy Griffith Show from the 1960s, and a phrasing used to denote a dominant discourse 
of White superiority and purity) were described to be under threat from the encroachment 
of “urban pathologies” (Achenbach, 2016) cueing non-White criminality, deviance, and 
poverty. A sense of surprise was woven into these reports of “urban” encroachment. One 
New York Times article, “Abuse of Opiates Soars in Pregnant Women” described “people 
who previously might not have used heroin or the needle [who] are more likely to use 
prescription opiates” (Belluck, 2012) and “heroin [that] is bought and sold in bars, 
nightclubs, homes and more unlikely places” (Bernstein, 2015).  
Of the articles reporting on critical factors prompting problematic opioid use, 
more than half pointed to the over-prescription of pharmaceutical opioids as the root 
cause. Regardless of political ideology, multiple articles repeated the phrase that 
physicians “give it out like candy” (Associated Press, 2012; Khadaroo, 2016; Turkewitz, 
2017). Reports like this included the stories of: Susan Davis, whose addiction began with 
a “prescription for a painkiller to cope with an old sports injury” (Khadaroo, 2016); 
Ashley, who was prescribed Percocet after a car accident at age 18 and “became hooked” 
(McDaniels, 2017); Sarah Wilson, who painkiller addiction began “after she suffered 
serious spinal injuries when her car was hit by a drunk driver” (McGinley, 2016); Felicia, 
who’s addiction began with a dentist’s prescription for tooth pain (DeWine, 2017); and 
Karla Jacques, who was given “painkillers by Navy doctors in Jacksonville, Fl[orida]” 
after eye surgery (Jaffe & Eilperin, 2016). The story line was identical: faultless injury 
and irresponsible prescribing practices lead to “cheaper heroin…then all manner of chaos 
  119 
and dysfunction” (Achenbach, 2016). The recent dates of such reports stand out, given 
the wide recognition that the opioid “crisis” had already shifted from prescription opioids 
to heroin and fentanyl at the time of their publication (CDC, 2019). 
Given the nature of narratives about prescription opioids, it was unsurprising to 
find accompanying articles demanding accountability from pharmaceutical companies 
and sounding a call for more rigorous prescribing practices to protect people from 
prescription opioids that can be a “ticking time bomb in your medicine cabinet” (Renkl, 
2018). Reports on legal actions leveraged against pharmaceutical companies were  
common in this analysis, such as the New York Times coverage of the state of Tennessee, 
which joined:  
five other states in suing Purdue Pharma, maker of OxyContin, for aggressive 
marketing practices that included downplaying the drug’s risk of addiction and 
exaggerating its benefits in treating chronic pain. “We believe Purdue’s conduct 
has been unconscionable, and we intend to hold the company accountable,” 
Attorney General Herbert Slatery said in a statement. (Renkl, 2018) 
 
The Wall St. Journal similarly drew attention to litigation efforts in California against 
Purdue that sought to recoup state losses from “medical care and rehabilitation services to 
treat opioid addiction, care for children whose parents are incapacitated by opioid use and 
infants born with opioid-related conditions, and law enforcement and public safety” 
(Randazzo, 2018). Some articles additionally focused on the advocacy of grandparent 
caregivers who were “joining forces to combat the problem. Mothers whose children died 
from addiction have started to picket clinics that they believed were reckless with 
prescriptions” (Tavernice, 2011). And people such as “Felicia Detty's mother, who 
pondered the “role…pharmaceutical companies played in her daughter's death,” and was 
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quoted asking rhetorically: “they had the ability to just consume all of our communities… 
But are they standing there when you kissed your child in a casket?" (DeWine, 2017).  
Media reports on the “collateral damage” (Satel, 2017) of the opioid “crisis” 
extended beyond lowered life expectancies for Whites. Regardless of political ideology, 
these articles identified social and economic burdens associated with perinatal and 
maternal OUD, such as the cost of caring for substance exposed newborns, increasing 
rates of Hepatitis C Virus and emergency room visits to treat injection drug use 
pathologies (e.g. endocarditis and sepsis), and overburdened foster care and criminal 
justice systems. The largest proportion of these articles reported on the impacts of 
neonatal opioid withdrawal syndrome (NOWS).  
Across all news sources, media coverage referenced increasing health care costs, 
while drawing on emotive language to evoke narratives of fetal victimhood. For example, 
a 2016 article in the Christian Science Monitor reported that “while babies and children 
are not the abusers of these drugs, they are often the victims. In the U.S., one baby is born 
every 15 minutes with neonatal abstinence syndrome— symptoms stemming from a 
mother's opiate use. This rate amounts to 22,000 babies a year, five times the amount 
from 2000” (Hinkley, 2016). Notable is the descriptor from conservative Wall St. Journal 
that classified the “sharp rise in the number of opioid dependent babies” in Kentucky and 
West Virginia as “heartbreaking” (Campo-Flores, 2012). In an article on the increasing 
cost of NOWS, the New York Times (Belluk, 2012) reported that “the average cost of 
taking care of each infant climbed to $53,400 from $39,400, adjusted for inflation.” The 
author went on to note that “Medicaid paid for more than three-quarters of the cases, 
since many of the women were low-income,” making pointed reference to economic 
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“burdens” driven by low-income mothers with OUD, a narrative reminiscent of historical 
media discourse around maternal crack and methamphetamine use. 
Media depictions of “opiate orphans” (Saslow, 2016) or “generation heroin” 
(Khadaroo, 2016) were drastically different than those of “crack babies” and “meth 
babies” who were “written off even before they could talk” (Vargas, 2010). In 1989, John 
Silber, former president of Boston University, described "crack babies who won't ever 
achieve the intellectual development to have consciousness of God." Washington Post 
columnist Charles Krauthammer wrote at that time, “theirs will be a life of certain 
suffering, of probable deviance, of permanent inferiority" (Vargas, 2010). In contrast, 
reports of “opiate orphans” evoked empathy via reports of the pain experienced by 
substance exposed newborns; importantly, these articles did not write off infants with 
NOWS as doomed with neurological or pathological deficiencies. For example, a 
Washington Post article quoted Leslie Kerzner, associate medical director of the Special 
Care Nursery at Massachusetts General Hospital in Boston as stating: "We don't think 
that they have any neurodevelopmental delays just from going through withdrawal… In 
most kids, the brain is very plastic and they kind of rewire" (Bernstein, 2015b). However, 
this same article was titled “When Life Begins in Rehab,” simultaneously conveying 
messaging that reinforced maternal blame and responsibility. 
As a hallmark of fetal victimhood discourse, distinct from fetuses and babies, who 
are cast as tragic, yet, redeemable characters, mothers who use opioids are predominantly 
cast as “White trash” —deviant and outside the dominant logic of Whiteness. The 
application of this logic echoes the narrative positioning of mothers in mediatized meth 
narratives. References to Walmart, Family Dollar, the “nation’s heartland,” and “mobile 
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homes” signal White, rural poverty in these news reports. For example, the New York 
Times article, “Parents Get Their Drug Fix, Even When Children Watch,” from 2016 told 
the story of: 
Ms. McGowen, 36, of Salem, N.H., [who] was driving around with a friend and 
sniffing fentanyl…After picking up her daughter, Ms. McGowen went to buy 
diapers at the Family Dollar store in Lawrence…an old mill town at the nexus of 
New England's heavy drug trade. As she was shopping in the toy aisle, Ms. 
McGowen collapsed and slumped to the floor on her back. Her daughter started 
wailing, prompting another shopper to alert a store clerk. Employees called 911, 
and one began recording the scene with a cellphone. (Seelye, 2016b) 
 
Further drawing on narratives of fetal victimhood that reinforce the pseudo-racialization 
of maternal and parental OUD, media reports increasingly shifted focus to the increase in  
grandparent-headed households and growing rates of adolescent suicide among children 
with parents who were either incarcerated or deceased as a result of opioid use. As the 
New York Times reported in 2016,  
with the rise in heroin use, grandparents are increasingly raising their 
grandchildren because the parents are either dead, in jail, in rehab or otherwise 
incapable of taking care of their children. Nationwide, 2.6 million grandparents 
were responsible for their grandchildren in 2014, the census shows, up 8 percent 
from 2000. Websites and Facebook pages like The Addict's Mom, Grandparents 
Raising Grandchildren, The Parents of Drug Addicts and Before the Petals Fall 
are proliferating, drawing tens of thousands of people. (Seelye, 2016c)  
 
Similarly, the Wall St. Journal reported in the same year that  
many who were preparing for retirement are suddenly faced not just with the 
unraveling of a previously functional adult child, but with several young mouths 
to feed. “For my husband's 35th anniversary at the company everyone asked if he 
was going to retire.” He said, “No, I have a newborn,” ‘Ms. Meisberger says of 
her husband, a 56-year-old UPS driver. “Don't get me wrong, I love the kids with 
all my heart and soul. But this should be our time.” (Whalen, 2016) 
 
In these articles, grandparents and children were the focus; mothers were either 
referenced as afterthoughts or described as lost causes. 
A “Crazy Quilt of Punitive Approaches”: Calls for Progressive Social Reform 
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The Christian Science Monitor reported in 2016 that “in some corners of 
America, the lives of children and teens are being shaped by heroin and opioid abuse. In 
turn, they could help reshape how America sees addiction” (Khadaroo, 2016). The 
collective response to the opioid “crisis” is rooted in a broader call for social and policy 
reforms that, as the Christian Science Monitor described, “focus on the well-being of 
children swept up in the chaos” (Tan, 2016). Because "honestly,” as the Wall St. Journal 
reiterated, “if something doesn't happen with this addiction crisis we can lose a 
generation of kids" (Whalen, 2016).  
Over 50% of articles from the 2015-2018 sample make arguments for policy and 
programmatic reform to address the opioid “crisis,” regardless of political ideology (half 
report on criminal justice reform and the other half on innovative treatment programming 
for people with OUD). In contrast, only four articles total from the 2005-2007 and 2010-
2012 samples report on this topic. One article from 2011 detailed an alternative to a 
prison program that allowed mothers charged with felonies, many of whom experienced 
intimate partner violence, to live with their children, thus diverting foster care placements 
for youth (Robbins, 2011). In an Economist article from 2010, a judge from 
Massachusetts was quoted critiquing the cost of incarceration versus treatment, 
commenting on the lack of equity in mandatory minimum sentencing wherein 
“possession of a tiny amount (14-28 grams, or 1/2-1 ounce) yields a minimum sentence 
of three years…[and] treats opium-derived painkillers such as Percocet like hard drugs, if 
illicitly sold” (Anonymous, 2010). Of note: mandatory minimum sentencing based on 
weight was widely criticized during the “crack epidemic,” when People of Color selling 
the rock form of cocaine were inequitably incarcerated at drastic rates compared to 
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Whites selling the lighter powder form of cocaine. These critiques did not yield any 
substantive policy reform at the time (Musto, 1999).   
A large proportion of articles from 2015-2018 that call for criminal justice reform 
(27.3%) reported on the harms done to mothers and children as a result of sentencing 
laws and incarceration rates. These articles, such as one from the Christian Science 
Monitor in 2016, sympathetically referenced the “heart-rending” tragedies (Thomson, 
2016) of opioid-related fatalities that have prompted bipartisan legislation such as the 
“Improving Treatment for Pregnant and Postpartum Women Act,” which expanded 
funding for comprehensive, residential treatment services (Hinkley, 2016). Another 
article from the Wall St. Journal in 2016 lauded bipartisan efforts, such as the nearly 
unanimous authorization of state and local government funding “to expand the 
availability of naloxone…[and make] special provisions to help prisoners, veterans, 
pregnant women and mothers fighting addiction” (O’Keefe, 2016).  
Calls for a “larger national conversation about the long-term effect of nonviolent 
felony drug convictions and mandatory sentencing” (Zezima, 2017) were epitomized in 
the sample by stories of people such as Laura Tarantino, who wanted to adopt children 
impacted by the “crisis.” Yet because of her prior arrests and time served in prison for 
heroin possession in 2009, Tarantino was not eligible to do so. Other articles critiqued the 
“crazy quilt of punitive approaches to pregnant women with drug problems” (Egan, 
2018), questioning practices such as civil commitment to treatment, and charges of child 
abuse levied at pregnant women with OUD. Many of these articles spoke to an increasing 
need for programs to promote family cohesion and address the “abysmal” record of mass 
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incarceration that yields high rates of recidivism which “breaks up and impoverishes 
families…magnifying the poverty and the race gap in America” (Hoffman, 2017).  
Articles that described progressive approaches included descriptions of the 
increase in drug and family courts providing “treatment programs…tailored to each 
participant’s needs, [with] caseworkers and a presiding judge [there to] closely track their 
progress” (Schonbek, 2017). Alternatives to incarceration programs for mothers were 
also featured, such as the “Women in Recovery” program based in Tulsa, Oklahoma, 
which “has a two-generation approach that works with…women and their children [and] 
offers counseling, intensive support, coaching on budgeting and conflict resolution, and 
help getting high school equivalency diplomas, housing and jobs” (Hoffman, 2017). A 
Washington Post article, “Raising Babies Behind Bars” (Jouvenal, 2018), examined the 
strengths and limitations of introducing prison nurseries in the U.S. This article called 
attention to the historically overlooked practice of shackling pregnant women during 
childbirth, and the need for prisons to have “medical plans, proper nutrition and other 
basics available for pregnant women” (Jouvenal, 2018).  
Similar to the focus on criminal justice reform, media coverage reported on 
progressive reforms to the healthcare delivery system. The focus of such innovative 
programming centered on the mother-child dyad, such as rooming-in programs which 
encourage mothers to breastfeed and provide “skin-to-skin” contact. A New York Times 
article, “A Tide of Opioid-Dependent Newborns Forces Doctors to Rethink Treatment” 
(Saint Louis, 2017), focused largely on the importance of “Mom [as] a powerful 
treatment” that helps to lower cost via the reduction in use of medication and hospital 
length of stays. Particularly in news reports from 2015-2018, ideologically liberal news 
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sources focused on overall strategies to improve care and outreach to pregnant women as 
a means to minimize barriers to treatment, including the importance of addressing the 
stigma experienced by pregnant women with OUD. One such example from the 
Washington Post in 2018 detailed the increasing use of peer counselors, or “recovery 
coaches.” The article focused on the importance of a treatment and intervention team that 
includes women who can “relate to how other people treat you, how your family treats 
you, how you've dealt with it all” (Lang, 2018).  
In a time when reports of fatal shootings of Black people by the police 
increasingly fill the news, the proliferation of articles reporting on the critical role of 
police departments and fire stations in staunching the opioid crisis stands in stark contrast 
to media coverage that centered on policing prior drug epidemics. One article described a 
trauma-informed program based in Ohio that coordinated services between schools, law 
enforcement, and families. According to Captain Ron Meyers, a 21-year veteran of the 
police department in Chillicothe, Ohio, “punitive tactics no longer work against drugs… 
We need to make sure the officers understand this is what is going to stop the epidemic" 
(Zezima, 2017). The Wall St. Journal reported about a “Safe Station” program in New 
Hampshire that allows “people to drop off newborn babies, no questions asked, at safe 
havens like fire houses” (Kamp, 2016). A Christian Science Monitor article from 2016 
described a Massachusetts program wherein police officers responding to a substance use 
or domestic violence call ask parents and guardians to sign a form that assigns a “child 
advocate.” Signing this form then allows that advocate to act in loco parentis and connect 
children to services (Khadaroo, 2016). While this type of programming was lauded as an 
additional safety net for families with substance use disorders, a critical public health 
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perspective should prompt an investigation into the racially stratified experiences of 
populations who would, or would not, consider fire or police stations and programs such 
as this as “safe.”  
While fetuses, babies, and caretakers were centered with compassion in media 
reports, women and mothers with OUD did not necessarily fare as well. Some of the 
centrist and conservative reporting applauded paternalistic programming that responds to 
“the victims of the crisis” (i.e. infants) and overlooks women with OUD. Even in 
ideological liberal news reports, it was rare to find articles that discursively positioned 
mothers with OUD as individuals with valuable lives beyond their mothering potential 
and capacity. The only article that did so was a New York Times article from 2016 titled 
“Rise in Infant Drug Dependence is Felt Most in Rural Areas.” Physicians quoted in the 
article promoted a lifecourse approach to treating OUD, cautioning that “focusing on the 
babies alone is shortsighted… To stem the rise in infant addiction…it is critical to treat 
the mothers' opioid abuse.” According to one pediatrician practicing in rural Vermont 
quoted in the article: “One has to appreciate that behind every incidence of neonatal 
abstinence syndrome, which is relatively easy to recognize and relatively easy to 
treat…there's a case of a mother dependent on opioids, and that's complex to treat” (Saint 
Louis, 2016).  
Findings from the Adverse Childhood Experiences (ACE) study were published 
in 1998, and established a positive association between exposure to childhood trauma and 
subsequent development of substance use disorders. Although an increasing number of 
articles in this sample referenced the psychosocial implications of the ACE study, overall 
reference to trauma was limited (15 total articles, which represents 12.4% of the total 
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sample; 10 of the articles are from 2015-2018). In 2016, an article in the Christian 
Science Monitor (Khadaroo, 2016) cited a study that children who accumulate six or 
more ACEs — traumas such as “interpersonal abuse or parental substance abuse” —are 
4,600 percent more likely to become intravenous drug users. While limited, these 
references to trauma become important when contrasted to decontextualized 
criminogenic narratives of crack and methamphetamine use among pregnant women and 
mothers. In the context of opioid use, such articles listed reasons why women “popped 
pills to numb the misery” (Anonymous, 2010), pointing to “sexual abuse and other 
traumas… experienced as a child” (Goodnough, 2018), including unstable household 
dynamics and exposure to a family member’s mental illness and intimate partner 
violence. In a New York Times article from 2017 featuring the story of a young mother, 
she was quoted recalling that “All I’d seen was domestic violence and chemical 
dependency from my mom and my whole family— I didn’t know any other way to live” 
(Schonbek, 2017).   
Articles that reported on the impact of trauma were important for conveying the 
message that “incorporate[ing] this emerging understanding of trauma” into public health 
and criminal justice programming requires shifting from asking people with OUD “‘What 
is wrong with you?’ to ‘What happened to you?’” (Burch, 2017). As such, articles in the 
sample on criminal justice reform that cited “trauma” and “trauma-informed” care 
described a gentle form of judicial oversight. For example, one New York Times article 
described the court of Judge Claire, where mothers attended “parenting courses, drug 
treatment and domestic violence counseling, guided by caseworkers and service 
providers.” Additionally, women “had weekly (and later, biweekly or monthly) court 
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dates” during which they met with Judge Claire, who individually assessed their progress 
(Schonbek, 2017). “Rather than scolding participants when they slip up”, Judge Claire 
reminded women of their progress, and encouraged them to “devise solutions to their 
own problems, recognizing that their ideas might be more effective than the court’s 
prescriptions” (Schonbek, 2017). However, according to Judge Claire, the entire court 
system is “working harder for the children’s interests” (Schonbek, 2017), reiterating prior 
themes of fetal victimhood that inform and underscore such program development.  
 
Media Erasures 
Notable to my analysis was the near absence of articles mentioning the influence 
of mental health co-morbidities on opioid and other substance use disorder trajectories 
(four out of the 121 articles, or 3.3% of the total sample). One article conveyed important 
data on mental health and substance use comorbidities, explaining that “nearly 8 million 
adults in the United States have co-occurring disorders, according to 2014 data from the 
Department of Health and Human Services” (Lang, 2018). A second article addressed the 
challenges co-occurring disorders can present to care delivery, describing a treatment 
program for pregnant women with co-occurring disorders wherein: 
More than three-quarters of the women…take medication for depression, anxiety, 
schizophrenia, bipolar disorder or post-traumatic stress syndrome… Most have 
hepatitis C. Opiates are now the favored drug for about 75 percent of the 
women… but they are often mixed with cocaine, marijuana and alcohol. Virtually 
every woman smokes throughout her pregnancy. (Bernstein, 2015) 
 
             Despite scant reporting on this topic, two of the four articles identified an 
important and under-investigated issue related to provider inconsistencies around 
prescribing protocols for pregnant women who are treated for mental health and 
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substance use comorbidities. One article presented two divergent stories of pregnant 
women with OUD. There was the example of Alicia, whose “tendency toward frenetic 
worry was worsened by the fact that her psychiatrist, on learning she was pregnant, had 
stopped her anxiety and depression medications”; this was further compounded by the 
challenge of finding a “doctor willing to prescribe [mental health medications] for a 
pregnant woman on methadone.” To manage her anxiety, “Alicia smoked marijuana 
during her pregnancy” (Egan, 2018), a practice that the American College of 
Obstetricians and Gynecologists counsels against (ACOG, 2019). The same article 
described the contrasting experience of Elizabeth, whose “psychiatrist, unlike Alicia’s, 
advised her to remain on her medications through her pregnancy… although he warned 
that the baby might experience a secondary withdrawal effect from the Zoloft” (Egan, 
2018). Although these media stories represent a miniscule proportion of the overall media 
sample, outliers such as these stories can be crucial to developing justice-based 
interventions.   
Despite increasing rates of opioid-related fatalities among African-American and 
Latinx populations, only 10.7% (n=13) of the total analytic sample reported on issues of 
race and racism. One article speaks directly to the “troubling racial inequit[ies]” (Egan, 
2018) in rates of foster care placements: “In 2016, nearly one-quarter were black. In 
Chicago, only 12 percent of children in foster care were white; in New York City, the 
figure was only 6 percent.” Yet this statement is qualified by noting the lack of “willing 
and suitable family member[s]” among this population (Egan, 2018; emphasis mine). 
This commentary differs from reports on the changing demographics of grandparent-
headed households that cue White rurality. For example, the Wall St. Journal story of the 
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Currans, who live in a “ranch house in suburban Columbus, Ohio” (Whalen, 2016) and 
had recently gained custody of their grandchildren, and the LeCompte’s who, before 
taking custody of their grandchildren, “went on Trivia Night. We're both golfers, we had 
freedom. We were on the verge of the next chapter of life. ...But it just went to hell in a 
hand basket” (Seelye, 2016c).  
The unifying theme in articles like “Children of Heroin Crisis Find Refuge in 
Grandparents' Arms” (Seelye, 2016c) was the social, emotional, and financial hardships 
for these caretakers, prompting Op-Eds such as “Why I Was Wrong About Welfare 
Reform,” written by Nicholas Kristof (2016b), a regular contributor to the New York 
Times that writes on reproductive health issues. In his Op-Ed Kristof lauded the value of 
financial safety nets for this older generation. Again, this shift in social thought is vastly 
different from racialized resistance to welfare reform during the crack epidemic that was 
inflamed by media reports of “crack mothers” and “welfare queens” which dominated at 
that time.  
Media coverage on the crack epidemic in the 1980s entrenched key drug myths 
that persist, and which provide important context during a time when the opioid “crisis” 
has shifted demographically and constitutionally (i.e., from prescription opioids to 
fentanyl and other illicit derivatives, and towards a more racially diverse demographic). 
The first myth was that crack was a different drug than cocaine, resulting in inflammatory 
media reports inciting panic and reinforcing the need for stringent legal action. The 
second myth was that crack was instantaneously addictive, an unsubstantiated claim. The 
third myth was that crack was an epidemic “rapidly spreading into the suburbs…like a 
medieval plague…literally destroying American society” (Reinarman & Levine, 2004, 
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p.187). The fourth myth was that crack use caused crime and violence, and the fifth was 
that crack use in pregnancy caused “crack babies,” who would be a long-term drain on 
society and perpetuate a dependent welfare class (Reinarman & Levine, 2004).  
Despite the critique and refutation of these myths since that time, there are 
similarities to some of the narratives around pregnant women and mothers with opioid 
use disorders in the present day. Five of the thirteen articles that addressed stratified 
racialized portrayals of women with OUD did offer structural critiques of the crack 
“scare,” particularly with regard to the notion of “crack babies.” In 2010, the Washington 
Post and in 2012, both the Christian Science Monitor and New York Times each reported 
on the unfounded “alarm” generated by this narrative, and the reality that the “biological 
underclass predicted two decades ago had failed to materialize” (Vargas, 2010). In 2018, 
the New York Times reported on the  “widespread horror at the thought of newborns in 
[opioid] withdrawal [that] has led, some experts feel, to a cultural overreaction 
reminiscent of the ‘crack baby’ hysteria of the late 1980s and early 1990s, which wildly 
overstated the negative effects cocaine would have on the children of pregnant women 
who smoked it” (Egan, 2018). In their critiques, each of these articles referenced the 
more likely culprit in developmental concerns over the lifecourse, including “economic 
hardship, family instability, poor education, and other factors” (Belluk, 2012).  
Two articles in the overall media sample pointedly named the role of racism in 
driving the diverging discourse and responses to the crack, methamphetamine, and opioid 
“epidemics.” In 2018 the New York Times wrote of an awareness that “race has worked 
the opposite way in… the perception of our opioid crisis as an epidemic, rather than a 
racial pathology, owes much to the fact that White Americans have been hard hit” (Egan, 
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2018). As the Washington Post wrote a few days following the New York Times article, 
this shift in discourse, attitudes, and responses is “pretty clearly racist” (Lang, 2018). The 
New York Times went on to include the impact of the intersections of “race and class 
bias,” quoting Lynn Paltrow, Executive Director of National Advocates for Pregnant 
Women, who spoke of the larger social perception of pregnant women as their “own 
special class of persons, entitled to fewer constitutional and human rights” (Egan, 2018). 
Barry Lester, Director of the Brown Center at Women and Infants Hospital in 
Providence, similarly reiterated in this same article: “You have to realize that there is a 
certain amount of prejudice against women who use drugs. The expectation — almost the 
wish — is that there’ll be something wrong with these kids so we can blame these 
mothers again, like we love to do” (Egan, 2018).   
Despite data from the Centers for Disease Control and Prevention from 2014 that 
shows Native Americans (NA) to have the highest opioid overdose death rate of any 
group in the United States, with 8.4 deaths per 100,000 people in 2014— a rate double or 
triple that of African Americans and Latinos (Zezima, 2018), this population is nearly 
invisible in opioid discourse. Similar to reports on disparate rates of foster care 
placements among African-American children, one of the two articles that referenced 
opioid use among NAs described a “crush on the foster care system so great that the 
unthinkable had become inevitable: 70 percent of the Cherokee foster children in 
Oklahoma had to be placed in the homes of non-Indians” (Hoffman, 2017). Yet despite 
reported alarm around the fact that “Cherokee children [are] disappearing” (Hoffman, 
2017), this article included a statement from Mr. Hembree, a descendant of a revered 
19th-century chief, who in reflecting on generational loss of “heritage, traditions and 
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memories” is quoted drawing from moralistic language that places blame squarely on 
“addicted mothers and fathers… [who] can’t care for themselves, much less anything 
else…, [and who] who don’t give a damn about what their children will carry on” 
(Hoffman, 2017).  
Does this type of reporting point to a potential need for intergenerational 
conversations and education around substance use disorders in NA communities, or is it 
more reflective of historical patterns of demonizing narratives of mothers (and people) of 
Color with substance use disorders? This is a particularly important question as the 
opioid “crisis” becomes a fentanyl “problem” and the demographics of opioid-related 
fatalities increasingly become racially diverse. Of the total sample of articles I analyzed, 
22 articles reference “fentanyl,” all during the period from 2015-2018. There are some 
notable departures from prior reporting on opioids. Unlike reports on “opioids,” which 
center on locations such as Tennessee, Ohio, and Kentucky, reports of fentanyl focus on 
urban centers, including Philadelphia, Miami, Milwaukee, and Boston, despite the reality 
that the majority of opioid-related fatalities are currently fentanyl related.  
A second departure is the pointed clarification that the “precipitous rise 
of…fentanyl” is an “illicit,” “man-made” problem, a contrast to the predecessing 
narrative of  “manufactured death” (Lewis, Ockerman, Achenbach, & Lowery, 2017)— 
opioid addiction via “legitimate” access to prescription opioids. I provided examples of 
how media reports anthropomorphized opioids in a manner that evoked panic around 
rural scarcity. In contrast, fentanyl was anthropomorphized to incite a panic reminiscent 
of the type of language used during the crack and methamphetamine “epidemics.” For 
example, in 2017 the Washington Post described a “rash of potent synthetic drugs. They 
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include fentanyl and carfentanyl, an opiate typically used as a large animal tranquilizer 
that can kill people when taken in even minuscule amounts” (Zezima, 2017). Another 
Washington Post article from 2017 additionally oriented that fear towards police officers 
and police dogs for whom, “any contact with fentanyl can be deadly” (Lewis, Ockerman, 
Achenbach, & Lowery, 2017).  
What should certainly give us pause, and calls for our attention, is the type of 
response called for to address fentanyl and other “illicit” opioids, and how that may differ 
from the prior trends to date during the opioid “crisis.” As the Christian Science Monitor 
reported in 2018: 
The safer route is often to lock somebody up. Take a bill Kentucky lawmakers 
passed last year. In an effort to fight the opioid epidemic, House Bill 333 
increased penalties for the trafficking of "any amount" of heroin and fentanyl. The 
legislation eliminated a feature of the 2011 reforms that distinguished "between 
low-level addict dealers and high-level traffickers," the CJPAC report said, 
calculating it will be responsible for approximately 40 percent of the state's 
projected inmate growth over the next decade. (Gass, 2018)  
 
In 1989, “President George H.W. Bush announced a renewed war on drugs, with “more 
prisons, more courts and more prosecutors” (Lang, 2018). In 2018, President Trump 
declared a “national health crisis… diverting more funding to research and state 
resources” (Lang, 2018). As the opioid “crisis” becomes a fentanyl “problem” and the 
demographics of opioid-related fatalities are increasingly recognized as racially diverse, 
it is crucial to make visible the role of whiteness to ensure a sustained commitment to 
progressive social reform and a just and equitable response to address opioid use.  
 By drawing from media reports of the opioid “crisis”, this chapter identified key 
themes that underlie the gendered triple standard faced by pregnant women and mothers 
with opioid use disorder which entrench the stigma faced by this population. A key 
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thematic finding identified in this chapter centers around the notion of fetal victimhood. 
A sole focus on the “victims of the crisis” (e.g. infants, children, and grandparent 
caregivers) obscures a deep need for programs and services to support women’s 
autonomous needs, as well as the needs of families. Furthermore, this chapter identified 
key silences in media coverage, including mental health comorbidities, trauma, and 
People of Color. As such, current and historical media coverage elides key factors and 
populations, thereby providing an incomplete frame for programmatic and policy 
responses to perinatal and maternal OUD. As part of a critical agenda, focused outreach 
to media as a means to ensure more representative coverage of the issue is essential. 
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CHAPTER 4 
MICRO-LEVEL (INDIVIDUAL) NARRATIVES OF THE BIOMEDICAL 
MANAGEMENT OF PERINATAL AND MATERNAL OPIOID USE DISORDER 
 
Chapter Overview 
 More so than other populations with opioid and other substance use disorders,  
pregnant and parenting women with OUD inevitably interact with institutions that 
biomedically treat and manage substance use disorders at some point during their opioid 
use or treatment trajectories. A growing awareness of the broad-scale impacts of perinatal 
opioid use and the traumas associated with maternal OUD has yielded national policy 
change to promote programming and support for women and children affected by opioid 
use and opioid-related fatalities. Despite increased access to treatment for OUD, 
however, rates of sustained treatment engagement remain low and opioid-related 
morbidities and mortality continue to rise.  
 This chapter presents brings together micro-level narratives from women, 
providers, and policymakers interviewed for this dissertation to provide a depth of 
knowledge around the lived experiences of treatment engagement, as well as barriers and 
facilitators to the holistic care and treatment of perinatal and maternal OUD. This chapter 
begins with a discussion of formal and informal biomedical treatment perceptions and 
practices, examining differences in medication preference, the challenges inherent to 
managing substance use and mental health comorbidities, and exploring what drives 
women to “get off the clinic” and disengage with treatment. Next, this chapter explores 
the influence of the recovery movement and associated discourse on the provision and 
  138 
experience of care, specifically examining the ways in which recovery discourse can 
unintentionally exclude the overwhelming majority of people with OUD. The chapter 
concludes with reflections on just and inclusive care for pregnant women and mothers 
with OUD.  
 
Formal and Informal Biomedical Treatment Practices 
 
“Hitting the Right Dose”: Medication Perceptions and Practices  
Expanded access to medications for opioid use disorders (MOUD) allows for 
women with OUD to choose between methadone, buprenorphine (suboxoneâ or “sub”), 
and naltrexone (vivitrolâ; naltrexone is contraindicated in pregnancy, however). Among 
all treatment modalities, methadone has the most comprehensive data supporting its 
efficacy, given the length of time it has been used in the treatment of OUD. Particularly 
at higher doses, methadone is associated with superior retention outcomes as compared to 
buprenorphine and naltrexone. Risk of methadone overdose occurs with low patient 
tolerance and concurrent use of central nervous system depressants, such as alcohol, 
benzodiazepines, and opioids. As of 2019, there remain limited studies that 
comparatively assess MOUD efficacy; additionally, there are no studies which explore 
patient predictors of comparative MOUD success (Blanco & Volkow, 2019; Nunes, 
Krupitsky, Ling, Zummo, Memisoglu, Silverman, & Gastfriend, 2015).  
As office-based therapies, both buprenorphine and naltrexone circumvent the 
structural and socioeconomic barriers inherent to the requisite daily, clinical visits for 
methadone treatment, as was elaborated on in Chapter 1. Both buprenorphine and 
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naltrexone have improved safety profiles as compared to methadone; however, treatment 
retention remains a challenge for both. Buprenorphine is self-administered daily in 
sublingual form; a six-month implant exists, but there are limited data supporting its use 
in clinical settings. Naltrexone is administered as an injectable dose that lasts for 28 days. 
The least amount of data exists for naltrexone outcomes; patients are required to be 
abstinent from opioid for seven days prior to naltrexone initiation, which presents a 
notable barrier to treatment initiation (Blanco & Volkow, 2019). In this project, Jordan 
was the sole participant treated with naltrexone. At the time I interviewed her, Jordan had 
been successful with maintaining her recovery for close to a year. Satisfied with 
naltrexone, she shared that its effects wear off toward the end of the 28-day course. 
Jordan’s provider prescribed buprenorphine for her to self-administer to support her 
transition between this tapering effect and her next monthly naltrexone injection. 
However, in a recent conversation with a pharmaceutical representative I was told this 
was not a recommended practice. 
Particularly for the first few “shaky” months of recovery, the structure of requisite 
daily clinical visits to receive methadone was noted as key for women who had been 
unsuccessful in buprenorphine treatment. Kathleen, who had been stable on methadone 
for nearly five years at the time of our interview, recalled being “discharged for 
noncompliance” (meaning her urine screens were positive for illicit opioid and other 
substances) from multiple clinics that prescribed her buprenorphine. For Kathleen, it was 
“too much freedom immediately” during the first six months when she was “still dealing 
with the same people, talking to the same people… [and not making] any of those 
changes yet.” She identified the “discipline” and “accountability” of daily visits to a 
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methadone clinic as essential. Yet accepting the notion of daily clinical visits was a 
mental shift that did not occur immediately: “it's so weird,” she told me, “I had never 
wanted to get on [methadone] because of having to go there every day and then I realized 
—  I was like, well I'm chasing down dope everyday… what's the difference, right?”  
For Sarah, having access to a two-week supply of buprenorphine, especially in the 
early days of treatment, felt “really dangerous. I would just cut them into pieces if I 
wanted to feel better. Say I got a bad phone call and I hung up and was all upset— I 
would take another piece. I started misusing it. I'm an addict, so the more the better.” 
Speaking to the pervasive stigma about people with OUD, she commented that “it's 
amazing how a lot of people don't trust addicts, [but clinics dispensing buprenorphine] 
can trust their patients to get home with a bottle.” The buprenorphine made her feel 
“really good, and for the most part I don’t have cravings” on it. But when she found 
herself “broke, and had to get the rest of my rent, [she] ended up selling a bunch of 
strips… It's stupid, but I ended up getting the rest of my money for rent…, but then I was 
screwed and I started getting sick and was withdrawing.” She relapsed at that point, and 
later shifted to methadone, on which she had been stable for close to one year at the time 
of our interview. 
For women in the early stages between active opioid use, detoxification, and 
initiation to methadone or buprenorphine, it can be common to rely on the informal 
practices of non-medically supervised use of buprenorphine to help transition through 
these stages. Women understand how to taper themselves to transition to treatment, and 
they agentically apply this knowledge to themselves, filling a role usually relegated to 
providers. As such, pregnant women and mothers with OUD often engage in this 
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informal, folk medical practice of sorts, and share this knowledge through informal 
networks.  
For pregnant women and mothers actively using or who have relapsed, fear of 
potential loss of custody is the notable barrier to treatment entry. It was relatively 
common for women to report illegally accessing buprenorphine (or “sub” or “strips” as it 
was most typically referenced) via social networks to either avoid or prepare for 
treatment entry. For Tammy, informal use of buprenorphine in conjunction with heroin 
allowed her to reduce the quantity of heroin she was injecting prior to entering a 
treatment program. She then used buprenorphine to help her manage her withdrawal 
symptoms during the process of treatment enrollment into a local methadone program. 
For many of the women, the time between making the decision to enter detox or a 
treatment program and when one actually received medication could feel exceedingly 
long while suffering withdrawal symptoms. This was a vulnerable transition period 
during which changing one’s mind could easily happen in the moments while waiting for 
a bed (for detox), confirming that a clinic had space for a new client, or completing the 
requisite enrollment intake procedures.  
Active opioid users are acutely aware of how to time a buprenorphine dose to 
avoid withdrawal symptoms. Part of the non-medically supervised use of buprenorphine 
requires “finagling the dose.” Tammy remembered: 
I was cutting back because if you take suboxone you can't do dope, you'll go in 
instant withdrawal. Because I was taking suboxone I couldn't do the dope, and I 
wasn't going there [to the treatment center] to put myself in withdrawal because 
that just defeats the purpose you know what I mean? So I weaned myself down [at 
home]. I was at two, three bundles a day and literally I weaned myself down to… 
I was doing one, two, maybe three bags. And then finally I didn't do any bags 
because I had to wait 12 hours to take the suboxone. And then of course I was 
super sick, but I took the suboxone and instantly felt better. But I wasn't taking the 
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whole strip, I was breaking it into threes, you know? And so as long as I wasn't 
sick I was good...If I took the whole strip I would have been okay, but I didn't 
have the means to do that. I wasn't trying to be sick, so I cut it into three and took 
a piece. It has a long hold on it so it was working, and I had a whole strip before I 
went into [the treatment center]. So I remember finishing the strip in the office 
before I went in. So I didn't really need the methadone because the suboxone I 
had in me. 
 
Once women are enrolled in a treatment program, finding the right dose and 
medication is essential. In the context of OUD, “hit[ing] the right dose” should allow 
women to “stop thinking about using all the time, stop feeling cravings, start eating 
normally,” and start doing activities they currently, or may have previously, enjoyed. But 
finding this right dose is not immediate, and something that I never heard treatment 
providers and staff discuss in meetings or conferences or symposia. As a partial agonist, 
buprenorphine will displace other opioids bound to the opioid receptor and therefore has 
a “plateau” effect; once a certain dosage is reached, there are no additional opioid-related 
effects. For individuals with higher opioid tolerances, buprenorphine dosages may be 
insufficient to prevent cravings, thus resulting in decreased adherence (Krans et al., 
2016). For some women, the ceiling effect of buprenorphine and naltrexone did not stave 
symptoms and craving, while some commented that buprenorphine and naltrexone 
“changed their life.”  
Methadone is a full opioid agonist and can be prescribed at a broader range of 
doses than buprenorphine. However, a common side effect of methadone can be extreme 
lethargy. Women commented that seeing others in the program who were “drooling and 
nodding off” is why they tended to avoid methadone. As Sarah put it, “if I wanted to be 
like that, I’d keep using heroin.” However, this side effect can be circumvented with the 
right dose. Women in the early phases of medication-assisted treatment often continue to 
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use heroin and other opioids as they find the right dose. For some, this practice meant that 
women were “getting high,” and timing their use of heroin with the period when 
methadone was wearing off, to maximize its euphoric effect.  
In the early stages of my research, I met with Carolyn Sufrin, medical 
anthropologist and author of Jailcare: Finding the Safety Net for Women Behind Bars 
(2017), a treatise on the experiences of incarcerated, pregnant women in the U.S. At some 
point in our conversation about my project, I critiqued a dominant narrative of medication 
assisted treatment, which is that the use of MOUDs is “substituting one drug for another.” 
Sufrin stopped me and asked, “well, are they? Are people substituting one drug for 
another?” This was an important question, to which I would usually rebut. My critique of 
the “substituting one drug for another” discourse relates to how it reinforces the stigma 
associated with MOUD, and aligns with a moral model of addiction. In many ways my 
critique to this discourse is reactionary, because I see the harm it can cause. But in that 
moment I paused before responding: “I’m not quite sure I know the answer to that 
question right now,” as I was not yet far into my interviews with women (some of whose 
treatment included MOUD). I still appreciate that this question prompted me to 
investigate the validity of the “substituting one drug for another” rhetoric. And while I 
am hesitant to state my answer for fear of it being used out of context, it would be 
unethical for me to exclude findings just because I don’t necessarily like them.  
The simple answer to Sufrin’s question is yes, sometimes people do substitute 
MOUDs for heroin, and sometimes people use MOUDs for their synergistic interactions 
with opioids and other substances. Yet a simple response is never adequate in the context 
of substance use and treatment. There exists a range of nuance and complexity to 
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substance use and treatment practices, which is why the opioid “crisis” persists. An 
alternate response to the question “is use of MOUD substituting one drug for another” 
might be the questions: “why does this matter?” or “does it actually matter?” According 
to a brain disease model of addiction, substance use, treatment, and recovery exists on a 
cyclical spectrum. If women do substitute a MOUD for heroin or other opioids as part of 
this cyclical trajectory in ways that support treatment entry and engagement and 
ultimately optimal health, I argue that practices such as this should be included under the 
umbrella of a harm reduction approach for people with OUD. Furthermore, a justice-
based approach to treatment for people with OUD should acknowledge and value the 
lived experience of people with OUD and investigate informal “folk” practices used by 
women. Yet the stigma faced by pregnant women and mothers with OUD drives tangible 
fears of institutions that remains a significant barrier to treatment entry among this 
population. 
At the time of her interview, Kathleen had over five years of stable methadone 
treatment and worked as a recovery coach in Hampden County, supporting women newly 
in treatment. Kathleen recalled her early days of methadone treatment:  
[E]very time I would get paid it would be the same thing: I would call the drug 
dealer, I would hit the same ATM in the morning, go meet him, then go to the 
clinic. It was the same routine, I loved the routine. But by this time I was on such 
high dose of methadone, the dope didn't even do anything. I didn't even feel it. I 
just wasted my money. It was just part of the ritual. 
 
For Kathleen, it was this moment that gave her the awareness she needed to change her 
routine and stop using heroin. Soon after our interview, Kathleen introduced me to 
Aimee, a new mother in recovery; Aimee’s parents had custody of her young son. After 
three years of chaotic and heavy heroin use, Aimee had been stable on methadone for 
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close to one year. As we talked about treatment Aimee told me, “people say like ‘oh 
you're switching one drug to another drug,’ but it literally saved my life. Without it I 
don't think I could have gotten clean…It's literally the only thing that worked for me and 
made me comfortable enough to stop using.” Getting to this point is often not immediate. 
So while some women may initially “substitute one drug for another,” it is often a 
necessary part of the transition to stability and recovery.  
 I learned from my interviews with women that in clinical settings, providers often 
tell them that they expect them to be “dirty” until they reach a “stable dose.” Yet for 
Tammy, this felt like a “green light” to “get high and get your dose,” in part because she 
didn’t know what being stable on methadone would actually feel like. When we spoke, 
Tammy had been to three methadone clinics in the region before finding a fourth that she 
liked. At her first clinic, she recalled being “overmedicated” by “putting myself on 110 
milligrams” of methadone (a contrast to her current, “stable” dose of 35 milligrams). 
Tammy described “definitely getting high” from the 100 milligrams, although she didn’t 
realize it at the time; this touches on an interesting point about structure and flexibility 
within the clinical setting. In her other clinics, the standard practice was to give women a 
daily dose at a set time. Tammy contrasted this approach to her current clinic, where 
“they don't come after you for your dose.” From her experience, her current clinic helped 
her identify what a stable dose was by requiring her to proactively ask for medication 
when she felt “sick”, as opposed to giving it to her before she may have needed it. 
Additionally, in the other clinics “they'll nail you to 40 milligrams right off the rip” when 
women first enter treatment. I ask Tammy to clarify: “so they'll give you 40 milligrams 
for the whole day?” She affirmed with a nod, telling me “normally that would last, but 
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when you're coming off three bundles a day it's not even close. So I ran out of there, I ran 
so fast.” At her current clinic, they space out the dosing in the initial treatment stage by 
giving women “up to 10 [milligrams] every six hours,” which she attributes to a more 
comfortable and sustainable transition from heroin to methadone.   
Both women and providers offered important insights into MOUD and pregnancy 
that have the potential to be incorporated into treatment for pregnant women. When I 
interviewed David, Chief Medical Officer and addiction specialist at a behavioral health 
hospital, he told me that some women will “seek treatment and then discover they're 
pregnant because of routine screening.” For women who are actively using when they get 
pregnant, their “pregnancy symptoms are masked by [or confused with] symptoms of 
withdrawal.” One woman in recovery, Karen, told me that her nausea was so severe she 
thought she “had e.coli.” Another, Katie “start[ed] shooting heroin” to help with what she 
thought was “dope sickness,” only to be surprised to learn she was pregnant. When 
Eileen told me about simultaneously using heroin and methadone during her pregnancy, 
she relayed commonly shared emic knowledge related to the physiological actions of 
MOUD in pregnancy. She explained that she used heroin with methadone because her 
dose did not feel stable, telling me, “when it comes to pregnancy…the baby takes 
everything from you…The methadone’s already mainly going to them, so it's like you're 
not necessarily getting it.” The medical literature would explain the need for a higher 
dose of methadone to increasing blood volume throughout the progression of pregnancy.  
Linked to this folk understanding of the physiological actions of heroin in 
pregnancy was the women’s conceptualization that they had “more time” to use heroin 
prior to childbirth. Eileen “was on the methadone and I didn't stop using until September 
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2. He was born on the 10th, but he was supposed to be on September 30th. So I thought I 
still had this time.” She echoed this thinking when I asked if she had relapsed at any point 
in her pregnancy, telling me, “the last time I used was probably seven months pregnant. 
The last two months I was clean, but I guess it stays in their system longer too…I don't 
really know how that works.” I did not realize until reviewing the interview transcript a 
few weeks later that Eileen had contradicted herself in recollecting her heroin use in 
pregnancy, so I can only speculate on some potential reasons for her conflicting 
chronology. It may have been muddled memory recall from active heroin use; it could 
have just as easily been a result of guilt or shame or fear. In future research, I will 
investigate folk pharmacokinetic understandings related to substance exposure timing and 
the sense that once a child is born, there are no more “chances” to use heroin. Again, key 
to folk understanding and practices used by pregnant women and mothers with OUD is 
not only around how such practices are discursively reconciled, but that these practices 
signify the agency of the person who is using substances—while commonly depicted as 
being “slave” to the drug, they are also actively administering substances to themselves 
based on wisdom gained through embodied experience that is then shared through 
informal social networks. 
 
Managing Mental Health and OUD Comorbidities 
Because of my interest in the intersections between mental health and substance 
use, during my interview with David, physician and addiction specialist, I asked him to 
weigh in on a news report I had read about the potential antidepressant effects of 
MOUDs. He told me that: 
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[I]t does happen. There is some evidence around the psychotherapeutic benefits… 
We do see that at times patients that will come into treatment [with] a long list of 
trying multiple SSRIs and other medications for depression or anxiety and not 
really seeing great therapeutic benefit… [After] starting on methadone treatment, 
three to six months later [those same people report] feeling much better and not 
feeling the need to be on medications for depression… Now that doesn't happen 
with everyone, of course, but it certainly happens to a percentage of people. They 
feel so much better on regular, stable, and consistent opioid agonist therapy that 
some of the symptoms of depression are lessened. [We see this with] 
buprenorphine to an extent. I don't know how much evidence is out there for 
[buprenorphine], but I have seen that as well in clinical practice. 
 
This anecdotal antidepressant effect of MOUD sheds important light on potential reasons 
why people habitually use opioids, and offers a potentially more plausible explanation 
than the narrative of instantaneous addiction at first exposure. Jordan described heroin as 
creating a “quieting” that “relieved” her stress and anxiety and allowed her to escape 
from an “abusive relationship that took over everything, like, my whole life.” For 
Kathleen, heroin made her feel “good,” “normal,” “worthy,” and “in control.” Opioids 
helped her feel “the euphoria” that she hadn’t felt since she “lost her voice” after being 
sexually assaulted as a child by a group of boys ten years her senior. Jordan echoed 
Kathleen’s reported feeling of normalcy and control, providing a narrative of heroin use 
that differed from that of someone who “nods off” and is disconnected. She told me: “I 
don't like the feeling of not being in control, and I think that's part of the reason why I 
like the opioids so much because I could function on them. It made me feel good and 
normal.” 
 This anti-depressant, or “normalizing” effect of opioids and MOUDs provides 
important context that enhances understanding of mental health and OUD comorbidities. 
When I asked Tammy if she “picks up” heroin when she stops taking her mental health 
medications (for anxiety and depression) she responded succinctly: “most definitely.” 
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Shaila told me that “every time I was not in recovery, I didn't take my medication.” When 
Lorraine was actively using opioids she was simultaneously prescribed a range of mental 
health medications for bipolar disorder that make her ”feel like [her] arms are 
burning…,[her] scalp is burning, and [her] chest. It feels like you're on fire and it's a 
really uncomfortable feeling…”, she remembered. “I definitely have a significant mental 
illness, and it's being exacerbated by the drugs that they're giving me cause they're giving 
me the wrong drugs.” Lorraine remembered feeling “chained” to all of the medications, 
and found that opioids helped to relieve the physical discomfort she was experiencing. 
Part of her recovery process was working with her physician to wean herself from opioids 
and all mental health medications to find the correct medications to stabilize her 
depressive bipolar swings, which were her historical trigger to self-medicate with 
opioids. When we talked, she was taking one mood stabilizer and one anti-depressant, 
and had been in recovery for over three years. She no longer had the physical side effects 
that made her “literally feel like” her “skin was crawling.” 
For many of the women I interviewed, enrolling in a treatment program for OUD 
was the first time they either received mental health medications or were stabilized on the 
correct mental health medication and dose. Jordan told me that “the first period of time 
that I really took my medication continuously was when I was in the [residential 
treatment facility]. I figured out that the medication they were giving me [for anxiety, 
prior to that] wasn't the right kind of medication.” The treatment facility worked with 
Jordan to find the correct medication, which she credited to her overall stability and 
success in recovery. After a suicide attempt driven in part by her self-identified guilt from 
losing custody of her son due to her active heroin use, Kathleen entered an in-patient 
  150 
psychiatric treatment program. She noted that this “was the very first time I was ever on 
medication that I took right, and I didn't have those raging thoughts where I'm staying in 
my head all the time.” She went on to reflect that “you don't realize until you experience 
it yourself how these meds really are beneficial when you find the right medicine [and] 
you're taking them as you're supposed to. It really did help.” 
 To improve the provision of care for women in treatment for OUD it is important 
to understand how women experience and understand the experience and treatment of 
mental health and substance use comorbidities. Tammy identified herself as “one of those 
people who always thinks — ‘oh, I’m better, I can stop taking my meds now.’” Similarly, 
when I asked Marguerite about why she had stopped taking her medication (for 
depression) in the past, she told me “I thought I was alright… I'm like, ‘alright I feel 
better now.’ I didn't realize you have to continue on taking them in order to keep the 
feeling of where it's supposed to be at, I didn't realize.” When asked if this is something 
that her doctors and other health care professionals have discussed with her she said, no, 
“they don't tell you a lot about it.”  
Kathleen told me that during a relapse she “ran out of this script and then ran out 
of that one” and had not gone back on her medications for depression since that time. She 
“would like to get off of the methadone eventually and just have my psych meds, [but is] 
“not ready to get off the clinic. I don't want to rock the boat. I feel like it's working, so 
why, you know?” At the time we spoke, Kathleen told me she self-managed her “racing 
thoughts” that mostly come at night by taking melatonin and an “over the counter sleep 
medicine.” She talked about wanting to try CBD oil as well. Her fear of “rocking the 
boat” was compounded by what she had heard from others that “some of the psych meds 
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affect the methadone, they seem to, like, eat it up.” I ask her if this meant that taking 
psychiatric medication in conjunction with methadone would increase her cravings, and 
she told me yes, from what she had heard from others “in the mornings where normally I 
would be fine, I could wake up in the morning with withdrawal symptoms.” This fear 
was significant enough for Kathleen to avoid taking psychotherapeutic medications for 
her anxiety and depression. 
Despite high rates of substance use and mental health comorbidities, there remain 
limited scientific literature on the effect of concurrent psychotherapy treatment for people 
enrolled in MOUD programs. In part, this explains the most recent shift in biomedical 
terminology away from medication assisted treatment (MAT), which encompasses 
counselling and psychosocial therapy and medications for opioid use disorder (MOUD), 
to purely a focus on MOUD (Blanco & Volkow, 2019). Surprisingly, few staff and 
clinicians commented on differing requisite psychotherapeutic components of medication 
assisted treatment protocols by type of MOUD. As part of federal regulations associated 
with methadone, patients are required to attend individual and group behavioral health 
counselling. For people being treated with buprenorphine and naltrexone in office based 
settings by primary care or other providers, this is not a requisite of medication access.  
Marina, regional substance use consultant for Department of Children and 
Families, viewed all MOUDs as equally effective, and believed that it was optimal for 
women to find the medication that worked best for their individual needs. She worried 
that buprenorphine and naltrexone providers “aren't expected to have the same structure” 
and observed “fewer people that are prescribed suboxone or on the vivitrol shot who are 
actually following through with consistent counseling or involvement in support groups.” 
  152 
She also voiced concern that some “people who are receiving that medication who are 
just taking the medication” versus receiving the holistic mental health support that is 
most likely to facilitate long-term recovery and stability. An increasing number of 
federally funded health centers and clinics offer buprenorphine in a clinical setting. From 
my observations, many of these settings appeared similar to methadone clinics, largely 
due to the demographic profile of Medicaid recipients. According to Olivia, director of a 
buprenorphine “clinic” in Holyoke that serves a largely Latinx, low-income population, 
and in casual conversation with a Physician Assistant that practices at a federally funded 
health center in Springfield that prescribes buprenorphine to a similarly racially diverse 
and low-income population, individual and group behavioral health counselling is a 
requisite of medication receipt in their current “MAT programs.” 
 
Getting “Off the Clinic”: Complexities of Treatment Engagement 
On the other end of the spectrum from women like Kathleen who are afraid to 
“get off the clinic,” were those who were adamant they did not want to be on opioid 
pharmacotherapies “forever.” Although some of the resistance to long-term treatment 
with MOUDs was linked to a larger discourse related to the moral economy of addiction, 
there were multiple intersecting factors that prompted women to leave treatment. Maeve 
was a young mother in early recovery that I interviewed at her home in Turner’s Falls 
(Franklin County). Supported by housing funds earmarked for mothers in recovery, she 
had recently moved into a small apartment with her young daughter. When I asked 
Maeve about her experience with MOUD, she informed me that she stopped taking 
methadone when her daughter, now nine months old, was about four months old. She 
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“didn’t want to stay on it forever because I just felt like it's substituting one drug for 
another. But also, [before moving into her current apartment] I was staying with my mom 
[and] driving [the two hours round trip] from Ware to Greenfield every day to the clinic. 
That got old real quick. So I was like, ‘no, take me off of this.’”  
When I met Kirsten she was living in a residential recovery house after she 
relapsed from tapering her methadone dose too quickly. She “was having a very difficult 
time within the life I wanted to live on methadone and I wanted off of it.” She “gained a 
lot of weight [and] could not find a full-time job because it was taking two hours every 
day” to get to the closest clinic. Kirsten’s primary care physician is an outspoken 
addiction expert in Franklin County, and is routinely contracted to speak at area schools 
and events. The physician agreed to admit Kirsten “into the detox and come down 10 
milligrams a day.” Kirsten recalls leaving the detox with “a bottle of four Xanax in my 
bag and a bottle of 5 Klonopin” to manage her anxiety. She “immediately took all of 
them and relapsed right then and there.” At the time of our interview, Kirsten was starting 
a buprenorphine protocol for the eighth time. She wishes “ I had never went on 
[methadone]. I had to be on that big of a dose” and the transition off was difficult. A 
month after detoxing from methadone, she was still experiencing withdrawal symptoms. 
“I was crawling out of my skin having major panic attacks.” Her providers wanted her to 
switch back to methadone, but she was clear that she was “not going back on methadone. 
Ever.”  At the time of our interview she was currently taking “a full strip of 8 milligrams” 
of buprenorphine. “I'm slowly coming off of it,” she told me, “but I really don't want to 
be on it. I don't want to be on anything.” 
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Further complicating an individual’s desire to “get off of everything,” regardless 
of their reasoning, are the gendered expectations placed on pregnant and parenting 
women. David is Chief Medical Officer and addiction specialist at a behavioral health 
hospital. Based on his experience, opinions around MOUD from partners and families 
“tend to get heightened even more when there's a pregnancy or a child involved.” From 
her clinical experience as a nurse midwife, Emily additionally offered that “one of the 
fundamental problems with the health care system” is the concentrated programming and 
support offered during pregnancy that is nearly absent once “the baby’s out…We see 
them four weeks postpartum, and then that’s it. We're not seeing them during this really, 
really critical time…when all women need more support.” Emily went on to reinforce 
that, especially for women with opioid and other substance use disorders, the time 
beyond four week postpartum is a time when “maybe you're newer in your recovery… 
[And] if the person doesn't have really good social support when her baby's not sleeping 
through the night that kind of thing can be a really big trigger. There's certainly far more 
relapse [during the] postpartum [period] than there is in pregnancy.”  
For pregnant women, structural and social barriers to treatment are compounded 
by internalized feelings of shame and stigma. Emily, a Certified Nurse Midwife and 
researcher, observed that pregnant women who come into her clinic are often “taking the 
buprenorphine and the methadone because they're supposed to, but they're not happy 
about it because they're aware that they're still exposing their baby to something… They 
don't want to harm their baby and they want to go off of everything.” Emily pointed out 
many women take MOUDs to avoid punitive repercussions in pregnancy. Once they get 
to the postpartum period, “they're feeling like, ‘okay great I can get off of this stuff now’ 
  155 
so maybe now they're not taking their medication anymore. [But] if they don’t have 
resources and [have a] lot of stress around being a new parent [and] if drugs are a coping 
mechanism” relapse can be common.  
Much like women who discontinue their mental health medications because they 
feel “better”, this was also one reason cited by women as a reason for early 
discontinuation of MOUD; in both circumstances, relapse can be a likely consequence. 
When I met Sarah in a residential recovery facility, she had struggled with maintaining 
her recovery. At the time of our interview she was living in the recovery facility, working 
to regain custody of her daughter. When reflecting on one of her relapses, she recalled 
that it happened “because I tapered down [her buprenorphine dose when] I thought I was 
ready to, but I wasn't.” As I probe for details, however, I learned that her story was more 
complex than this. She remembered that “on suboxone I felt good, you know? I had never 
been on medication like that before so I kept taking more and more to feel good, to feel 
better, to feel even, you know…” She trails off at this point, but it is clear she is talking 
about feeling “high”. After two years on buprenorphine, Sarah began to feel like it was 
no longer effective. She “slipped” by taking some Percocetâ from her mother, who 
“doesn’t do hard drugs, [but] is a prescription medication addict.”  
Broader social shifts towards an embracing of a brain disease model of addiction 
are encouraging. Amelia, President and CEO of a philanthropic foundation that supports 
programming and policy development around opioid use prevention, has attended two 
meetings at the White House as part of President Trump’s “Initiative to Stop Opioid 
Abuse.” She commented that she has been “pleased” to hear key figures in the 
administration, such as “Kellyanne Conway, the commissioner, and the Surgeon 
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General” all define addiction as a chronic illness. She simultaneously cited the persistent 
problem of insurance policies that have not “caught up…to actually reflect that belief.” 
Although some people might get “30 days or 60 days of treatment, that is the very high 
end and then it goes away.” In clinical and policy settings it was common to hear the 
comparison made between OUD and Type 2 Diabetes as a way to articulate the 
importance of access to MOUD. Although women in recovery have told me these two 
disease are definitely not the same, that addition is a different classification with broad-
reaching consequences—specifically around relationships and parenting— Amelia 
commented that if OUD “is like diabetes…, [MOUD] or ongoing therapies are the same 
as having insulin for the rest of your life” and insurance policies needs to evolve to 
support and promote sustained treatment.  
Maeve’s experience getting into a treatment program during pregnancy illustrates 
how insurance barriers can play out in real time, impacting pregnant women and mothers 
with OUD on a daily basis. After completing a two-week detoxification program in 
Greenfield, Maeve transitioned to a two-week, in-patient Clinical Stabilization Services 
(CSS) program. She  
didn't want to come home because I knew I'm just gonna repeat the same patterns 
over and over again. I told them to find me a halfway house that I could get into, 
and they told me it's gonna be a wait. I said “screw it, I 'd rather wait and be sober 
and give birth to a beautiful, healthy girl than possibly a stillborn.” So I waited it 
out at CSS as long as my insurance would hold me. 
 
Maeve got discharged from the CSS program after her “insurance cut me off and my time 
was up.” She moved in with her mother to wait for a bed to open at a residential recovery 
home. Maeve began “using pretty much the entire time back at my mom’s waiting for the 
halfway house to call.” When Maeve was notified of a vacancy, she was told it would not 
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be for another month; ten days of sobriety was a requisite for entry to the program. 
Despite these obstacles, Maeve’s story was a success. She “took that time to get sober 
again to get everything out of my system so I could pass a drug test” and moved into the 
residential recovery facility within the month. After her daughter was born, they lived 
together in the facility for five months, at which point they moved into independent 
shelter housing.  
No matter who is bringing it up—whether it be women in recovery, social 
workers or clinicians—the sense of panic around the lack of available beds, and the 
potential of losing one’s bed is palpable. During various meetings I attended throughout 
this project, I heard providers and staff relay versions of the following worries expressed 
by pregnant women and mothers with OUD: 
if I go to detox, will there be a bed for me in the residential program? For 
how long? If I quality for the rooming in program at the hospital after I 
give birth, will I lose my bed in the family residential housing? how long 
will they keep it open? What if my partner starts using again? What if I 
lose custody— will I still have my bed? 
 
In Western MA, which has a population of about 800,000 people and one of the 
highest rates of NOWS in the state, there are less than 20 beds specifically 
designated for postpartum women and their infants. In MA, 60% of pregnant and 
postpartum women with OUD experience homelessness, shelter housing is 
constantly shifting people across the state, and all residential recovery housing 
runs at full capacity with wait lists. 
In an effort to improve maternal and infant health outcomes local hospitals have 
implemented rooming-in programs to support maternal-infant bonding and reduce the 
severity and cost of NOWS. Program stipulations limit enrollment to women that have 
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“proven” their treatment success during pregnancy. The Uplift Program is one such 
program that was developed at an area hospital in Greenfield. The goal of the Uplift 
Program is to reduce incidence and severity of neonatal opioid withdrawal syndrome, 
postpartum depression, and postpartum relapse through a rooming-in program. An 
additional program goal is to promote cohesion of the maternal-child dyad by 
establishing and implementing a formal process for women to track their treatment efforts 
and outcomes prenatally, to build a strong case to present to their DCF case worker post-
birth.  
Because it serves a small population, the hospital in Greenfield is well equipped 
to support mothers enrolled in the program. Volunteer “cuddlers” and nursing staff attend 
to infants while mothers leave the hospital to access treatment during the postpartum 
period. Based on the program’s success in Greenfield, the Uplift Program was launched 
in Springfield at the largest maternity hospital in the region. In this program, women are 
required to commit to a 2-3 week stay and provide their own food. Women are required 
not to leave their rooms. Neither staff nor hospital volunteers are allowed to care for 
infants due to “liability issues” when women need to leave for various elements of their 
treatment, which are mandated to maintain custody. Mothers that are on what is referred 
to as the “custody track” are given the least amount of support— in part because hospital 
staff are hesitant to promote bonding activities if loss of custody is imminent. These 
divergences provide important details on challenges related to “upscaling” evidence-
based programming in differing contexts. 
 
The Recovery Movement: Discourse, Politics, and the Other 80% 
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…almost all of the treatment and programs are abstinence-only focused. But if 
that's not someone's reality, what ends up happening are the secrets, the lies, the 
shame, the hiding, and the not being honest. And [then] their needs are not being 
met. 
-Lauren, Director of Harm Reduction Services at a community-based organization 
 Less than 20% of people with opioid use disorders enter and sustain the 
recommended and evidence-based biomedical treatment; rates are lowest for women 
(USDHHS, 2016). Yet it is this proportion of the population of people with OUD to 
which the bulk of resources are directed. The transtheoretical stages of change model of 
health and behavior (Bensley & Brookins-Fisher, 2009) that is central to substance use 
treatment programming emphasizes the importance of stages of “readiness” as 
fundamental to treatment uptake and sustained treatment. Although it is consistent with 
the scientific literature that a desire or “readiness” for treatment yields optimal treatment 
engagement outcomes, should this mean that the needs (treatment and otherwise) of the 
eighty-plus percent of pregnant women and mothers with opioid use disorders who may 
not be “ready” to enter treatment be overlooked? Based on a justice-based model of 
public health approach the answer is unequivocally no. However, the reality remains that 
approximately only ten to twenty percent of people with OUD enter treatment or 
recovery spaces. 
The “Voice” of Recovery 
 Lauren is program director at a local syringe access and exchange program; she 
has the lived experience of heroin use, has been in recovery for nearly two decades, and 
is a staunch advocate for people who are active injection drug users. When we met in her 
office, Lauren was quick to point out that she “loves recovery.” She spoke of the strides 
made around access to treatment and recovery programs and the de-stigmatization of 
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treatment that has been made possible in large part by the concerted activism of the 
recovery movement since 2013 or 2014. She recognizes that “there is some excellent 
work going on” and an overall “acceptance [of people with OUD], especially pregnant 
and parenting women [enrolled in] medication assisted treatment.” At the same time, she 
was critical. Because the “focus is so much on recovery, it's the majority voice at the 
table.” The problem with this, from Lauren’s perspective, is that recovery has become the 
“main narrative” that has “stifled the voice of other people's experiences.” When she 
attends meetings, she is typically “the only one that's representing any form of active 
drug use.” When I asked Lauren if she could “wave a magic wand and make one thing 
happen” she told me there “needs to be more competence about how to talk to people 
around active drug use.” She wants providers to be more informed around principles of 
“harm reduction, [such as] how to use safely within the environment that you exist in.” 
She underscored that this conversation “can take many forms, but the person that you're 
working with has to be part of that conversation— because it's their life.” Lauren sees a 
need for “improvements that can be made with working with pregnant and parenting 
moms, [such as] allowing for honesty… hard feelings, and just really, really needing [for 
providers] to hold back judgements.”  
As happened with almost every clinician/service provider I asked the “if you 
could wave a magic wand” question to, Lauren paused to wonder aloud why her wish 
was not that people would never use heroin or other substances in the first place. I 
appreciated that no one had opted to respond in this way— the easy and unrealistic way 
out of providing a meaningful response, in my opinion. Lauren’s answer, as someone 
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with the lived experience of active heroin use and someone vocal about the limitations 
imposed by the treatment and recovery movement, was crucial. She went on to say: 
[T]here's just so much maltreatment among healthcare providers with the 
interactions with people that use drugs… [If] somebody goes to the hospital, 
whether it's for an overdose or whether it's for whatever related to injection drug 
use, and if there's any interaction at all about drug use, it's always about detox and 
getting off… So a lot of times a story that's not told a lot is that people revert to 
lying, and that is such a common response. Or if [they don’t lie but] they're not 
interested in treatment, providers do not know what to do next with the person… 
So the person ends up leaving with no further information aside from: if and when 
you want to stop using then there's help, but there's nothing for that person while 
they're using… 
 
The dominant practice of primarily attending only to treatment and recovery leads 
to a lack of surety among treatment providers that can extend beyond the treatment and 
care of active substance users when they enter the medical system (often via the 
emergency room). When I asked Linda, a new mother in recovery, about her experience 
of care during pregnancy, she referred to the Uplift Program in Greenfield. Lisa 
remembered being open with her providers about being in recovery. She recalled they 
“threw in a few extra tests cause they wanted to make sure [she was not actively using 
opioids] and I get that.” When she met with the nurse in charge of the Uplift Program in 
Franklin County to talk about her recovery supports: 
[The nurse] assumed that I was on methadone or [buprenorphine]. She didn't even 
ask, just assumed, which was really interesting… A lot of people are taking that 
path nowadays, especially if you're using and then you become pregnant, like you 
have to have something for the child not to go through withdrawal and all that. 
But I actually was a little offended. I was like, “just because I'm in recovery 
doesn't mean I'm on something else, ya know?” [And] she was like, “oh so I don't 
know why we're meeting.” Then I'm like, “I guess not…” 
 
The nurse enquired about Linda’s support systems for her recovery during pregnancy and 
afterwards, and that essentially ended the appointment. I responded to the anecdote, 
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stating “that is interesting, though it’s sort of like all of a sudden…” Linda completed the 
sentence before I was able to complete my thought: “I was dismissed” she said. 
 
Women-Centered Care and Gendered Behavioral Modification 
Treatment approaches based on gendered notions of behavioral modification 
remain standard within substance use treatment settings. Nohea is director of a residential 
recovery facility for women, and has over 30 years of experience in the substance use 
field as both a “consumer of therapeutic communities,” and working at the direct care and 
administrative staff level. During her interview, she told me, “nobody is struck sober.” 
Nohea views recovery as a “process of being sober for a period of time, relapsing, 
experiencing the consequences of that, getting sober again, and little by little making the 
changes you need to make to be able to sustain a lifetime of recovery.” She shared her 
observations around interpersonal dynamics of people in recovery, based on her work 
with this population since 1983. She has noticed that in early recovery, women appear to 
go through some type of “regression” where they “act like they're 15 years old, yelling 
and screaming about so and so.” In her opinion, this is a common occurrence because 
“they say that we are as old as we were when we picked up our first drink. That's when 
you stop aging, and many times that happens at 14 or 15 years old…” It is this narrative 
that largely informs the need for largely paternalistic behavioral interventions and 
education around “coping skills” within treatment settings. As Nohea sees it, the “good 
work” comes when “we try to smash down those things so people can kind of get to a 
place where they can hear other people and become willing.” In women-centered 
programs behavioral modification is informed by individualistic narratives of “self-
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improvement” that “builds resiliency.” Nohea credited her own long-term recovery to the 
“behavioral tools” and “help with socialization” she learned from her work and treatment 
in substance use programs.  
The women living in the residential recovery house all spoke highly of Nohea; 
they specifically appreciated the balance of flexibility and rules that she intertwined into 
the structure of the program. Freedoms like going “to meetings by yourself, [or] to the 
store by yourself” may seem trivial, but this autonomy was cited by women as crucial, 
and what makes some programs stand out over others. Jordan appreciated that she was 
“allowed” to go to her room or go outside if she needed “some alone time.” In her prior 
treatment facility, women were not allowed those freedoms, and were required to spend 
the bulk of their days in the living room or kitchen. Unsurprisingly, Jordan found it “hard 
when you live with 30 women [in] those two small spaces and you all just have to sit in 
each other's face all the time.” Kathleen, a recovery coach supporting women in 
Hampden County, recalled a “horrible, horrible” behavior modification program she 
attended. “I didn't need to be taught to push my chair in, I didn't need to be taught 
manners and that's what they worked on… [T]he the residents were supposed to call each 
other out— it was like tattle tailing on yourself and each other.” She left the program 
after three months “and of course was using again” almost immediately.  
Kirsten was living in the residential treatment facility in Holyoke run by Nohea at 
that time of our interview. An element of the support Kirsten received from Nohea was 
reflecting on the “problem” of  her own “self-sabotage.” Kristen reflected that she 
“doesn’t know how to live sober on [her] own” and doesn’t plan on leaving the 
residential facility “anytime soon.” Although she had “graduated a few programs” she 
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“self-sabotage’s every time… I've made every mistake there is to make. When they make 
suggestions not to get a boyfriend, [and] not to do this behavior [or] that behavior, I've 
done them all.” Kirsten told me that drugs have “burned her brain,” but I observe her to 
be noticeably intelligent. As we sat in a front room of the house to begin our interview, 
Shaila barged in and demanded to be interviewed by me. Kirsten spoke to her gently, and 
Shaila became visibly less agitated. Kirsten went on to explain to Shaila that she has 
created a schedule for the pregnant women and mothers in the house who want to talk 
with me. While I had observed women who appeared to be mentally foggy, Kirsten 
struck me as a clear-headed natural leader, as evidenced in part by her self-appointed role 
as interview coordinator for the house.  
At the end of our interview, I asked Kirsten about her future goals, which 
included: tak[ing] “care of myself financially,” getting a job — “I’ve always wanted to be 
a nurse” — getting her driver’s license reinstated, and “hopefully be[ing] in my 
children’s life.” As she listed these seemingly basic goals I wondered about the barriers 
to achieving them: were they truly about “self-sabotage” or more a function of stigma and 
the barriers to housing, employment, and custody routinely faced by women with 
histories of OUD? Furthermore, the individualistic narrative of OUD for women conflicts 
with a chronic disease model of addiction and can be harmful, situating the vulnerability 
of relapse as a “choice” that becomes embodied by women as an internal “weakness.” 
Such notions of relapse are impoverished concepts that do not “accurately attend to the 
complex phenomenology of addiction and feelings of failure and worthlessness” (Garcia, 
2010, p.170). Amy’s words illustrate: if “you're not strong enough and…if you don't 
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believe that you have that power and control over yourself, you're not gonna be able to 
say no.”  
It is my conversation with Marguerite that made the notion of “behavioral 
modification” and “socialization” stand out as particularly deficient. Marguerite had lived 
in the women’s residential recovery facility for two months; she had primarily struggled 
with crack and alcohol addiction for much of her adult life. Her husband was “taking 
care” of their home, and their children were currently living in foster care at the time we 
met. When I asked Marguerite about her experience in the residential recovery program 
she told me that “we have groups that help us out with our character defects, our coping 
skills, [and] a little bit of everything.” When I probed about her “character defects” she 
told me: “I'm very kind hearted and I’m very open minded.” Her statement made me sad. 
“Are those bad things?” I asked. “I can listen very well,” she told me, “but being kind 
hearted can be very bad because you take everything in and you don't release.” From a 
critical public health perspective wherein the goal is a justice-based approach to 
treatment, I question the validity of a treatment model that prompts women to view 
kindheartedness as a fundamental personality flaw.  
 
12-Step Model of Recovery 
 A discussion of recovery and the recovery movement would be incomplete 
without mention of narcotics and/or alcoholics anonymous, otherwise known as the “12-
Step” program model. At its core, this model is abstinence-based, and is yet another 
space where the 80-plus percent of people who are not in treatment often feel 
unwelcome. Yet having a supportive social network of people in treatment and recovery 
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can be essential as a person shifts from active substance use to treatment to long-term, 
sustained recovery. At the time of this writing, Katie had been in recovery for more than 
eight years. We initially met during a digital storytelling workshop in Greenfield that I 
co-facilitated during my preliminary data collection. About a year after that workshop, 
she and I met at another digital storytelling workshop where she worked as a community 
support liaison. Katie assisted me with recruiting women who live in Greenfield for this 
project, and also agreed to “test” my interview questions before I began interviewing 
women in recovery. According to Katie, the key to her long term recovery was changing 
“people, places, and things,” a common recovery mantra repeated in nearly every 
treatment space I entered throughout this project. Many of the women I spoke to repeated 
some version of what Linda told me about the role of the 12-Step community: “It saved 
my life.” For many women in this project who had maintained their recovery for more 
than a few years, 12-Step programs remained integral to their daily lives via meetings and 
accountability, the trust and friendship gained from shared lived experiences and mutual 
support, and a sense of belonging within a larger community.  
For some of the women, however, the interpersonal politics of the recovery 
community were off-putting. Linda told me that the 12-Step community was “just not my 
thing anymore… I still use some tools from it but…there is a lot of drama around it.” 
When I probed for what she meant by “drama” she told me it’s “political in the sense that 
let’s say you become a treasurer, and you have people doing the chair and they think they 
have authority over you. For me it was just like, I don't want to be a part of this drama 
anymore.” Karen touched on similar “drama” and personal “politics” when talking about 
the leadership of one of the community-based recovery centers in Franklin County. Karen 
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is a mother in recovery and close friends with Katie, who was an active fixture in the 
Franklin County recovery movement. Karen didn’t provide details beyond telling me 
there was an “incident” after which Katie was banned from a Greenfield recovery center 
for 30 days. Karen was visibly agitated by this and showed her support for Katie by 
deciding that “as long as she wasn't allowed in there, I didn't go in there either.”  
For both Linda and Katie, though, the support from a community of people with 
the lived experience of opioid and other substance use disorders was essential in a world 
where, despite gains around addressing the stigma faced by people with substance use 
disorders, people in recovery either tend to alternately silence their history or stick to the 
“recovery community” where they know they will be seen as more than the monolithic 
master narrative of “addict.” Even though Katie wanted to support Karen by not going to 
the local recovery center, she told me she would still “stop by” when she was nearby so 
she could say hello and connect with friends. Similarly, Linda recognized that “when I'm 
in need, and…desperate, and when I feel a certain way, I will go. Like, I've been to NA a 
few times recently, ya know? AA and NA is always gonna be there, and there's always 
someone there I can talk to and relate with.” In response to my question about what 
supports are important for women in recovery, Linda talked about her struggle with 
postpartum depression. “[T]here's just there's times, even now, and especially when he 
was really little when you get no sleep and…you just have no energy, ya know? 
Sometimes to be able to say to someone without them judging, ‘I just really wanna take a 
fucking pill right now’ and have them not judge me, I need that. I still need that, and [I] 
get that in the recovery community…” 
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Lauren, director of a community-based harm reduction substance use and 
reproductive health program, credited the recovery movement with redressing stigma and 
shame around alcohol and substance use disorders. “But a side effect of that,” she told 
me, “is that it's hard to have a voice if you don't agree with abstinence and the 12-Step 
model of recovery.” She worried about the impact, particularly considering that “the 
[substance use treatment] field is overwhelmingly staffed by people in recovery…and the 
whole treatment system is based on the foundation of AA.” For Lauren, this insight is 
based in part from her work with active injection drug users; it is also deeply personal. 
Although she sees that the “intention” in the recovery movement is for recovery to be 
individually defined, she talked about her experience deciding to drink alcohol as a 
person in recovery from heroin use. After nearly two decades of recovery, she still could 
not “identify with the recovery movement” because she drinks alcohol and was therefore 
not considered “in a lot of people's eyes, especially the abstinence based programs” as 
being in recovery. She remembered that when she “started drinking 13 years ago, I had a 
lot of close friends…I totally understand why they did this, but I just got dropped by that 
entire community. People that were my friends just stopped talking to me, [and] I was 
completely outcasted.” She told me that her “life moved on and I was fine.” As she 
reflected back on that time, though, I could see her face redden; it was visibly still an 
upsetting memory after all these years. I appreciated her candor and reflection when she 
told me: “I can't imagine all the other people who have gone through that. Losing that 
sense of support from absolutely everybody you know [was so] isolating and shaming.” 
At the same time, and with time, she told me “I get it. My friends who dropped me were 
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afraid for their own sobriety… In their minds I [had] just relapsed and they just [couldn’t] 
have anything to do with me…”  
Although there is a growing sense that an “abstinence-based model” can and does 
include MOUD, this is not a universal truth. As Emily, nurse midwife and researcher sees 
it, there is still a debate around whether MOUD “counts” as “really being in recovery.”  
She sees a “lot of people [in the recovery community] who personally held themselves to 
a standard, and they hold other people to a standard of— it doesn't count as long unless 
you're on no substances whatsoever— you're not really sober unless you're not taking 
these medications.” Emily has worked with pregnant women who tell her that people at 
NA or AA meetings can be “particularly harsh” when women “disclose” their substance 
use. But “heaven forbid you tell them you're on medication assisted treatment.” From 
what patients have told her, doing so is something pregnant women can be “verbally 
crucified for that in that setting.” Furthermore, despite significant improvements in 
quality of care provision for women with OUD, Emily reminded me that she was 
currently aware of providers who do not support the use of MOUD. From her view, 
“we're setting people up for failure if we're acting that way as providers. Some people 
may be successful with [no MOUD], but some people are going to be really successful on 
methadone forever, just like if they take insulin. And if you're pushing people to this 
standard of —it doesn't count, you're not good enough unless you get off of it— and then 
they relapse, we haven't done any good. We've only harmed…”   
 
Investigating an Ethic of Care 
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Given Emily’s reflection on causing harm, what does an ethic of care look like 
wherein the provision of care does not cause harm? Answering that question requires 
understanding how relapse, a core component of a brain disease model of addiction, is 
addressed within the institutions that manage perinatal and maternal OUD. Furthermore, 
a deeper understanding of the experience of fear and stigma as barriers to care help to 
elucidate the lengths people will go to avoid treatment. Finally, an understanding of what 
it feels like to alternately feel cared for and judged within treatment settings provide 
critical insights for envisioning a justice-based model of treatment and care.  
 
Fitting Relapse into a Chronic Disease Model of Opioid Use Disorder 
 Under a brain disease model of addiction, OUD is classified as a chronic disease 
wherein relapse is an expected occurrence. Yet within the systems that manage opioid use 
disorders (medical, legal, and social services), there lacks a chronic disease framework 
for addressing relapse when it happens. According to Marina, substance abuse 
coordinator for the Department of Children and Families, “we all like to say that relapse 
is part of recovery and it's part of the disease of substance use disorder, but then we don't 
know what to do with it when someone relapses… We react in a way that is punitive and 
full of consequences for that person.” Sally, who directs opioid programming at a state 
department of public health, reinforced Marina’s point:  
systems like DCF and the court system are abstinence based, and there isn’t room 
for people to relapse within those systems. If you relapse, and again that doesn't 
mean using medication assisted treatment, it means relapsing, then there are 
punitive responses often associated with losing children… One of the biggest 
reasons that people often don't call 911 [if someone is potentially overdosing or 
needing support] is the fear of losing housing and losing custody of kids. 
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Lauren agreed that there is little “room for error” in the medical, legal, and social service 
systems, and “staff in these systems can be [in]sensitive to women who use any form of 
drugs if they're pregnant.” 
Marina views relapse as a critical “opportunity to learn” for people with OUD. 
One challenge she noted is the lack of a consistent definition for what constitutes relapse. 
Relapse is often “just a word that just gets thrown around” in “the field of substance use 
treatment.” From her standpoint, someone who “relapsed six months ago and is still 
using? That's active use, not a relapse.” And that differs significantly from “someone who 
relapses and quickly gets into treatment or reaches out and asks for support.” But in 
institutional settings that manage OUD, she does not see these two events as being 
distinguished from one another. She sees both relapse and active use as having punitive 
“consequences” as opposed to “ taking the time to assess and really understand, was this 
a relapse or are you actively using at this point in time?”  
 
Fear and Informal Systems of Care 
Obviously you know how much stigma there is around being a drug user and 
being first a female, but never mind being a parent and never mind being 
pregnant. I do know that historically there is an underutilization [of services] by 
females[due to] lack of access to services, a lot around children, a lot about being 
outed as drug user… There's just a lot of shame and stigma…  
-Lauren, director of harm reduction services at community-based organization 
 
She didn't fatally overdose, but she overdosed when her kid was in the home. She 
obviously lost custody, but then also had a charge of child endangerment, which 
goes on her permanent record. Not only does she have to face the stigma of losing 
her kid, but also this additional stigma every time she's looking for a job or what 
have you—on her record is this charge of child abandonment or child 
endangerment. 
-Sally, Director of Opioid Overdose Prevention Programming, Dept. of Public 
Health 
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 Fear and stigma are known barriers to engaging with treatment that can be further 
compounded by relationship and family obligations. Part of that fear relates to an 
unknowing of how it might feel to stop actively using. Sally, director of opioid overdose 
prevention programming at a local Department of Public Health, summed up the barriers 
she has observed from working with women across all stages of the using and recovery 
spectrum. Beyond the fear of losing custody, she spoke to an all-encompassing fear 
wherein: 
[P]eople are not willing to go into treatment because they're afraid of losing their 
job or housing, afraid of leaving their partner, and afraid of like things falling 
apart like they do… The fear of treatment itself and stopping drugs, it's scary. If 
you're pregnant you get fast tracked into [care and] if you have a child it can be 
hard to access programs, especially if you're not part of DCF and don't want to be. 
 
Lauren believes that isolation that stems from fear and stigma plays a notable role in 
addiction severity, overdose fatalities, and treatment engagement. “When you're thinking 
about parenting or [being] pregnant, in my mind it is compounded… There's a reason 
why we see so many more men than women, there [are] just so many more barriers to 
access tied around being a mother:  more fear about being recognized, or [caring for] a 
child and not being able to access services…”  
Family can be a common source of informal support and care, especially for 
women with children who are afraid to lose custody. Maeve told me about relapsing 
when her daughter was four months old, shortly after her daughter’s father fatally 
overdosed. She remembered that “my true friends stuck by me… Some of them would 
give me sub [buprenorphine] to get me through the sickness, and then once I realized that 
wasn't working [a friend] took my daughter so I could go to detox and clean myself up 
again and come back out as a new person.” However, the lengths some women or their 
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families would go to avoid care stood out. Lorraine told me that her mother had a 
“nervous breakdown” when Lorraine was young. She described a four year “postpartum 
depression” during which her mother was “in and out of electric shock therapy” and on 
high dose anti-psychotic medication until she “got off all medications and got better.” 
When Lorraine had her own “nervous breakdown” at age 14, her mother was “petrified” 
from her own experiences with archaic mental health treatment. Her parents “didn't ever 
take me to be evaluated.” Her mother “tried to nurse [her] at home and that became 
something [they] did… It happened so many times… She tried really, really hard. She 
didn't want me to get into the system, which ended up happening anyway.” Lorraine told 
me that she was 21 when she finally entered a treatment facility after she tried to 
intentionally overdose.  
While I am aware that Women of Color are statistically more likely to lose 
custody of their children compared to White women, some women have families that will 
step in to care for children if the women are unable to do so. Lauren commented that in 
“family-oriented cultures,” such as the Latino community, family support and 
intergenerational homes can be protective. Families often step in when women are 
actively using or in treatment, allowing children to bypass the foster care system. When I 
talked with women, I recognized that the ability to avoid the various health, legal, and 
social service systems was a definitive function of having a strong family network, that 
was not solely attributed to “culture.” Marguerite’s children never got “taken” because 
she would drop them off with family if she was actively using. When Karen’s nephew 
“was dirty, [her sister] was dirty, and she was gone on a run somewhere,” she and her 
parents became primary caregivers, thus evading a relationship with social services.  
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Some women credited their success in treatment to unwavering family support. 
Even though Kathleen “put her family through the ringer over and over again… they still 
never threw me out never turned their back, never gave up.” Jordan recalled that “I really 
clung to my mom for help in that situation because I didn't know anything about it. I was 
just so scared about it all… It's really, really scary when you first realize you can't put a 
substance down. I was like, ‘I don't know what to do, I need you to help me with this, I 
have no idea what to do.’” Both women cited this unconditional support as critical for 
both their sense of self and treatment success. In contrast, women with minimal family 
support struggled in their treatment. Tammy told me she “would have loved to have 
family to intervene and do something for me… At least somehow I would have known 
somebody cared enough, but nobody did so…” When I asked what might have been 
helpful during times when she was actively using, her wishes were not complex: they 
could have “at least came to me and got me off the streets and told me to get help.”. Now 
that she is “clean” she wonders “where they all are now.” I asked if they knew she was in 
a treatment program. “I don’t know, I don’t know. Maybe” is all she said, before 
indicating she was ready to move on to a new topic.  
 
Caring in the Clinic 
 Regardless of whether women opted to receive MOUD treatment, or which 
MOUD they preferred, women in various stages of treatment and recovery agreed that 
abstinence or pharmacotherapies alone were not enough to maintain their treatment or 
recovery. When asked about their experiences of treatment and care, women honed in on 
a sense of being cared for, and the importance of “finding the right counselor” for 
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encouragement and motivation. This could be particularly challenging, though, in an 
industry where there is perpetual turnover of staff. When Aimee told me that in “five 
years [I’ve had] probably 14 counselors,” I recognized that as par for the course. Aimee 
considered only two of her 14 counselors to have been “good.” When I commented that 
was “not a great track record,” she reported that “half of them I only had them for a week, 
two weeks, a month… They don't stay long, so it's always a turn over. Literally every 
week there's a new counselor and somebody leaves…” This means that women are often 
required to retell their “story” with each new staff member, particularly in clinical 
settings where time and staff are a limited resource. Although staff should be reading 
women’s medical records, they often do not, and end up “constantly” asking the same 
questions. Aimee found this “frustrating.” For her, attentive care means not having to 
“constantly have to tell people the same thing about me,” a particular concern given the 
prevalence of trauma among women with OUD, and the guidelines for trauma-informed 
care. 
When I asked Aimee to describe Bill, the “best” counselor she has had, she told 
me that not only does he “know everything about everyone,” but he listens closely and 
“can just read you.” Even more, Aimee liked him because “he doesn't judge anyone and 
he doesn’t always say the bad things about you. He wants you to think positively, and 
you don't always hear that from counselors. It's nice when they're actually like that and 
it's just totally different…” For Sarah, an ethic of care is similarly basic and fundamental. 
She told me about an in-patient treatment program where she was “treated so well… they 
were like, the best people.” She described the staff as “caring,” “loving,” and “genuine.” 
“It was like talking to a mom or an aunt or a dog.”   
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Beyond his kindness, what stood out to Aimee about Bill was that he was drawn 
to his work because of his own recovery. And it was this “understanding” that appeared 
to be a lynchpin that builds both trust and hope. When reflecting on her interactions with 
Bill, Aimee elaborated that it is “nice to just hear his stories and see where he is now, 
especially when you're at a low. He's just shined through everything and he makes me 
have hope.” When I showed up to Aimee’s apartment to interview her, she and Kathleen 
were pulling into the parking lot. Kathleen was Aimee’s recovery coach. Much of her 
work consisted of driving women who either didn’t have licenses or cars, or who lived in 
locations with limited public transportation, to the various appointments they were 
required to attend as stipulations for maintaining or regaining custody. Kathleen had her 
young son with her, and we all walked into Aimee’s apartment together. At the start of 
the interview Kathleen was changing her son’s diaper and playing with him on the couch. 
When Aimee talks about Bill, Kathleen chimed in from the couch to add that when she 
“was skipping the clinic” she had a counselor who she had not “clicked with at all.” Like 
Aimee, Kathleen attributed this lack of connection to the fact that her counselor “had no 
experience with addiction other than just textbook.”  
 Aimee and Sarah’s stories of feeling cared for in clinical and treatment settings 
were rare. From the various meetings I attended over the course of two years, I observed 
divergences between people who work at the managerial and policy level versus those 
who work in direct care (and often lower paying) positions. The people who attended 
meetings and conferences about improved care provision were primarily in managerial 
positions at the very least. It was these people who appeared to be aligned with a chronic 
disease model of addiction, in which access to treatment and minimal exposure to stigma 
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are crucial for success in recovery. Yet this perspective did not immediately trickle down 
to front-line care workers who were most often working directly with pregnant women 
and mothers in various stages across the substance using spectrum.  
Caring Addiction Services is a regional organization that provides trainings for 
people working in the substance use treatment field. Their trauma-informed trainings for 
caregivers working with pregnant and postpartum women were routinely referenced and 
shared in the meetings I attended. However, Tammy told me that based on her time spent 
in one of their treatment facilities that they “had the worst staff. They looked at you like 
you were just a piece of shit. I didn't like that because in the end we're still human 
beings.” In regards to clinical care, Amy talked about her experience giving birth to an 
infant with NOWS, and remembered that some of the hospital staff were “really judgey 
because of my situation. I had one nurse literally straight up tell me I was not getting my 
son back.” Amanda simply said that when she received prenatal care she was treated 
“like I was a junkie.”  
At its foundation, a justice-based model of care and treatment would encompass 
all pregnant women and mothers with OUD. As it currently exists, however, clinical and 
treatment settings that manage and treat OUD among this population predominately serve 
those who are either abstinent from all substances, or increasingly, those who are 
maintained on mediation assisted treatment pharmacotherapies. Despite macro-level 
(scientific) narratives that define OUD as a brain disease and chronic illness under which 
relapse is expected, this narrative is not automatically taken up by staff, nor incorporated 
into current policies and procedures. In part, a notable challenge are the disconnects 
driven by who is “sitting at table”— largely professional staff at high-level administrative 
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positions. Although these individuals are often aligned with a chronic disease model of 
OUD, frontline care givers do not necessarily buy in to that narrative. Furthermore, 
individuals with lived experience of opioid and other substance use disorders who are 
invited into spaces where provision of care and services are discussed, are largely those 
from the “recovery community” who are guided by a 12-Step model of recovery that can 
be at odds with evidenced based approaches to treatment as per a brain disease model of 
OUD. Almost universally absent were the voices of people who actively use substances, 
or those who might be “going through the motions” of taking the requisite MOUDs or 
psychotherapeutic components but who were not doing the “inner work” of recovery.  
During the ethnographic component of this project when I attended local, 
regional, and national meetings, symposia, and conferences convened around perinatal 
and maternal OUD, I attended a presentation by a Massachusetts district attorney (DA) 
that was given at a community health center in Hampden County. The DA was interested 
in building a case around discrimination experienced by pregnant women who were in 
recovery, specifically around the state-specific practice of automatically reporting 
substance exposed newborns to DCF, regardless of whether that exposure is from illicit 
substances or MOUD. In response to a question from one of the presentation attendees, 
the conversation shifted to housing access and discrimination experienced by people with 
substance use disorders. According to the DA, people with substance use disorders are 
protected from discrimination under the affordances offered to people with disabilities 
under the Equal Rights Amendment. However. This protection is only offered if a person 
is considered to be in recovery. When probed by the audience on how “being in 
recovery” was defined under this legislation, the DA replied with something to the effect 
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of “there is no standard definition of what constitutes recovery.” This anecdote reiterates 
the challenges inherent to a lack of universal definition of recovery. Given the range of 
the ways women experience “recovery” and the accepted understanding among 
professionals that recovery should be assessed individually, limiting this concept to a 
defined set of factors should not be considered an antidote. Perhaps more important to 
address, however, are the contingent protections offered to people with substance use 
disorders, which exclude currently relapsed or active substance users. Recovery models 
must be broadened to provide just and equitable treatment. An entry point can be the 
simple acknowledgement that all individuals are deserving of care, regardless of where 
they fall along the substance use continuum.  
Building on findings presented in Chapter 3, individual-level narratives shared by 
women, staff, and policy makers presented in this chapter further illustrate the myriad 
ways in which a gendered triple standard is directly linked to the stigma experienced by 
women with perinatal and maternal OUD. Although research on women with OUD is 
increasing, treatment practices and approaches have historically been informed by 
findings from research conducted strictly with men. By making visible the experiences of 
women, this chapter identifies women-specific factors that enhance our understanding of 
what is often myopically categorized as “non-compliance”. Personal experiences and/or 
shared stories of bias experienced by pregnant and parenting women underlie an inherent 
fear of institutions that manage OUD among this population. This fear in turn prompts 
women to engage in “non-medically supervised” use of MOUD to delay or transition into 
treatment. At the same time, folk practices such as “finagling the dose” or off-brand use 
of MOUD have potential to inform treatment protocols based on the lived experience of 
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women engaging in systems of treatment. Furthermore, experiences of discrimination 
experienced by women within treatment settings perpetuate fear and avoidance of 
institutions that are intended to provide support and care for this population. Building 
from positive experiences shared by women additional can guide justice-based 
approaches to treatment and care that ultimately support the optimal well-being of 
women and families.   
Informed by findings presented in this chapter, I call for justice-based treatment 
for women and mothers with OUD that is informed by the four ethical tenets of public 
health practice: beneficence (i.e. active promotion of good), non-maleficence (i.e. active 
avoidance of harm), justice, and autonomy. More specifically, justice-based treatment for 
women and mothers with OUD should: (1) recognize that all people with OUD (and other 
substance use disorders) are deserving of dignity-based care, not just people in treatment 
or “recovery”; (2) incorporate and apply principles of harm reduction across all stages of 
the substance use continuum; and (3) recognize and respect the autonomy of individuals 
by valuing the expertise of people’s lived experience and promoting collaborative and 
shared decision making.  
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CHAPTER 5 
MICRO-LEVEL (INDIVIDUAL) NARRATIVES OF TRAUMA WITHIN THE 
CONTEXT OF THE BIOMEDICAL MANAGEMENT OF PERINATAL AND 
MATERNAL OPIOID USE DISORDER 
 
Chapter Overview 
 Trauma discourse as pertains to opioid and other substance use disorders among 
pregnant women and mothers largely focuses on exposure to adverse childhood and 
lifetimes experiences. Staff working with this population are attuned to the reality of as 
Marina put it, “they all come with a trauma history.” In her role as substance use disorder 
consultant for the Department of Children and Families (DCF), she has heard “horrific” 
stories of client intakes that are largely filled with reports of “the third generation or 
fourth generation of children with parents who have substance use issues.” David’s 
definition of trauma from his work as a physician and addiction specialist includes 
“substance use disorder, epidemics, poverty, violence, war, and all these other things 
[such as] displacement, and families been torn apart at the borders.” In his view these 
factors are “creating trauma everywhere, [and] I think we haven't recognized that 
there…is a huge population that's at risk…[And] when that exposure [to a substance] 
does happen…addiction can develop.” Increased awareness of the impacts associated 
with exposure to trauma has yielded critical changes in the delivery of care for women 
and mothers with substance use disorders. Emily reported that in the hospital where she 
works as a nurse-midwife, as part of their commitment to providing trauma-informed 
care it has been standard practice since 2015 to screen pregnant women for “intimate 
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partner violence, reproductive coercion, and depressive symptoms” as well as the “Five 
P’s” (substance use by a woman’s parents, peers, and partner during her pregnancy and in 
the past).  
When asked about facilitators of sustained recovery, Amelia, President and CEO 
of a philanthropic foundation that supports programming and policy development around 
opioid use prevention, told me that it “goes back to what people need to be healthy: a 
house, a job, and a date; [the] date [being a] euphemism for personal meaning and 
personal relationships, whether those are friendships or other things. I think that's what 
gives people hope.” All providers/staff generally agree that structural barriers such as 
transportation, insurance access, and socioeconomic marginalization are key barriers to 
sustaining recovery. What remains less clear, however, are the nuanced factors that 
constitute what David referred to as “how somebody feels about staying in treatment long 
term.”  
Building from macro-level (public media) and meso-level (scientific) narratives, 
this chapter broadens current definitions of trauma within the substance misuse 
scholarship to extend beyond the interpersonal (i.e. adverse childhood experiences, or 
ACEs) and structural (e.g. lack of transportation, employment, or insurance coverage) 
and takes a pointed look at the institutional violence imbedded into policies and 
procedures specific to the treatment and management of perinatal and maternal OUD. In 
this chapter I argue that the intertwined institutions (e.g. medical, legal, and social 
services) that manage opioid use disorder according to biomedical dictates enact a 
converging constellation of violence on women. This, in turn, becomes a form of 
embodied trauma, directly influencing substance use trajectories of pregnant and 
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parenting women with OUD. To illustrate, this chapter identifies and discusses three 
forms of institutional violence as experienced by women in this project: 1) civil 
commitment to treatment as a form of direct bodily violence, (2) loss of custody as 
visceral violence, and (3) institutional erasures as symbolic violence. 
 
Institutional Violence 
 While applying a social determinants of health framework to OUD has led to 
positive efforts around increasing access to health care and transportation, for example, it 
can often be void of an examination of the role of power in dictating differential access to 
goods, resources, and optimal health outcomes. In keeping with the larger call for a 
critical public health agenda, this chapter draws from anthropological theory on structural 
violence to focus on three forms of institutional violence identified in this project. 
Structural violence refers to the inequitable distribution of power enmeshed into the 
political economic framework of society that drives divergent patterns of health and 
wellbeing (Farmer, 1996). Institutional violence is made possible by structural violence, 
and pointedly refers to institutional policies and practices that are considered part of a 
larger system that is perceived to be fixed (Curtin & Litke, 1999; Foucault, 1963). As 
with structural violence, it is the illegibility of institutional violence that is most 
problematic.  
The first example of institutional violence presented in this chapter is of direct 
bodily violence, an experience most aligned with exposure to interpersonal physical 
violence. The most pronounced example of bodily violence referenced in this chapter is 
the use of physical restraints and withholding of MOUDs as part of standard procedures 
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utilized in civil commitment of individuals into substance use treatment. Unlike 
interpersonal acts of bodily violence such as intimate partner violence and childhood 
sexual abuse, which social mores do not outwardly condone, interpersonal acts of bodily 
violence as part of standard institutional practices are accepted as “business as usual” or 
“best practices.”  
The second example of institutional violence in this chapter is of visceral 
violence, an underexplored topic in the violence literature and one that is crucial to 
consider when examining the intimacy of pregnancy and mothering. In one of two 
publications discussing visceral violence, Sarah de Leeuw (2016) examines the 
biopolitics of colonialism and the visceral violence of being displaced from home and 
family as experienced by indigenous women and children in British Columbia. In the 
second, Clisby & Holdsworth (2014) explore the concept of visceral violence as relates to 
women’s mental health over the lifecourse. However, their conceptualization of visceral 
violence is as a synonym for interpersonal experiences of gender-based violence, 
specifically exposure to sexism and sexual violence among school-aged girls. While de 
Leeuw’s conceptualization may be most closely aligned with the notion of visceral 
violence as set forth here, it draws from a decolonial perspective that while certainly 
critical and relevant to mental health and substance use among pregnant and parenting 
women, has a specific set of biopolitical factors that are not universally applicable to all 
women with OUD.  
The last example of institutional violence in this chapter is of symbolic violence. 
Drawing from Bourdieu (1989; 2001), symbolic violence refers to daily enacted “gentle 
violence” that reinforces and internalizes socially patterned and hierarchical raced, 
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classed, gendered, sexed, and othered ideologies that are “exercised upon a social agent 
with his or her complicity” (Bourdieu and Wacquant 2002, 167). Symbolic violence is 
best identified via the silences or absences — of topics or people — woven throughout 
this project. As one example, nearly every woman interviewed for this project had been 
separated from their family and placed in a foster home for at least some length of time as 
children. Yet the role of intergenerational family separation was never discussed by 
women or clinicians, staff, administrators, or policy makers as a potential risk factor for 
problematic substance use. Additionally silent was the role of race and racism, as well as 
“drug siloing” (i.e. overlooking polysubstance or non-opioid use; Knight, 2015) on opioid 
use and treatment trajectories. 
 
Civil Commitment to Treatment as Direct Bodily Violence 
 
“Sectioning” as a “Last Option” 
Civil commitment to a treatment facility is an increasingly utilized practice in 
MA, largely driven by the dramatic rise in opioid-related fatalities in the state. 
Colloquially referred to as “sectioning” or “being sectioned” (a reference to Section 35 of 
Chapter 123 of MA state legislation specific to Public Welfare, Title XVII), civil 
commitment to treatment results in up to 90 days of state-mandated detoxification and 
“clinical support services”. A person cannot “section” themselves. The process must be 
formally initiated through the legal system by a spouse, blood relative, guardian, police 
officer, physician, or court official (Commonwealth of MA 2018). Once a petition is filed 
with the court, a warrant is issued and the person being “sectioned” is remanded to a 
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holding cell to be evaluated by a court appointed official prior to a court hearing. The 
decision to civilly commit an individual is based on the co-presence of an alcohol or 
substance use disorder and imminent “likelihood of serious harm” to oneself or others 
due to their substance use disorder. Recent updates to Section 35 legislation require that 
the court report the person’s name, social security number and date of birth to the state 
Department of Criminal Justice Information Services, barring access to firearms for up to 
five years and making their record of civil commitment publicly available 
(Commonwealth of MA 2018), a process historically reserved for people convicted of a 
criminal offence. Access to MOUD as part of treatment is not standard when being 
sectioned and can depend on the facility to which one is committed (i.e. a treatment or 
correctional facility). 
MA state guidelines identify civil commitment as a “last option,” yet in 2016 over 
6,000 people were civilly committed via Section 35 (Commonwealth of MA 2018). 
“Sectioning” is indicative, in part, of the lack of available resources for loved ones who 
may feel like they have no other option, and for whom the potential of biomedical 
treatment through any means necessary offers hope. Lauren is Director of Programs at a 
community-based organization that offers substance use harm reduction services, such as 
syringe access and disposal, overdose prevention programming (e.g. naloxone training 
and other harm reduction education), as well as a range of reproductive, sexual health, 
and social services (e.g. HIV and STI testing, family planning services, access to PrEP, 
nutritional counseling, and referrals to health insurance enrollment, child-care, fuel-
assistance and housing services). When we met, she spoke to the increasing practice of 
“sectioning” as increasingly facilitated by “parents and people that are just really afraid 
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for their children, and wish they could just be taken out of the street because they're just 
so worried about them.” Yet Lauren expressed concern about the impacts of policing 
people with OUD in this manner. “Parents have a pretty powerful voice and [the] 
emotion [of it] catches people… [W]hat they're dealing with is real, but a lot of policy 
makers have [responded with] sectioning, and the correctional system already has a lot of 
power…” At the time, when Aimee described what compelled her parents to “section” 
her, I could imagine the desperation driving that course of action: “by that point I had 
overdosed quite a few times. My dad found me in the bathroom…I think that kind of 
scared the shit out of him. [T]he next day I was sectioned.”  
Due to progressive state policies, it is not standard practice in MA for pregnant 
women to be “sectioned.” However, a lifecourse approach (Hser, Longshore and Anglin 
2007; Lu & Halfon, 2003) prompts us to consider how a lifetime of experiences influence 
health in the present moment; specifically, how the experience of being “sectioned” 
during one’s life may influence a pregnant and parenting woman’s decision to access 
OUD services. On a population level, women who are actively using when they get 
pregnant typically engage with the medical system only in the final trimester of 
pregnancy; this was the case for all women in this study who, like Aimee, were using 
heroin or a combination of heroin with MOUD pharmacotherapies until close to their 
delivery date.  
I met Aimee through Kathleen, a recovery coach who worked with pregnant 
women and mothers with OUD. Aimee was aged 30 at the time we met. Her small and 
tidy apartment was in the back of a housing complex tucked off of a main road in 
Agawam, a primarily White town in Hampden County. Although her parents currently 
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had custody of Aimee’s nine-month old son, his presence was everywhere— toys stacked 
neatly under the TV for when her father would bring her son to visit, a push-bike behind 
the couch, and a high chair pulled up to the kitchen table. The wall art was a combination 
of her son’s drawings and framed inspirational quotes. At age 16, Aimee was prescribed 
benzodiazepines to manage her anxiety. Following an abortion at age 18, when she 
remembered being “literally forced out of the car and told [by her mother she] had to do 
it,” Aimee described a “spiraling moment” of substance use that lasted from ages 19 to 
28. Starting with non-medical use of prescription opioids at age 24 then heroin at age 26, 
Aimee described that period as a chaotic cycle of heroin use, voluntary treatment, and 
civil commitment. Aimee used heroin in conjunction with methadone through the seventh 
month of pregnancy; at the time we spoke she had been stable on methadone for nearly 
one year.  
Women who had been sectioned were fundamentally opposed to it. For Aimee, 
the experience of being sectioned was traumatic, resulting in a fear and avoidance of the 
institutions designed to support women in her situation. Bring sectioned made her “feel 
like a criminal. You're thrown in handcuffs, put in a paddy wagon, and shackled with 
people who are getting dropped off at the jail on the way. It's not a pleasant experience at 
all.” “You're shackled” I asked?  I was incredulous. Aimee continued: “yeah, to each 
other. It's a nightmare. Hands and legs shackled. It's not fun.” Aimee described the 
treatment facility as “horrible,” recalling that there were “50 people in one room at a 
time, [and] four people in each bedroom.” Access to MOUD as part of being “sectioned” 
is not standard. In most instances, a person will be treated with MOUD, if they are 
already initiated on that medication through a clinic. However, by and large people being 
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sectioned are actively using illicit substances; if they are taking MOUDs it is not under 
medical supervision. It did not surprise me when Aimee shared how important it was for 
her to feel “safe” in order to seek clinical care. 
In January 2016, the MA state Governor signed legislation that banned the 
historical practice of civil commitment of women2 with substance use disorders into 
correctional facilities as opposed to treatment programs. Although I initially thought 
Aimee’s experience was in a jail, it was not. Nickia, however, had been remanded to a 
women’s jail prior to the legislation being passed. She received no treatment or 
counseling, and for her “safety” was not allowed to come into contact with people 
serving time; she spent most of her days in a cell, ate all her meals in a cell, and rarely 
spent time outdoors.  
When I met Nickia she was one of a few African-American women living in a 
women’s residential recovery facility. She has been “sectioned” by her family for her 
alcohol use disorder 28 times; the last two times she had entered treatment was of her 
own volition. In the 28 times she was “sectioned,” Nickia was never offered addiction 
counseling or “comfort meds” to ease her “detox”. Like Aimee, Nickia was strongly 
opposed to civil commitment. But in nearly the same breath, she invoked the 
vulnerability of being unable able to access treatment when she wanted it: “they could not 
find me a bed. I sat in crisis for two days. They found me a bed, [but I wouldn’t go to] 
treatment because they were forcing me to like to say, ‘you want to hurt yourself’ [then] 
you can go here. I'm like, ‘I don't want to hurt myself.’ I need help.”   
 
2 This legislation was not extended to men, who can currently be civilly committed to correctional facilities 
and expected to wear the institutional clothing issued by the correctional facility to which they are 
remanded. 
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“I Knew I Was Gonna Leave This Place and Use Again” 
Prior to being “sectioned” by her parents, Aimee had voluntarily entered into 
detoxification and 30-day treatment programs a few times, yet had been unable to abstain 
from heroin for any substantial length of time. When I asked if she thought mandated 
treatment was effective, Aimee touched on the concept of “readiness” as a critical 
component of treatment initiation, engagement, and efficacy that was repeated throughout 
the project. “I had literally just started using heroin at that time, so it was still new to me. 
I wasn't done experimenting. I knew I was gonna leave this place and literally use again. 
Like, that's just all I had in my mind for that whole time. I just wasn't ready.”  
Training for people that provide addiction counseling services (e.g. recovery or 
peer coaches, clinicians, and social workers) centers on motivational interviewing 
practices that draw from the transtheoretical stages of change behavioral model, which 
conceptualizes relapse as one stage of addiction and recovery (Bensley & Brookins-
Fisher, 2009). According to Marina, substance use consultant for DCF, “we don't 
necessarily respect the stages of change and how motivation plays a factor…just because 
you locked [someone] up for a month doesn't change that.” Yet notions of readiness and 
individual “motivation” come into direct conflict with a brain disease model of addiction, 
which points to “physical changes in areas of the brain that are critical to judgment, 
decision-making, learning and memory, and behavior control...[that] help explain the 
compulsive nature of addiction” (NIDA 2019). How, then, do we reconcile the NIDA 
definition with what Aimee told me about getting to the point of “really wanting to stop” 
using after nine years of “spiraling” and chaotic use: “you have to, like want it. If you're 
not at that point you're just gonna keep using, ‘cause I know I did for years.” 
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In her critique of “sectioning,” Lauren, director of a community-based substance 
use harm reduction program, brought up a pivotal question about the long-term success of 
mandated, rapid detoxification. Similar to Aimee’s point about “readiness,” Lauren’s 
comment similarly centered on autonomy. Relating sectioning outcomes to mandated 
withdrawal for incarcerated populations, she commented that “we know people are 120 
times more likely to die from an overdose within the first two weeks of being released 
from prison.” She acknowledged that “there’s always that person [sectioning] will work 
for,” but had spoken with providers who observed differences in outcomes between 
“people that are forced into treatment versus people that go in on their own.” Based on 
their anecdotal observations, mandated treatment “isn’t near as successful.” 
Rather than simply critiquing the biomedical management of perinatal and 
maternal OUD however, it is important to examine their liminal complexities. Wherein 
the use of the word liminal (derived from the Latin word “limen”, meaning threshold; 
Mirriam-Webster, 2019) pushes us to consider states of being in spaces of ambiguity, the 
notion of liminal complexities asks us to take a step further and contemplate the ethical 
conundrums and complexities held in these spaces. For example, parents who civilly 
commit their children to mandated treatment often do so out of love and a true fear their 
child may fatally overdose, such as with Aimee’s parents. Yet this route to treatment can 
mean being physically restrained with shackles, refused MOUDs, or being sequestered to 
a jail cell for “safety” reasons. And while a brain disease model of addiction leaves us to 
understand the brain to be “hijacked” and incapable of autonomous thought or action 
among people with OUD, how do we interpret when women and staff refer to “readiness” 
as key to treatment engagement, particularly when referenced by women with persistent 
  192 
histories of substance use disorders? Does the notion of “readiness” signal autonomy and 
opposition to a brain disease model of addiction, or an internalization of a moral model of 
addiction that remains imbedded in OUD programs and services? And what about what 
Sally, in charge of opioid programming for a state public health agency, referred to as 
“non-chaotic” substance use, referencing individuals that regularly use opioids in ways 
that do not align with “chaotic” use patterns that constitute the DSM-V definition of 
OUD and which signal a level of control or choice? And what of women like Yadira, 
stable on methadone for four years after a history of heroin use that began at age 13 after 
she ran away from home, who talked about wishing her parents had sectioned her, 
likening it to a show of care? Lastly, for some women like Karen, treatment by any 
means necessary was a welcome respite from the “daily hustle” of sexual and physical 
vulnerability, even though it meant “walk[ing] into any emergency room and saying 
you’re gonna kill yourself. They have to take you, they have to. So that’s what you do, 
that’s what I did.” “So would you cut yourself?” I asked her. “Yeah, oh yeah,” Karen 
replied. “I just needed somewhere to get away…I needed a break.” Exploring the 
questions that emerge from examining these liminal complicities have potential to guide 
important policy and programmatic efforts to improve treatment delivery and outcomes. 
 
Loss of Custody as Visceral Violence 
In this chapter visceral violence refers to acts of institutional violence that result 
in loss of custody, and are experienced by mothers as deep, physical emotions. The 
Merriam-Webster dictionary (2019) defines visceral as an adjective with three meanings: 
“(1) as if in the internal organs of the body, (2) not intellectual, and dealing with crude or 
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elemental emotions.” Extending this definition to the sensory, I conceptualize the 
complimentary definitions to be (1) deep, and below the surface; (2) of the heart, not the 
head; and (3) felt as anguish, perhaps expressed aurally through caterwauling or 
internalized; deep into the bones and gut.   
 
“Parental Capacity to Care” and Stratified Mothering 
A biomedical model of OUD recognizes relapse as part of its chronicity; as such, 
“success” in substance use treatment typically requires multiple attempts (NIDA, 2019; 
USHHS 2016). However, as discussed in Chapter 4, relapse often runs counter to 
expectations of maintaining or regaining child custody. In MA, substance use that 
impacts what DCF workers refer to as “parental capacity to care” (Department of 
Children and Families, 2018) is the primary reason that social service organizations 
remove children from their homes and place them into foster care (MADHHS, 2018). 
However, the determination of who has the right to parent is highly subjective. Women 
talked regularly about how hard they work each day to prove their maternal fitness 
(Lupton 2012), tracked by checking off varying tasks from an ever-present, perpetually 
shifting, and seemingly insurmountable to-do list. Tanya described 
[L]iterally walking hours, to take one bus to another bus, to take a bus for an hour 
here to hit my recovery, to go to IOP (intensive outpatient treatment), to go to my 
appointments, to come here to do whatever I needed to do to make my recovery 
work. Because I could not mess up. There was no way. If I did, I'd never see my 
kids again. I need them. I live and breathe for them. They're my life. 
  
Marina, regional substance abuse coordinator for DCF, underscored this sense of 
how hard women work: “I don't know how we expect people with substance use 
disorders, and mental health, and lack of resources, and a lack of support to get to 17 
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different appointments in one week every week for a period of time…. I don't know [if] 
I'd be able to do it.” Tanya described in further detail what her day often looked like: 
I walked from Royalston to Phillipston (13 miles), I'd get a bus from Phillipston 
to the Ocean State Job Lot in Athol, and then I'd take a bus from Ocean State Job 
Lot in Athol to Greenfield. And then I'd walk in Greenfield and do what I needed 
to do here. Then I'd walk back to the bus, bus back to Athol, then bus back to 
Phillipston, and then I'd walk (13 more miles back to Royalston). I was in great 
shape but I was literally walking hours. Then I got a job in Ocean State [Job Lot], 
but my hours were after or before the bus. So I had to walk from Royalston to 
Athol to work (7 miles)…[T]hen I would jump a bus from work, to Greenfield, to 
my appointments, back to work or whatever, and then I'd walk home. 
Occasionally I'd get a ride, but typically it was me and my feet. 
 
The topic of DCF came up in nearly every conversation with women, who 
repeatedly reported on the inconsistencies between workers who are charged with 
determining their “parental capacity to care.” Initially, I wasn’t sure if these 
inconsistencies were objective, or more a result of women’s subjective exasperation with 
the constant surveillance and requirements that often had to be completed with limited 
support and resources. When I asked Marina about institutional guidelines around 
recovery and reunification (of children with families), she told me there are none. “The 
department doesn't have a list of things someone has to accomplish. It's really about kind 
of assessing their stability, their insight, how they're utilizing supports, and you know, if 
they're ready to parent at that point in time.” When I tell her I imagine this might be why 
women talk about inconsistencies across staff, she explains: 
[W]hat we say at DCF is “we don't have substance use cases, we don't have intimate 
partner violence cases, we don't have mental health cases, we have impact cases.” 
So it's a case by case; there's no straight guidelines… [B]ut what it comes down to 
is: decisions are made very differently in different area offices even within the same 
region. You could have both moms doing the same exact thing and at the same 
place and have a very different decision. 
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When I asked if this was something that DCF is aware of, Marina told me, “yes it's just 
one of those things. We're just such a big system.” She continued: “I say every day that I 
love what I do within DCF. I would never want to be a social worker or a supervisor 
making decisions about removing children, returning children, [deciding] where children 
are going…I mean, the amount of responsibility that they have and the difficult decisions 
that they have to make…” She didn’t complete her sentence. Yet it is these 
inconsistencies that reproduce inequalities along lines of race, place, and poverty, and 
require us to pay close attention to the intersectional layers of perinatal and maternal 
OUD.   
During one afternoon at Well Families, a community center that provides classes, 
resources, and childcare for primarily low-income Families of Color in Springfield, I met 
Jamie, a recovery coach who had worked across the region for over five years. She 
illustrated these disparate experiences around the determination of “parental capacity to 
care” when she told me: 
[A] family that lives over on Belmont Ave [African American neighborhood in 
Springfield] who smokes pot, you know, there's got to be a [child] removal. [But] 
a family in Agawam [primarily White town in Hampden County] who for lack of 
a better term is shooting dope seven ways to Sunday, [the discussion is about 
trying] to figure out [if they] need a parent aid. Sometimes I think [the case 
workers] don't even realize they're doing it. 
 
From Jamie’s perspective, these contradictions simply boil down to “race and 
economics.” Implicit bias routinely impacts care delivery and women’s experiences in 
systems of treatment and management. 
When I inquired about the racial profile of her clients, Kathleen confirmed that 
most of the women she supported as a recovery coach are “White, come from nice 
families— not nice rich neighborhoods— but they all fit the same profile.” “Not to be 
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rude,” she qualified, “but I know one of the other recovery coaches that works here. Most 
of her case load is um Black, and a lot of them [are] cocaine and alcohol users not 
opioids… I don't know, it just seems to me, like, White people like opioids and Blacks 
tend to like crack cocaine…” She expressed irritation that while most of her clients had 
open custody cases with DCF, “all the ones that I have had where their cases have closed 
[are] Hispanic or Black, come from lousy neighborhoods, and do not have great sports or 
stuff.” Giving an opposite perspective on inconsistencies in custody determinations, she 
told me, “I swear sometimes [case workers] don't want to go to those neighborhoods or 
deal with certain people…I’ve said a lot of times it depends on who the worker is. I just 
don't understand why the rules are not universal.” 
LaTonya is the program coordinator at Well Families. She told me that the 
majority of women that receive their services are Latina or African-American. She 
estimated that 60% of the women she works with have lost custody of their children as a 
result of either heroin or marijuana use during pregnancy. In Massachusetts, medicinal 
and recreational use of marijuana is legal as of 2018. With a national trend towards state-
by-state legalization, recent public health efforts have focused on education around the 
importance of avoiding marijuana use when pregnant or breastfeeding. In many of the 
meetings attended for this project and during interviews with providers/staff, the issue of 
“what to do” about marijuana use among pregnant and breastfeeding mothers was 
constantly referred to as “tricky.” Reading between the lines “tricky” mostly inferred two 
things: confusion around the lack of clear policies and guidelines, and intrapersonal 
conflict about the extent to which marijuana use was harmful.  
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Marina, who consults with DCF on substance use cases, told me that she was 
increasingly consulted on “substance exposed newborns as a result of marijuana because 
even within DCF people are like, ‘I don't know what to do with marijuana.’” Returning to 
determinations of “risk” and “parental capacity to care,” implicit bias can directly shape 
which women might be absolved of marijuana use. Expanding on what constitutes 
“impact cases,” Marina explained that a “18 or 19 year old mom with a newborn baby 
who's smoking marijuana, who also has untreated mental health [issues], a lack of 
support system, was raised in our system…Those factors versus a mom who's 36 and has 
a 15 year old [and is] smoking marijuana on the weekend…[N]ot to minimize it, but it 
just it looks different.” 
When I met Eileen at the Dunkin Donuts in West Springfield, she was on 
probation after being arrested for buying heroin “on the street;” she was currently using 
cannabis to manage her anxiety. Eileen had a “marijuana medical authorization card” to 
present as part of her custody requirements. She referred to the medical marijuana card as 
an “iffy thing” due to the fact she had two DCF workers with conflicting views on 
cannabis use. Although her case was being managed by the Holyoke office, she was also 
assigned a case worker in Springfield, based on the fact that she lives in West 
Springfield. She told me the “Holyoke lady was like, ‘yah, go get your card and you’ll be 
ok.’ But when she got reassigned to a “worker” in Springfield, her prior worker dis not 
relay that same information to him. Her new case worker was “giving me crap…and I felt 
like it made them feel fishy about me,” which in turn made her feel anxious about the 
status of her custody case, which was about to be closed. “I really hope it doesn't get 
turned around,” she told me,” because “that would be some bullshit.” She expressed fear 
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and frustration that those institutional conflicts were “gonna fall back on me.” “That's not 
right,” she concluded, this time directing her comment to her baby, who she had been 
attentively feeding and playing with throughout the interview. 
 
“So What's the Point? What Am I Doing This All For?” 
Substance use treatment literature and discourse cites the importance of having 
hope and a “sense of purpose” as crucial to treatment success (Polcin, Mulia, & Jones, 
2012). Becoming pregnant and mothering were consistently identified by women in this 
project as that sense of purpose, and a reason for them to maintain recovery. Take Linda, 
who recalled that after the death of her nephew from sudden unexplained infant death 
syndrome during her pregnancy: “I don't know what prevented me from using other than 
being pregnant with my son. Like for me that was enough to not pick up, cause I wanted 
to. I really, really wanted to.” And Sarah, who identified that her main motivation for 
going into treatment was “to be healthy and alive and safe for my daughter.” And Aimee, 
who told me that the birth of her son “just kept me at that point, like, I don't want to use 
anymore. I had something better, I had a point of living clean— living the good life.” 
Yet, one of the first things mothers along the substance use continuum lose is 
their right to parent. When I met Tammy, she was angry about how little contact she was 
allowed to have with her son, and expressed fear that he would be adopted by his foster 
parents. She was visibly distraught as she told me  
I want to see him, you know? I have the right to see him. I've been doing so good. 
I've completed every program, I've hit every milestone, I've completed parenting 
classes… I go to extra parenting classes. I do everything I'm supposed to do. I am 
supposed to get Facetime at least once a week, and now they duped me out of that 
and said it's once a month. So now I got to re-take them to court, and that takes 
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time filing motions… I'm stuck between a rock and a hard place, and meanwhile 
my baby just saw me for the first time in 8 months. 
 
In her job as a recovery coach, Kathleen works primarily with pregnant and parenting 
women. She told me that like Tammy, most of the women she worked with who have 
“done so much work and have tried so hard, and still don't have [their kids] back? They're 
like, so what's the point? What am I doing this for?!” Furthermore, as Tanya described 
her experience of losing custody, you can see how clearly the process of taking a child 
can be experienced as deeply visceral: 
I was a mess, I was really not handling it well. They're taking my kids, you know? 
They told me I was acting inappropriate and if I wanted to see my children again, 
I needed to act appropriately for their sake. [I] needed to pull myself together 
because I was acting outrageous.  And I'm like, “I'm crying because you're taking 
my kids!” 
 
For Marguerite, losing custody was visceral; the pain of her loss was embodied, 
and expressed as depression and anxiety. When I asked if she had experienced, or been 
treated for either depression and anxiety before, she affirmed: “I have…. but it hit me 
hard when my kids were taken. It hit me really hard. I couldn't eat, couldn't sleep, all I do 
is lay around and look at the ceiling. I cry a lot. I cry. That's the only way I can deal with 
it.” For many women, losing custody meant simultaneously losing their hope and drive to 
sustain recovery. Shaila remembered that after losing custody of her daughters, “I would 
just get more high and more high.” But instead of feeling better as she expected at the 
time, “it was just making it worse. People say they are crazy when they lose their kids, 
and I was really crazy…I couldn’t stand being away from my kids. I was a fucking 
mental case.” 
 The fear of losing custody drives women’s choices to avoid treatment late into 
their pregnancies, largely due to state mandates that require medical institutions to 
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automatically report maternal substance use to DCF. Eileen told me she was “trying to 
use [buprenorphine] off the street ‘cause I didn't want anybody to know. I didn't want to 
get in trouble yet… I knew DCF was coming no matter what.” Even when women do 
seek treatment and prenatal care, Emily, a nurse midwife, commented that “the first 
question they ask when they come in is ‘are they [DCF] gonna take my baby?’ And that's 
a real fear.” Amanda, who was seven months pregnant and had lost custody of her other 
three children at the time we met, rubbed her belly and told me: “I'm just so deathly 
afraid they're gonna come take my baby in the hospital.” LaTonya, program coordinator 
at Well Families, remembered  
a lady that was here in our group [who] didn't tell DCF she was pregnant for like 
five and a half, six months. So they prolonged her case to get her other kids back 
because she didn't tell them. But she [was] so scared. She [was] like, “this is my 
opportunity to take a baby home, and try to raise it without you guys.” 
 
  Referring back to notions of how a gendered triple standard influences the bias 
experienced by women with perinatal and maternal OUD, women can experience 
negative repercussions around their “parental capacity to care” as a result of a partner’s 
instability from active substance use or untreated mental health conditions. Emily, nurse 
midwife at an area hospital, recalled one instance where a pregnant woman went into 
premature labor after being physically assaulted by her partner. Clinical staff at the 
hospital reported the case to DCF, who took custody at birth due to “safety 
considerations.” Yet, as Emily pointed out, not only was the woman recovering from a 
physical assault at the hands of her partner, she was “further traumatized” after losing 
custody of her newborn child. “When I see scenarios like this,” she told me, “I think we 
could be doing better.” During my interview with Aimee, she disclosed that her son’s 
father had a propensity towards violent outbursts when he was actively using. At one 
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point Aimee and her partner are both “kicked off” their clinic after he got into a physical 
altercation with another patient. She told me she felt “lucky” because she was able to 
calls another clinic and get enrolled within the week. But, she “did relapse going from 
clinic to clinic.” They “did an emergency discharge,” which meant that instead of 
tapering her dose, she “went from 80 milligrams to none the next day. It was awful,” she 
remembered.  
It is here in this examination of mothering and the right to mother that we again 
bump up against the liminal complexities of maternal OUD. Although loss of custody and 
maternal status was perhaps the most prominent and pivotal experience that negatively 
influenced women’s care seeking and substance using trajectories in this project, some 
mothers pointed to a time void of the demands of parenting as critical to their early 
recovery and treatment success. And while leaving children at home when engaging in 
drug seeking is perceived as neglectful, some mothers identified leaving as a necessary 
act of care and protection that was far better than using and “being high” in front of their 
children. Furthermore, simultaneous to policy inconsistencies around custody 
determinations of “parental capacity to care” is the reality that, according to Marina, a 
regional substance use consultant to DCF, staff making these decisions are often new to 
the overall workforce, young, inexperienced, not parents themselves, underpaid, and 
likely to leave that position within their first year due to the emotional weight of the 
work. Many of these decisions are further complicated for women with husbands or 
partners who may be physically violent, resulting in both direct and indirect harm to 
women. It is in examining these liminal spaces that we begin to know the complexities of 
how pregnant and parenting women with OUD navigate their many roles: as woman, as 
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mother, as sister or daughter or partner, and not simply as “addict” or “woman in 
recovery.”   
 
Institutional Erasures as Symbolic Violence 
What is stated out loud is never a comprehensive appraisal of any situation. A key 
element of any critical methodology is therefore an assessment of the silences, spaces, 
and gaps— in the literature, discourse, and policies— to provide a complete assessment 
of any topic of investigation. In the context of institutional violence and perinatal and 
maternal OUD, institutional erasures identified in this project included: the impacts of 
intergenerational family separation, maternal erasures, and the impact of “drug siloing” 
(Knight, 2015) on substance use and treatment outcomes.  
 
Intergenerational Family Separation 
In April 2018, the Trump administration enforced a highly controversial “zero 
tolerance” policy at the Southwestern border of the U.S, forcibly separating children from 
parents as families were attempting to cross into the U.S. without documentation. There 
was an almost immediate proliferation of graphic imagery, protests, and public outcry 
across multiple sectors critiquing the enforcement of the policy and the foot-dragging on 
the part of the administration to reunify families. In August of 2018 the American Public 
Health Association (APHA) released a public statement decrying the policy as 
“inhumane” and setting the “stage for a public health crisis.” The content of the statement 
is pivotal to my argument for the need of a critical interrogation of the field of public 
health, and bears repeating in its near entirety: 
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As public health professionals we know that children living without their parents 
face immediate and long-term health consequences. Risks include the acute 
mental trauma of separation…and in the case of breastfeeding children, the 
significant loss of maternal child bonding essential for normal development. 
Parents’ health would also be affected by this unjust separation. Furthermore, this 
practice places children at heightened risk of experiencing adverse childhood 
events and trauma, which research has definitively linked to some of society’s 
most intractable health issues: alcoholism, substance misuse, depression, suicide... 
(APHA 2018) 
 
Of course, what is striking is that this exact statement could be made about the 
separation of children and families that occurs on a routine basis in the U.S. via the 
intertwined institutions that manage perinatal and maternal OUD. And while the APHA 
does link family separation to heightened risk of future traumas and health issues such as 
harmful substance use, much of the public health literature fails to conceive of family 
separation as a form of violence and trauma in its own right. Exposure to parental 
substance use and sexual, emotional, or physical violence in the home are considered risk 
factors for intergenerational patterns of substance use, and are primary reasons for foster 
care entry (NIDA 2019). However, the violence of family separation is seemingly absent 
from scientific conceptualizations of risk factors associated with substance use 
trajectories. Nearly all the women who participated in this project had spent some length 
of time in foster care in their youth, yet it was never discussed in any of the biomedical 
spaces that I entered during this project, nor in the scientific literature. 
Maeve is a young, single mother early “in recovery.” When I asked her to 
describe herself from ages one to seven, she remembered being “scared, um lonely. Like, 
abandoned.” She was placed into her first foster home at age six, and by the age of 16 had 
lived in five foster homes. In addition to the trauma from being separated from parents 
and home, it is standard for siblings not to be fostered together— largely due to 
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availability of space, as well as the training and preferences of foster parents. When I 
asked Maeve if she and her brother were close, she told me:  
[N]o. I [feel] really guilty [be]cause my brother’s dad was in prison…I got to 
leave the foster home and go live with my dad, and my brother had to stay in the 
foster home because he had nowhere else to go. So sometimes I feel like my 
relationship with my brother is the way it is because he feels like, you know, I left 
him there.  
 
Taking a step back from the lifelong impacts of the separation of Maeve’s family 
of origin and speaking again to the liminal complexities of maternal OUD, removing 
children from an unsafe home and placing them in foster care can be a necessary 
decision. The deeper challenges come with inconsistencies in terms of which families are 
separated and which receive services, as well as the lack of appropriate support for 
children and parents to process an experience that has lifelong impacts— a “void” that is 
“gonna get bigger” in Jamie’s words. As Jamie observed from her work as a recovery 
coach and experienced as a woman with lived experience of substance use who had 
permanently lost custody of her children, all “the child knows is all of the sudden their 
father or mother is gone.” Marina, substance use consultant to DCF, summed it up like 
this:  
[W]e have babies, right, newborns, who are removed at birth… going night to 
night. We think about developmentally what that means, we're setting kids up for 
all sorts of problems. We're taking children from unhealthy environments where 
who knows what has happened thus far, and we're putting them in a different kind 
of unhealthy environment that doesn't necessarily support them healing or… 
moving forward.    
 
When I asked Maeve to describe motherhood as a woman in recovery, she paused 
for a full five seconds, sighed deeply, and told me “it’s hard.” Although Maeve’s mother 
and brother lived within short distance from her home, because of their multiple 
separations their relationships were strained. Maeve had little tangible support. As I 
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looked around her apartment I noticed few personal items, minus a hand drawn sign that 
had the name David written in cursive letters. I realized as the interview progressed that 
David was the father of her child, although she didn’t name him until nearly the end of 
the interview. As she talked about him with her head back and eyes closed, I looked 
closer at the sign and noticed dates, realizing long before she got to it that he had recently 
died of a heroin overdose. I counted the months in my head as she talked. Only seven. 
And her daughter had just turned one. When I left her apartment, I kept returning to her 
description of herself as a young child: scared, lonely, abandoned.  
For people who may benefit from the supports that are offered by DCF and other 
social service programs, such as counseling and support groups, the potential of losing 
custody is a substantial enough fear that those resources can be underutilized. For women 
who spent time in (or interacting with) the social services system as children, this fear 
was deeply ingrained from youth. Take Maeve, who remembered that her “mom really 
wouldn't let us talk to people or build communications with people because she was 
afraid we would say something to somebody, and they would call DCF and they would 
take her kids.” Even Katie’s mother, who did the “right thing” by reporting to police 
Katie’s sexual assault by an uncle-in-law, encouraged her children not to speak openly to 
their DCF worker because “they're out to get us, they're bad people.” When I asked Katie 
if she received therapy or support to process this experience, she told me she did have a 
therapist and DCF case worker that she liked, but the messaging from her mother felt 
“really conflicting. I felt like I couldn't talk to anybody, I couldn't.” Even Linda’s foster 
parents, who likely needed support themselves around the demands of fostering children 
with trauma histories, made clear that accessing support from DCF was a “big no-no.” 
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 Women with pending custody cases were similarly avoidant and fearful. David, 
addiction specialist and physician at a behavioral health and substance use treatment 
hospital, confirmed this fear to be well founded, as do essentially all policy, 
programmatic, and direct care staff interviewed for this project. However, this topic was 
never addressed in any of the meetings, symposia, or conferences I attended over the 
course of eighteen months of ethnographic observation in those spaces. Kathleen, 
recovery coach and mother with five years in recovery, explained how this fear could be 
considerably problematic for women who become pregnant while they have an open 
custody case with DCF. She told me about a client who had finally been “granted her 
transition” (trial reunification period with her children who are currently in foster care). 
But when DCF discovered she was pregnant, they stopped the transition and were 
ambiguous about how long the pause might be; that they needed to “see a little bit more 
progress.” Kathleen told me she understood this was part of the institutional policies and 
procedures in this circumstance, but rightly pointed out that it is important for DCF to 
“not, you know, make it so [mothers in treatment are] afraid to tell you anything.”  
 When I first listened to women’s stories about their childhood experiences with 
DCF and interfamilial separation, I considered that these circumstances were the result of 
outdated program policies. Based on women’s ages, their experiences would have taken 
place anywhere from 15- 30 years prior to this project. However, in interviewing women 
with children currently in DCF custody, I observed some of these disruptive patterns to 
repeat. As one example, DCF policy requires that any adult interacting with a child in 
DCF custody undergoes a CORI (criminal offender record information) check. While this 
policy is understandably implemented with good intention, Amanda was clearly agitated 
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when she told me that “it’s like my kids are in jail.” While Amanda was living in a 
residential recovery facility for her alcohol and cocaine use disorders, her children were 
being fostered by family members. “[T]hey can’t sleepover at friends’ houses, they can’t 
have friends pick them up and drive them to practices… I mean, they don’t want to call 
their friends parents up and say, ‘can you go through a CORI check?’ You know?” When 
her son turned 18 years old he was considered by DCF to be an adult, and had “to go get 
fingerprinted and have the court check on him so he can go visit his own brother.” Not 
only does this type of policy expose children to social stigma, it can negatively impact a 
child’s relationship with a parent who has lost custody. Furthermore, this policy can place 
logistical burdens on foster parents, who may need support, especially if they are family 
members who are “helping out.” Amanda shared that because only two people are 
approved to transport her children, this often made “life really hard” for her sister and 
brother, who were caring for her children while she was in treatment. 
 
Maternal Erasures 
Again returning to the notion of a gendered triple standard, more than other 
populations, pregnant and parenting women with OUD have limited autonomy in the 
decision to engage with the institutions that manage OUD according to biomedical 
dictates. As such, exposure to institutional violence is nearly inescapable. The 
predominant approach to managing OUD centers around “fetal victimhood” (Knight, 
2015), which erases pregnant women and mothers at-large as having needs that run 
concurrent to ensuring a healthy pregnancy and birth. This erasure is underscored for 
women whose maternal status may no longer be recognized by the biomedical institutions 
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and policies that manage OUD (i.e., those that are no longer pregnant; whose children are 
no longer “cute” babies, or who have lost permanently custody of their child/ren; women 
of color; and those who are currently, or have been, incarcerated). 
During my interview with LaTonya at Well Families, she called Jamie into the 
room. Jamie is a woman in long-term recovery. Through Well Families, Jamie was an  
outreach worker, supporting women in recovery who also had experience in the criminal 
justice system. I explained to Jamie that I was interested in learning about the experiences 
of pregnant and parenting women with substance use disorders. I told her I was 
fundamentally opposed to the criminalization of addiction. Without skipping a beat she 
told me that part of her “story was I never got my kids back…I was incarcerated. I did a 
number of…bids, but my last one…was a two to three-year bid and I lost custody of my 
children.” She told me “I’m still a mom,” to which I agreed. As part of her work as a 
recovery coach she tells her clients they “don't have to be a mom in the conventional 
sense” and identified a significant need for curriculum to support women in recovery to 
manage the emotions associated with loss of custody, permanent or otherwise. 
Drawing from her personal experience, as well as from working with clients who 
have lost custody of at least one child in the past, Jamie observed that “maybe mom didn't 
get to parent her first four kids, she gets stable in recovery, or maybe she’s actively using, 
gets pregnant again, and decides ‘I want to be a mom to this kid’ so she goes into 
treatment. Sometimes it's successful, sometimes it's not.” This was the case with 
Amanda, who did not have custody of her three children and was currently pregnant. She 
told me that her sister-in-law, who had temporary custody of her youngest son, “is not 
very happy that I'm pregnant…She thinks it’s selfish of me— why would I have another 
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baby when I don't have my other ones…” Reinforcing the need for better strategies to 
acknowledge and address how this impacts women in recovery, Jamie commented that “I 
think a big part of that is dealing with the feelings around the shame and the guilt of 
losing [her other child/ren] and now parenting this child.” Not to mention the “anxiety of 
‘that's child's gonna get taken away from me at any point in time’” LaTonya added. 
“Absolutely. That too,” Jamie agreed.  
Because I am curious about the absence of Women of Color in the larger opioid 
discourse and within many of the in-patient or residential recovery treatment spaces, I 
inquired about this during my interviews with staff whose work puts them indirect 
contact with Women of Color with substance use disorders. Nohea, who has over 20 
years of experience in the field of substance use treatment and currently directs a 
residential recovery treatment program for women, commented that she has observed 
“many more People of Color being funneled into jail, many more people with less 
financial resources, less family support… [W]omen are able to parole from jails if they 
have family support, if they have a safe place to go.”  As she had observed, if a woman is 
going to be paroled to “South Bridge Street in Holyoke where my mom lives, and she's 
gonna support me, they're not gonna want me on South Bridge Street. But if [she] 
come[s] from a good family on Northampton Street, they might be more likely to approve 
parole, and have more access to treatment and less, you know, prison.”  
When I met with David, addiction specialist at the behavioral health and 
substance use treatment hospital in Holyoke, I was curious to hear his observations about 
the racial demographics of the hospital’s treatment population. I know that the 
community surrounding the hospital is nearly half White and half Latinx, yet I observed 
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that the pregnant women and mothers who received treatment at that location were 
predominantly White. When I asked him directly “where are the Women of Color?” He 
responded that they are “likely at the Mill Street site,” which is the hospital’s community-
based methadone clinic located in Springfield, a community that is approximately 45% 
Latinx, 35% White, and 20% Black. Yet when I drove the four miles to a federally 
funded health center in Holyoke that dispenses buprenorphine to people with OUD, that 
patient population was nearly universally Latinx. When I went to the “Mill Street site” I 
observed it to be a run-down old house, tucked back off a main thoroughfare in 
Springfield. My map application on my phone geotagged the location as “methadone 
clinic” and it was standard to see police cruisers driving slowly by, or circling through the 
parking lot. Most of the times that I was at that location there was a long line of clients 
waiting to be given their daily methadone dose. The clinic population was predominantly 
Latinx and Black, with a few White clients. Future ethnographic research is needed to 
elucidate whether differing demographics across clinical and community-based locations 
is related to the proximity of each site, insurance factors, race and ethnicity of staff, or 
also potential level of comfort in community-based versus clinical settings.  
Applying an intersectional lens to the framework of a triple gendered standard 
calls for an examination of how race and culture further impact barriers to treatment. 
During this project, while I did see many Women of Color enrolled in outpatient 
treatment programs (i.e. methadone and buprenorphine “clinics”), I observed that there 
were few non-White women enrolled in the long-term, in-patient treatment facilities that 
I entered. Women and staff speculated on commented on the shifting demographics of 
opioid-related overdoses in the state when I inquired. Lauren, Director of Services at a 
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community-based organization that offers substance use and sexual health harm reduction 
services, noted that although “the overdose rate has doubled among Latinos and it's 
drastically r[isen] among African Americans, in our programs in Holyoke and 
Springfield, only half of the people we see are Latino, [and a] very small amount are 
Black, African American…”  Nohea attributed this discrepancy to the criminalization of 
substance use that disparately impacts People of Color.  
Nickia is one of the few Women of Color interviewed for this project; she is an 
African-American woman in her mid-30’s who started drinking alcohol at age 10, and 
had been in and out of treatment programs for over 20 years. When not in the residential 
recovery program, she worked with the Hampden County Sheriff’s office speaking to 
women in jail about treatment and recovery; she was clearly personally invested in 
substance use treatment for the Black community in particular. She told me she was 
quickly enrolled into a residential recovery program for women because Moana, program 
director, was “looking for people of minorities to get in quicker.” But still, she continued, 
“just look at this house.” “I’ve noticed,” I tell her. “Yah, there's two people of color, no 
three. Marguerite’s half mixed. So it’s me, Lisa, Marguerite,” She said. Although there 
are Latinx women living in the house, it’s clear from Nickia’s comment that she was 
strictly referring to women that identify as Black. She recalled that when she was 
sectioned to “jail in Chicopee last time, it’s not funny, we counted how many Black 
people were in treatment in the whole jail. There was 10 of us, everybody else was 
White, young…”  “And getting treatment,” I ask? She nodded affirmatively. “And a 
heroin addict, it's crazy.” She continued: “and, we didn't even get to the Spanish people 
but it was just crazy. And that that's just something we were doing on our own, ‘cause 
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when you think of jail honestly in my head you think it's some big Black girls. But none 
of them are in treatment. In Chicopee at least…”  
I expressed to Nickia that I did not view her to be a “spokesperson for all Black 
people,” but was eager to hear her perspective as one of the two Black women 
interviewed for this project. Nickia shared that overall the African-American community 
“look down on treatment. People don't know I've been in treatment. I don't tell them 
‘cause it's embarrassing.” When she entered treatment, Nickia and her family told people 
that she was in Jamaica visiting family. From her perspective, there are few Black women 
in treatment because mental health and substance use issues are “frowned upon” within 
the Black community. With regard to substance use among younger African-Americans, 
she tells me: “it's my dad’s era, not ours.” Among her peers, she reflected that “damn sure 
we look down on people who are on drugs.” 
 
Drug Silo-ing: Non-Opioid Use During a “Crisis” 
“We have a crisis in our hands. We have to deal with that and that's where most 
of the public resources are going.” 
-Amelia, President and CEO of a philanthropic foundation that supports 
programming and policy development around opioid use prevention 
 
A telescopic focus on opioids and opioid related overdoses has largely resulted in 
the erasure of key at-risk sub-groups of substance users. The first are women who 
struggle with alcohol or other substance use disorders, who can be underprioritized for 
treatment access, or who do not get their needs met in treatment settings that devote 
considerable time to opioid overdose prevention education. The second are pregnant 
women and mothers with OUD that are polysubstance users.  
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The eight women who were pregnant or had children and lived in the residential 
recovery facility were so eager to speak with me that I came back three mornings in a 
row to make time for them all3. When I showed up on the second morning I could see the 
women congregated at a picnic table outside of the building, smoking cigarettes and 
waiting for me as I crossed the street from my car to the building. When I came up to the 
group and said good morning, they were in the middle of arranging the order of 
interviews for that morning and the next.  
On the second day I spoke with Amanda, Marguerite, and Nickia, who were all 
enrolled in the program for alcohol use disorders. Amanda additionally had a history with 
cocaine and prescription opioids, and Marguerite with cocaine. All three women told me 
some version of what Emily told me: “the truth is, you could die from withdrawal from 
alcohol, not a withdrawal from heroin. [With heroin] you may feel like you're dying, but 
you won't, you know?” These comments stood out as representative of their larger feeling 
of being overlooked and having their addiction viewed as inconsequential within the 
larger opioid discourse. Emily illustrated that in “the house [residential recovery facility] 
it’s all about heroin, heroin, heroin. [And] when I would go to a detox, it's just heroin, 
heroin, heroin.” Amelia, President and CEO of a philanthropic foundation that supports 
programming and policy development around opioid use prevention, is a member of a 
national policy task force on opioids and has attended two meetings at the Trump White 
House at the time of our interview. I asked her where alcohol falls into policy 
conversations on opioids. Although I was wondering more technically if alcohol is placed 
 
3 All IRB approved project documents include the phrasing “opioid or other substance use disorders.” 
Findings from women who did not have OUD provided crucial context to this project. Furthermore, the 
decision to include them felt to be the least ethically questionable, given their current living circumstances 
and general vulnerability.  
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under the umbrella of substance use disorders, she paused. “It’s funny,” she told me. 
“People don't talk about it, but if you look at the data— and we've looked at youth survey 
data— that's what kids use more often than anything else. And, alcohol's actually the 
number one substance for reasons why children are taken from homes…I think [alcohol] 
kills far more people than opioids do, so does tobacco. But opioids continue to be what 
people are talking about.” 
For Emily, Marguerite, and Nickia a strict focus on opioids meant they felt like 
people generally viewed their alcohol addictions as “not as bad” as heroin or other opioid 
addictions. When Emily discussed her experiences with relapse, she told me it doesn’t 
matter if you’ve relapsed for six months or two. “It’s just as devastating” no matter the 
length of time. Reflecting on her alcohol use disorder, Nickia talked about “losing 
everything”— the trust of her children and mother, as well as her home. As a 
consequence of drug siloing (i.e. strict focus on opioids as the only problematic 
substance) in treatment spaces, Emily, Marguerite, and Nickia felt that treatment 
programming was often irrelevant. Nickia found the focus on opioids “distracting” to her 
treatment, and would often disengage.  “I come to treatment now and all they got here is 
Narcanâ and heroin…I don't even know what that shit looks like. I'm here for alcohol.”  
When I asked Nohea, director of the women’s residential facility, about the 
women’s comments about feeling overlooked, she smiled and replied that the narrative 
among women that “I'm not like you because my drug of choice is very different from 
yours” was familiar. In response, she routinely reiterated to women that it “is the same 
illness, just a different vehicle to get there. It costs the same kind of unmanageability and 
powerlessness in our lives and takes the same things. Alcohol will rob you of everything, 
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[as will] heroin and cocaine and opioids. Absolutely.” In community meetings she tells 
women: “if you can't locate yourself in the next addict, if there's something so 
dramatically different about that next addict, [if you think] you're not as bad as them, you 
have work to do…” However, at the start of our interview she made brief mention of 
funding being diverted from alcohol and into opioid programming, and I circled back to 
this point as we concluded the interview. Nohea referenced Access to Recovery (ATR), 
which is a voucher system funded by the MA Bureau of Substance Addiction Services. 
Under this program people in treatment programs are eligible to use the vouchers for 
basic needs (clothing and hygiene products), bills, transportation, educational 
programming, health services (medical co-pays as well as yoga and nutritional 
counselling), and recovery coaches (MA Access to Recovery, 2019). But, Nohea told me, 
“if everybody's feeding at the trough, the money's gonna run out.” The state now 
stipulates that only people with OUD can qualify for ATR funds. Nohea has heard 
women in the recovery home with alcohol and cocaine addictions say “what do I have to 
do, shoot a bag of dope to get some ATR around here?!” Most women want “the $300 
[voucher] so they can get to Walmart [for] clothes and stuff because many of them don't 
have clothes.” “That’s not such an unreasonable ask,” I comment, to which Nohea 
agreed. “No. It really isn’t.”  
 A concerning trend that David had observed was that alongside increasing 
numbers of opioid-related overdoses was the “steady involvement of cocaine and 
benzodiazepines in all of those overdose stats[istics].” He identified an immediate need 
for programs to identify innovative approaches to treat cocaine and benzodiazepine use, 
particularly when they co-occur with OUD. The challenge that David observed was that 
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overall, “benzodiazepine or sedative use disorder [in conjunction with] opioids is a huge 
issue that's not being very well addressed.” From his observations there is “not a great 
place” for cocaine or other stimulant use disorders in the current system, “other than 
outpatient treatment, which has variable success rates.” There are “not great treatments 
for either because we don't really have medications for them and they have powerful 
physiological components and we're not necessarily tracking those (co-occurring 
overdoses) as well.” Overall he expressed concern that these issues are being overlooked 
“amidst the opioid overdose crisis.” Kathleen told me she had noticed more women than 
men with “the benzo problem.” At a recent staff meeting at the behavioral health and 
substance use treatment organization where she works as a recovery coach “the men 
coaches were saying that none of their clients have any kind of issues with benzos.” She 
wondered aloud if that was “because most women tend to talk about their feelings and 
stuff and [are] more open” emotionally.  
Women and providers offered important insights on polysubstance use. Both 
David and Kathleen agreed that people enjoy the “synergistic euphoria” [they experience] 
with the combination of opioids and benzodiazepines. However, this comes with a high 
risk of respiratory depression and overdose. Kathleen tells me that people who “shoot 
dope will shoot coke too.” Kathleen explained that although she has never “done cocaine, 
most of the people that I talk to say they love the difference. If they're super, you know, 
doped up from the heroin, the coke brings them back up.” According to her, unlike 
simultaneous benzodiazepine and heroin use that can “crush your breathing,” heroin in 
conjunction with stimulant use can be “dangerous to your heart” because it can cause 
“problems regulating [when] you go from either really high to the low.” With regard to 
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the use of other illicit substances in conjunction with MOUDs, Moana explained why 
women who are “on methadone [and] also using on the side might be using cocaine,” 
instead of heroin or other opioids as might be expected. People who are taking 
methadone or buprenorphine are more likely to “relapse onto some other drug…They 
might not feel [heroin or other opioids] when they're on methadone, and they're certainly 
not gonna feel it on suboxone. [But] cocaine? Cocaine is gonna be the problem.”   
While much of the addiction discourse is focused on the multiple forms of 
violence and trauma that contribute to disordered substance use, this chapter shifts that 
focus to make legible the institutionally inflicted traumas interwoven into treatment itself. 
Each example of institutional violence discussed – bodily, visceral, and symbolic – make 
the case that a robust critical public health agenda around perinatal and maternal OUD is 
crucial. Massachusetts is a state with considerably progressive policies around OUD. 
Although the passage of the SUPPORT Act in October 2018 does earmark funds for the 
treatment of pregnant and postpartum women with OUD, it does not overturn policies in 
23 states and the District of Columbia (D.C.) that currently categorize substance use in 
pregnancy to be child abuse. Nor does it call into question the three U.S. states that 
classify substance use in pregnancy as grounds for civil commitment to treatment 
(Guttmacher Institute 2019). I can imagine the three forms of institutional violence 
described in this chapter to be present, and likely magnified, through these policies in 
place in many of states outside of Massachusetts. 
Over the course of this project, conversations around structural violence (e.g. 
poverty, lack of housing and transportation) shifted to the fore. Although discussions also 
touched on the impact of trauma on opioid use trajectories, the primary focus remained 
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interpersonal violence. As part of a critical public health agenda, I argue for the need to 
consider, envision, and categorize institutional violence as a distinct form of violence and 
trauma navigated and negotiated by pregnant and parenting women with OUD. The 
notion of visceral violence as explored here is an important contribution to the literature 
on forms of violence and is particularly relevant for any examination that considers the 
biopolitics of pregnancy and mothering. By erasing experiences of institutional violence, 
efforts to provide person-centered care, to support families, and to promote optimal 
health will remain incomplete and deficient.  
In this chapter, I explored institutional policies and practices that function as 
barriers to care seeking and engagement. For pregnant women and mothers with OUD, 
fear of institutions are rooted in experiences of discrimination and stigma, particularly for 
those that are active substance users. Furthermore, this chapter illustrated how an 
acceptance of harmful practices as “business as usual” can directly and negatively impact 
a woman’s substance use trajectory. Additionally, this chapter applied a intersectional 
lens to the concept of a gendered triple standard, providing key examples of both implicit 
and explicit bias experienced by Mothers of Color in current opioid treatment settings. 
This chapter highlighted key practices that perpetuate stigma in care, and which call for 
the development of programs and policies to reduce bias among care providers in 
treatment and other institutional settings that are designed to serve pregnant women and 
mothers with OUD and other substance use disorders. Finally, this chapter introduced the 
concept of liminal complexities as an analytic tool to generate important questions around 
current and problematic treatment approaches. Taking time to explore and answer some 
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of these “wicked” questions can help to guide the development of innovative and justice-
based treatment approaches.  
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CHAPTER 6 
CONCLUSION 
 
To close each interview that I conducted for this dissertation, I posed the question: 
“what does recovery mean?” Provider responses followed a similar thread. According to 
Emily, nurse midwife and researcher, recovery is a combination of “sobriety, coping 
mechanisms, and living a healthy life in balance.” According to Sally, director of opioid 
programming at a state department of public health “recovery should be defined 
differently for each person.” Her definition also considered the varied substance use 
practices of people with OUD, with examples that ranged from people who “abstain from 
all substances” to those whom “recovery means not using opioids” while continuing to 
use other substances. Amelia, President and CEO of a philanthropic foundation that 
supports opioid related policies, responded that “there is still that group of people, 
including the traditional [Alcoholics Anonymous] and [Narcotics Anonymous] groups, 
that believe recovery means total abstinence. Then there are others who say OUD and 
other addictions are a chronic disease and…evidence-based medications are not only 
acceptable, but should be supported.” Marina, substance-use consultant for the 
Department of Children and Families, defined recovery as “living a healthy life, whatever 
that happens to be, with the treatment and support…to maintain that.” The shared theme 
in these definitions revolved around avoidance of opioid use. 
 When posed with this same question, women with OUD in this project barely 
referenced substance use in their conceptualization of recovery. For Lorraine, recovery 
simply meant “happiness.” Aimee defined recovery as the “freedom [to do] things you 
don't do [when you are actively using substances], like actually living.” For Jordan, 
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recovery meant “peace of mind” and experiencing “different, fun, awesome things in 
life,” like hiking and skydiving, which she was eager to try. Sarah had “worked really 
hard to get to where I am.” For her, recovery meant “strength.” For Eileen, being in 
recovery felt like a “big weight was uplifted off of me.” This made her “feel 
complete…like I'm actually who I really am.” From Tammy’s perspective, recovery 
“means the world. It means peace of mind. It means safety. I don't think I ever felt more 
safe in my life. So that's what recovery means to me, it means my life.”  
 Throughout this dissertation I have advocated for a critical public health approach 
that promotes just care for pregnant women and mothers with opioid and other substance 
use disorders. As the diverging definitions of recovery provided above illustrate, 
centering the voices of women and mothers across the substance-using spectrum are 
paramount to a critical public health approach. Via macro (news media) and meso 
(scientific) narratives, “imagined characteristics of disembodied” (Loseke, 2007, p. 661) 
pregnant women and mothers with OUD become cemented into the social imaginary, 
often reducing women to a heterogeneous set of risk factors to be managed. Micro-level 
(individual) narratives complement social “knowing” about perinatal and maternal OUD, 
by providing complex nuance informed by the self-reflection of “embodied selves about 
their selves” (Loseke, 2007, p. 662). As I argue throughout this dissertation, examining 
the intersections of these discursive layers can yield critical insights to advance optimal 
health of pregnant women and mothers with opioid and other substance use disorders.  
Essential to my analysis was an examination of the stigma experienced by 
pregnant women and mothers with OUD, and how the direct experience of bias can shape 
treatment engagement and ultimately, optimal (or sub-optimal) health. As such, in the 
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introduction I presented Kremer and Aurora’s (2015) framework of stigma for perinatal 
and maternal OUD that they derived from the moral and social panic observed by Alonzo 
(1995) in his work with HIV+ individuals. Drawing from this framework, I introduced 
the concept of a gendered triple standard as experienced by pregnant women and 
mothers with opioid and other substance disorders. Building from what Sanders (2014) 
refers to as the “gendered double standard” faced by women with substance use 
disorders, in this dissertation I conceptualized the intersecting identities of female and 
pregnant/mother as a triple standard. I argue throughout this work that being held to this 
gendered triple standard intensifies the stigma faced by pregnant and parenting women 
with OUD as they navigate the medical, social service, and legal institutions.  
In this conclusion key findings are first summarized from the three discursive 
resources analyzed for this dissertation: macro-level (public media), meso-level 
(scientific), and micro-level (individual). Next, I present an analysis on the intersections 
across these three narratives. Drawing on reflections on how these narratives speak to, 
reinforce, and resist each other, I present recommendations for both policy and the 
practice of caring for pregnant women and mothers with opioid and other substance use 
disorders. I close with a reflection on the liminal complexities inherent to the treatment of 
perinatal and maternal OUD as a springboard to envision just care for pregnant women 
and mothers with OUD.  
 
Key Findings: Macro, Meso, and Micro- Level Narratives 
 
In this dissertation I set forth to examine three discursive resources that shape the 
social construction of perinatal and maternal opioid use in the United States (U.S.) across 
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all strata of social life: macro-level (public media), meso-level (scientific), and micro-
level (individual) narratives (Loseke, 2007). Macro-level (public media) narratives 
produce the master narratives (McKim, 2017) of perinatal and maternal OUD that 
become embedded into the social imaginary. Macro-level narratives analyzed for this 
dissertation were assessed for the ways in which they established symbolic boundaries 
and streamlined the complexities of perinatal and maternal opioid to frame and inform 
policy priorities. As descriptive stories of events, public media narratives create the 
“master narratives” of pregnant women and mothers with OUD. Meso-level (scientific) 
narratives are those that produce institutional identities, thereby determining and defining 
imagined targets of policy and practice. These evidence-based narratives directly inform 
service provision and policy development by defining the risks and needs of pregnant 
women and mothers with opioid use disorders as they engage with institutional settings 
that manage their opioid use disorders. The scientific literature on perinatal and maternal 
opioid use disorder analyzed for this dissertation was assessed for key findings on risk 
factors and evidence-based treatment protocols that inform service provision and policy 
development for this population. Micro-level (individual) narratives are stories of 
personal experience and identity. Those analyzed for this dissertation included individual 
stories of opioid use and treatment among pregnant women and mothers, as well as 
individual stories from the perspective of service providers and those who work directly 
with this population.  
In keeping with standard conventions within the field of public health, meso-level 
narratives (i.e., the scientific, peer-reviewed literature) were presented as “the state of the 
field,” as part of the standard literature review in chapter one. Additionally, chapter two 
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presented findings on overall thematic content and trends in the peer-reviewed literature 
(scientific narratives) on perinatal and maternal OUD. The majority of peer-reviewed 
journal articles on perinatal and maternal OUD were published between 2012 and 2018. 
Of these articles, nearly 80% focus specifically on pregnancy and the postpartum period 
as relates to neonatal and infant health outcomes. The content focus of peer-reviewed 
journal articles published on pregnancy and the postpartum period fall into three 
categories: epidemiology and best practices for perinatal and postpartum OUD, 
epidemiology and best practices for the treatment of NOWS, and gender-specific care. 
Scientific articles that focused specifically on women that where neither pregnant nor 
postpartum (i.e. had children older than one or two years old) were nearly non-existent in 
this analysis (2.5% of the overall sample).  
In chapter three, I presented findings from my analysis of the macro-level (public 
media) narratives. Key findings in the chapter focused on the social construction of 
pregnant women and mothers with OUD via discursive depictions and thematic content 
of the sample of media reports. As with temporal trends of the scientific literature, media 
reports on perinatal and maternal OUD were concentrated in 2015-2018 (70.2%), with 
over 80% of reports from liberal sources, and less that 20% from conservative and 
centrist sources combined. A novel contribution from this media analysis is the finding of 
a slightly greater number of media reports that depict pregnant women and mothers with 
OUD disparagingly versus sympathetically, a contrast to prior literature. Disparaging 
representations of pregnant women and mothers with OUD predominantly centered on 
narratives of fetal victimhood. Sympathetic depictions reinforced the importance of 
treatment and incarceration for women with OUD as pivotal to their recovery. syndrome 
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by highlighting how media coverage that predominantly centers on “fetal victimhood” 
(Knight, 2015) continues to erase women with OUD as having autonomous needs that 
run concurrent to ensuring a healthy pregnancy and birth outcomes. 
The thematic content of media reports largely focused on the economic burden of 
neonatal opioid withdrawal syndrome (NOWS), and shifting demographics that cued 
tragic notions of the unravelling of White, rural, America. Articles focused on lowered 
life expectancies for White populations, and an increase in grandparent-headed 
households associated with increasing rates of parental loss of custody as a result of OUD 
were central to this narrative. Many articles concomitantly called for criminal justice 
reform and innovative-treatment approaches to prioritize treatment over the 
criminalization of substance use disorders. Calls for progressive social reform around 
OUD stand in stark contrast to prior narratives on Black, crack users and “White trash” 
methamphetamine users that were used to leverage policies to advocate for the 
criminalization of substance use disorders. Central to the narrative of White, rural decline 
was the character of the “good girl, gone bad,” who prior to being prescribed opioids to 
treat an accident or other physical trauma was a valued member of society (e.g. mother, 
teacher, or student). A key solution proposed to the problem, then, was the purported 
need to restrict access to prescription opioids in order to curb OUD and opioid-related 
fatalities. While important, a focus on restricting prescribing practices elides a) the 
subsequent increase in access to a cheap heroin supply, and b) the reality that the current 
opioid “crisis” is being driven by illicit opioids. Few articles in the sample reported on 
trauma, mental health comorbidities, or the increasing racial stratification of the opioid 
“crisis.” 
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Findings from my analysis of the micro-level (individual) narratives are presented 
in chapters four and five, although some text extracts drawn from the interviews are 
included in chapters one through three to add nuance to findings from those chapters. 
Chapter four provides critical context on the use of medication for opioid use disorders 
(MOUD), including factors that inform women’s MOUD preference, and informal 
practices related to the “non-medically supervised” use of MOUDs to support the 
transition from active opioid use to stabilized MOUD treatment. In chapter four, I also 
highlight important findings related to substance use and mental health comorbidities, 
including interview participant reports of experiencing a “normalizing effect” via opioids, 
as well as anecdotal reports on the anti-depressant effects of methadone, in particular. 
These findings contribute important insights on the sensory dimensions of opioid uptake, 
treatment, and recovery.  
Chapter four additionally addresses the differing impacts of the “recovery voice” 
predominating in clinical and community-based treatment settings and within informal 
treatment communities. A consequence of this recovery voice is that the 80-plus percent 
of people with OUD who do not seek or receive evidence-based treatment are routinely 
overlooked. Clinical and community-based interactions with active substance users (i.e. 
an emergency room visit for a non-fatal overdose) commonly become missed 
opportunities to provide harm reduction education, or for humane interaction, which 
might encourage a person’s future treatment engagement. Likewise, an important 
question arising from my analysis is to ask, “who is at the table?” during meetings and 
events convened with the intent to improve services and outcomes for this population. 
People “at the table” are most likely to be individuals who represent the voice of recovery 
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and treatment (i.e. recovery coaches, clinicians, and model patients—not active substance 
users). Further, in chapter four I discuss the observed disconnect between people “at the 
table” (those often holding higher-level, administrative positions who buy into a brain 
disease model of addiction) versus those providing direct care, who may be more aligned 
with a moral model of addiction that is unforgiving of relapse and the use of MOUD. 
Finally, chapter four concludes with my reflections on an ethic of care and what it means 
to be “caring in the clinic.” 
In chapter five, I introduce the concept of “liminal complexities” as an important 
analytic tool for prompting critical examination of the ethical quandaries posed by the 
treatment, and in many cases non-treatment, of perinatal and maternal OUD. I argue for 
the need to expand current conceptualizations of trauma beyond the interpersonal, to 
consider the role of institutional violence on women’s substance use and treatment 
trajectories. I begin by providing examples of punitive procedures that are used when 
women are mandated into substance use treatment (i.e. “sectioned”). Experiences such as 
being shackled or being denied MOUD or other “comfort medications” are key examples. 
Although in Massachusetts women are not “sectioned,” women with OUD who were 
interviewed for this project and who had experienced being sectioned prior to pregnancy 
were unsurprisingly leery of institutional spaces. Finally, I touch on the often silenced 
forms of institutional violence that impact opioid and other substance use trajectories, but 
which nevertheless produce harm for women. This includes key events in the lifecourse, 
such as trauma incurred by intergenerational family separation via the child service 
system. For most women, one’s children are key motivators for treatment entry and 
engagement. As such, loss of custody is an additionally traumatic event, experienced 
  228 
viscerally by women and commonly internalized and expressed as depression; relapse 
following loss of custody was cited as common. I end chapter five by identifying key at-
risk populations that remain overshadowed by current strategies to address the opioid 
“crisis”, including women and mothers of color, polysubstance users, and people with 
alcohol or other non-opioid substance use disorders.  
 
Discursive Intersections 
One theme cutting across macro (public media), meso (scientific), and micro 
(individual) narrative levels is the increasing attention to perinatal and maternal OUD as 
framed by a broader focus on the prevention of “fetal victimhood.” This trend in focus 
tends to overlook the needs of women and mothers outside of pregnancy and the 
immediate postpartum period. At face value, an increased focus on infant outcomes 
makes sense: the dramatic rise of opioid-related fatalities in the U.S. saw an 
accompanying spike in rates of infants born with neonatal opioid withdrawal syndrome 
(NOWS). Much like the reactive response of first responders and emergency room 
departments scrambling to develop overdose protocols, hospitals and neonatal intensive 
care units were similarly positioned to prioritize perinatal OUD and NOWS cases as part 
of the triage process. Given the initial lack of preparation, prevention, and protocols to 
manage NOWS, it was unsurprising to discover that media reports predominantly include 
public interest type stories and focus on the economic burden placed on hospitals in 
response to NOWS. Responding to the limited literature on perinatal and maternal OUD 
as well as NOWS prior to 2007, the bulk of scientific peer-reviewed literature primarily 
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centers on evidence based practices for the treatment of perinatal OUD to prevent NOWS 
(i.e. access to MOUD). 
Increasing access to MOUD for pregnant women is, quite frankly, essential in 
most circumstances. Scientific research that identified positive outcomes related to 
MOUD access was crucial to passing legislation such as the SUPPORT (Substance Use 
Disorder Prevention that Promotes Opioid Recovery and Treatment) Act in 2018, which 
earmarked increased funds for the treatment of pregnant and postpartum women with 
OUD. Efforts to investigate and promote bonding within the maternal-infant dyad (e.g. 
breastfeeding and skin-to-skin contact) hold similar import, with long-term implications 
for the promotion of family-centered programs and policies. Digging deeper, however, it 
is useful to apply the concept of a gendered triple standard as an analytic tool to examine 
the broader impact of efforts that continue to cement notions of fetal victimhood into the 
social imaginary. Much like anti-abortion rhetoric, narratives of fetal victimhood erase 
pregnant women and mothers as having autonomous needs that are concurrent— and of 
equal importance— to ensuring healthy outcomes for neonate and infants. As an 
example, the more recent research trends reflect an increase in studies that investigate 
“mother” as a variable with a direct association to infant outcomes, such as infant 
outcomes as a function of maternal exposure to MOUD/opioids and the relationship 
between breastfeeding and severity of NOWS, as well as overall hospital length of stay 
(Hensley, Sulo, Kozmic, & Parilla, 2018; Lemon, Naimi, Caritis,&  Platt, 2018; Jannson 
et. al., 2017; Schiff & Patrick, 2017). 
What then happens to the needs of women with OUD who also happen to be 
mothers? In Massachusetts, data shows that rates of opioid-overdoses drop in the final 
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trimester of pregnancy, and spike dramatically by the third month postpartum. These time 
trends mirror the influx and subsequent reduction in programming and funding to support 
this population. While getting a break from mothering can provide a necessary reprieve 
for some women to focus on their early recovery, loss of custody can be a pivotally 
harmful experience that erodes the hope and sense of meaning that many women need to 
maintain their recovery. And furthermore, women who lose custody also lose their 
maternal status, which may have previously granted them priority access to housing and 
treatment programs. Without housing or treatment, these women have a difficult time 
proving their maternal fitness, and ultimately their right to regain custody. For women 
who permanently lose custody, few programs attend to the long-term mental health 
impacts of this determination; nor are links made to permanent loss of custody and 
substance use trajectories, in part because these women are no longer considered mothers.   
Despite a brain disease model of addiction touted as shifting conceptions of OUD 
away from a moral model of addiction, moral notions of addiction remain deeply 
entrenched in cultural perceptions and institutional practices. Macro-level (news media) 
narratives that discursively cast women and mothers in a sympathetic light often do so 
with the caveat that the women earned this positioning by getting on the “straight and 
narrow” via treatment, and in many instances mandated treatment via incarceration or 
family court stipulations. In these stories, women are quoted as being grateful for carceral 
intervention, regardless of how they came to be. An additional theme shared across the 
macro (news media), meso (scientific), and micro (individual) narratives is the impact of 
the recovery movement, and the “voice of recovery” which erases the needs of the 
majority of people with OUD who are active substance users.  
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The largest proportion of meso-level (scientific) narratives identified best 
practices for the management of perinatal and postpartum OUD. As individual-level 
narratives detailed in chapter four, however, one consequence associated with this 
dominant voice of recovery is the erasure of the nearly 80% of people with OUD that do 
not engage with the “gold standard of care” (i.e. MOUD). This results in multiple missed 
opportunities for education around harm reduction with people who are actively using 
substances. Even more importantly, this is a missed opportunity for basic human 
connection within the treatment setting. As Kathleen, recovery coach interviewed for this 
project, told me, “I never met any addict that doesn't want to be free from it… everyone I 
ever talked to wished they never touched it, wished they could be free of it.” Most 
importantly, as Tammy, mother in treatment, stated bluntly in chapter four, “in the end, 
we’re still human beings,” referencing moments when experiencing being treated as the 
opposite. 
One disconnect in the scientific literature is the lack of understanding around 
ways to address barriers to sustained engagement with MOUD for mothers beyond the 
postpartum window. Known and documented barriers to treatment include access to 
childcare, insurance coverage, and stigma/fear of judgement, in addition to intersections 
between mental health and trauma. Despite this knowledge, however, addressing this 
treatment gap remains a notable challenge. Reference to MOUD is nearly absent in 
macro-level (news media) narratives. Given the function of news media in shaping public 
perception, and thus policy priorities, increased inclusion of evidence-based approaches 
to treatment in news media would be beneficial. Micro-level (individual) narratives 
contribute novel understandings as to how women with OUD experience MOUD, 
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reinforcing the import and centrality of the voice of communities directly impacted by 
issues being researched. These findings underscore the need for methodological 
approaches that recognize the inherent value of qualitative methodologies for eliciting 
pivotal findings that can complement population-level data.  
Findings presented in chapter four provided key insights that can inform 
improved and justice-based approaches to treatment. For example, women shared 
strategies they used to find the right MOUD dose, and how they used MOUD to 
transition into treatment. As one example, the practice of ripping buprenorphine strips 
into small pieces to self-administer during the intake process into treatment helps women 
stave withdrawal symptoms so they are able to complete the intake process. As opposed 
to simply classifying such practices as “non-medically supervised” use of MOUD, “folk” 
practices such as this might help guide efforts to enhance treatment entry. Additionally, 
reasons that women want to “get off the clinic” provided essential information on the 
delivery of care. For example, the decision for women to avoid or enter treatment during 
pregnancy can in part be dictated by fears of punitive repercussion, such as loss of 
custody or legal consequences. While this fear can be an important motivator for some 
women to enter treatment, women who do not perceive treatment entry to be a choice 
may be more likely to want to “get off the clinic” as soon after giving birth as possible.  
An important finding is the overall lack of public media attention to the 
association between trauma, mental health co-morbidities, and opioid use trajectories 
among pregnant women and mothers with OUD. The prevalence of substance use and 
mental health comorbidities are consistently evident in the scientific literature. However, 
contextual factors associated with substance use and mental health comorbidities are less 
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understood in that literature. Micro-level narratives identified a “normalizing” effect of 
opioids as experienced by women. For some women, this normalizing effect allowed 
them to feel “in control”, and was cited as a reason why some women felt better when 
using opioids. Furthermore, this narrative of control and sense of normalcy is divergent 
from the social construction of the lethargic opioid user “nodding off” and disassociating 
from the world.  
An additional factor related to mental health and opioid use comorbidities that 
stands out as important to investigate is the potential anti-depressant effect experienced 
by some people enrolled in methadone and buprenorphine treatment. There is scant 
scientific data supporting this association, yet this association provides important insight 
into why people may continue to use opioids despite known detrimental and often lethal 
consequences. In clinical and community-based treatment spaces, women are typically 
told to avoid retelling “war stories” that delve into sensory experiences of active 
substance use. The reason for this informal rule is a worry that such stories may carry the 
potential to trigger relapse. However, in the example of Lorraine from chapter four, 
opioids helped her manage the side effects of mental health medications, such as 
experiences feelings of “burning” and “tingling”; “like you’re on fire.” Without creating 
the space for Lorraine speak to this experience, this important factor may not have come 
to light. These findings reinforce the call for narrative methods as central to a critical 
public health research agenda. 
As stated in Chapter One, according to the Substance Use and Mental Health 
Services Administration (SAMHSA), trauma is an “almost universal experience” (2014, 
p.2) shared by women and mothers with substance use and mental health co-morbidities. 
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In talking with Olivia, director of outpatient opioid treatment programming at a 
community health center, she told me that her organization is investing in trainings for 
staff around “secondary trauma.” When I asked for clarification, she spoke of the 
vicarious trauma experienced by direct care staff (e.g. social workers and recovery 
coaches) whose jobs require that they routinely listen to women relay experiences of 
exposure to multiple traumas across the lifecourse. I can recall the deep anxiety I felt 
after learning of the multiple traumas experienced by each women I interviewed. Some 
days I could literally feel my breath shorten for hours after completing a particularly 
difficult interview. I had plenty of data from the interviews with women around trauma 
exposure, but opted to primarily leave those stories out of this dissertation. In part, this 
was an active choice to avoid the use of what decolonial scholars Tuck and Yang (2014) 
refer to as “pain narratives,” wherein “emerging and established social science 
researchers set out to document the problems faced by communities, and often in doing 
so, recirculate common tropes of dysfunction, abuse, and neglect” (p. 229).   
I consider a focus on trauma and the integration of trauma-informed care to be an 
important evolution in the fields of public health and health care, broadly, and also 
specifically for pregnant women and mothers with OUD. Because my interview approach 
with women was guided by a lifecourse approach, the first question I posed asked them 
each to reflect on their lives in seven-year periods. It was not until reviewing transcripts 
that I noticed a pattern that at first I was not certain how to interpret. Most women began 
their response to this open-ended prompt by say something to the effect of: “I had a good 
childhood. I was loved.” As interviews progressed however, nearly every woman 
revealed histories of multiple traumas. At the end of her interview Nickia, who was living 
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in a residential recovery facility for her alcohol use disorder at the time of our interview, 
told me: “You know what I hate? When [therapists and other providers] say, ‘well did 
something happen in your childhood? Were you like molested or something?’ That's 
what pisses me off. No, I wasn't. Never!” Hearing her say this helped me to understand 
more clearly why women would seemingly contradict their statements about good 
childhoods with evidence of severe traumas. Much like the call to avoid pain narratives, 
being reduced to their categorical exposure to trauma contributes to a sense of erasure for 
women with OUD as possessing qualities beyond their wounds and subsequent substance 
use. This point can help to guide approaches to dignity-based treatment. 
As Chapter Five illustrates, it is crucially important to broaden notions of what 
constitutes trauma, and to integrate an assessment of institutional policies associated with 
the management of perinatal and maternal OUD as a risk factor influencing opioid use 
and treatment engagement. While interviews with women routinely touched on examples 
of institutional violence, this is a topic that was absent in public media and scientific 
discourse, and largely with providers as well. During the 18 months of ethnographic 
observation that took me to multiple meetings, symposia, and conferences convened 
around perinatal and maternal OUD, efforts to promote family cohesion and maternal 
infant bonding were discussed. In that time I only witnessed one person introduce the link 
between loss of custody, mental health outcomes, and relapse. Furthermore, there was an 
absence of discussion on the intergenerational trauma experienced by parents, children, 
and siblings separated from their families, and the implications of that experience on 
mental health and substance use trajectories. Although I did ask providers about the 
practice of “sectioning” (i.e. mandated treatment) during interviews, no one spoke to the 
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harms related to the policies and procedures used. The fears associated with institutional 
violence (e.g. experiences of being sectioned and loss of custody) shed light on barriers to 
care seeking for pregnant women and mothers with OUD. Similarly, micro-narratives of 
what it felt like to be alternatively cared for, or in Tammy’s words, being “looked at like 
you were just a piece of shit,” elicited critical nuance related to women’s experiences 
during clinical encounters that can inform future treatment protocols for this population. 
In closing, a notable and shared silence across all three narrative levels was in 
regard to key at-risk populations excluded by an overarching narrative that depicts the 
opioid “crisis” as predominantly impacting White, rural communities. This focus results 
in a siloed approach to addressing substance use disorders that excludes People of Color, 
polysubstance users, non-opioid users, and people at risk for HIV. As such, increasing 
reports in public media narratives of “opiate fatigue” (i.e. lagging compassion for people 
with OUD experienced by first responders, police, and medical providers) beginning in 
2018 is an important trend to which we should attend. When reflecting on how whiteness 
has been represented historically in drug epidemic literature, reports of opioid fatigue 
align with a fetal victimhood discourse that exclude the needs of women as autonomous 
from childbearing and rearing, and are similar to the pseudo-racialization of 
methamphetamine users. Yet distinct from both the crack and methamphetamine 
epidemics, the broader social response to the opioid “crisis” calls for progressive social 
reform, and for the treatment rather than criminalization of substance users. There is 
increasing public awareness that the opioid “crisis” is now about illicitly obtained and 
derived opioids. As such, the narrative of the faultless “kid next door” who becomes 
addicted as a result of unregulated prescribing practices is becoming less pervasive. 
  237 
Considering the near erasure of People of Color as part of the opioid “crisis” despite 
increasing opioid-related fatalities in Communities of Color, vigilant attention to macro, 
meso, and micro level narratives on OUD will remain integral to ensure a sustained focus 
that promotes treatment over the criminalization of substance use. As history tends to 
repeat itself, however, we should heed the cyclical nature of drug intolerance, during 
which a rise in nationalism is historically linked with trends towards the criminalization 
of substance use (Musto, 1999).  
 
What Next? Recommendations for Research and Practice 
Key recommendations for research and practice presented below are informed by 
the myriad liminal complexities inherent to the experience and treatment of OUD 
identified in this research. For example, complexities such as Nickia’s frustration with 
provider questions around trauma that invalidate her memories of being cared for as a 
child should prompt investigation into the application of trauma-informed practices. 
Additionally, the reality that “sectioning” commonly feels like the only option for parents 
and loved ones calls attention to significant gaps in access to treatment, and the need to 
include families and social networks in treatment engagement efforts, as well as 
providing support to those effected family members. Furthermore, the practice of 
withholding MOUD for people being involuntarily commitment to treatment, but offering 
it to people who voluntarily enter treatment is steeped in moralistic approaches to 
treatment that highlight the need to ensure that institutional practices align with a brain 
disease model of addition. Recognizing that staff working for DCF do make biased 
determinations of custody, but are also most likely to see first-hand cases of parental 
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neglect due to OUD should inform trauma-informed training for such staff that take into 
consideration the impacts of trauma not only on women in treatment, but staff as well. 
Finally, the reality that sometimes “substituting” MOUD for heroin or fentanyl is a 
necessary step for people to achieve treatment stability highlights the importance of 
shared decision making. Importantly, an embodied and critical public health approach to 
perinatal and maternal OUD requires that we explore and discuss the liminal complexities 
such as these that do not present easy or immediate solutions.  
Prioritizing community-partnered efforts to collaboratively develop sustainable 
and effective efforts are paramount to the development of dignity-based approach to 
address perinatal and maternal OUD. Community partnered efforts to inform the 
implementation and de-implementation of programs and policies that address key critical 
turning points across the lifecourse associated with stress, embodied trauma, and harmful 
mental health and substance use trajectories among pregnant women and mothers with 
opioid use disorders are essential. There is no true way forward without the voice of 
people who have direct knowledge, experience, and expertise around what it feels like to 
be a pregnant woman or mother struggling with active substance use, engaging in 
systems of treatment, or working towards or maintaining “recovery.” 
From a larger, policy perspective, research, policy, and practice on perinatal and 
maternal OUD should be informed by:  
1) A lifecourse syndemic approach to treatment and prevention  
a. Extend focus to women and mothers outside the window of the 
perinatal and postpartum periods; 
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2) A holistic and un-siloed approach that is proactive, preventative, and 
considers key at-risk populations, including: 
a. People of Color 
b. Polysubstance and non-opioid users 
c. Active substance users and people at-risk for HIV. 
Five specific recommendations for research and practice are listed by chapter, and 
informed by existing meso-level (scientific) narratives. 
From macro-level (news media) narratives in chapter three: 
1) Increase outreach to news media outlets across political ideology to ensure 
accurate and more comprehensive reporting on opioid use, opioid use disorders, 
risk factors, treatment, and populations of concern.  
From macro-level (individual) narratives in chapter four: 
2) Develop training protocols for practitioners who come into contact with active 
substance users and people in treatment to include: 
a. Principles of cultural humility to promote respect and tolerance 
b. Education for providers on harm reduction for active substance users; and 
3) Investigate “folk” practices and pharmacokinetic knowledge identified and 
utilized by women in this project, including but not limited to: 
a. Practices used to transition into treatment (i.e. “non-medically supervised” 
use of buprenorphine) 
b. Practices associated with identifying appropriate MOUD dosages (i.e. 
“hitting the right dose” and “finagling the dose”) 
c. Knowledge about signs of pregnancy and use of opioids during pregnancy 
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d. Knowledge about interactions between MOUD and mental health 
medications. 
From macro-level (individual) narratives in chapter five: 
4) Assess longitudinal outcomes associated with intergenerational family separation 
via the foster care and criminal justice system 
a. Substance use initiation, treatment, and associated outcomes; and  
5) Extend definition of trauma exposure to include institutional violence, which 
encompasses 
explicit, 
implicit, and 
visceral 
violence 
(Figure 19) 
b. Survey development  
i. Ethnographically developed definition of institutional 
violence 
ii. Pilot and validate 
c. Collect data using developed tool 
d. Advocate for addition of institutional violence to existing 
standardized substance use tools (e.g. National Epidemiologic 
Survey on Alcohol and Related Conditions, National Survey on 
Drug Use and Health, etc.). 
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Spaces of “the Otherwise” 
What was striking to me as I conducted interviews for this dissertation was the 
consistency with which women thanked me for taking to the time to not only ask them 
questions, but to listen to each of their life histories. When I interviewed Jordan in a 
residential recovery facility for women she was the ninth or 10th pregnant woman or 
mother with OUD that I interviewed for this project. As our interview concluded she 
thanked me and said “I think this is great. This is actually the first time I've had 
somebody do something like this for me.” I asked her to elaborate. Jordan explained that 
despite her multiple months in the residential program and countless appointments with 
multiple substance use counselors in a range of settings, she had not been asked to 
elaborate on many of the contextual factors shaping her life, and in turn, her substance 
use and treatment trajectory. I was surprised by this comment, because I was aware of the 
extensive intake processes required for women when they enroll in treatment programs. 
She relayed that in such settings she would typically be asked about age of uptake and 
duration for each substance she had used. Additionally, she would be asked about her 
history in treatment programs. Although she would be asked about trauma history, this 
was typically presented as a rote yes or no question for a checklist. She would be asked 
about current exposure to violence in the home, also posed as a yes or no question. She 
explained that what was different with the questions I asked, was my interest in the 
details that were specifically relevant to her life. She reinforced how valuable it was to 
her not only that I cared to ask, but that I listened closely to her responses and reflected 
back to her about what she shared. 
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 Jordan’s comments about her interview experience reinforced to me the need for 
asset-based methodologies within public health research. The bulk of public health 
methodologies seek to define and identify factors that drive poor health. Importantly, 
many of these data are often leveraged to develop programs and policies to address needs 
and barriers, as is the case with the development of trauma-informed approaches to 
substance use treatment. Yet an unintended consequence of an approach that strictly 
focuses on deficits at both the interpersonal and community level, are that they can 
reinforce stigma— a notable concern when working with marginalized populations such 
as pregnant women and mothers with substance use disorders.  
The field of public health is in need of more justice-based interventions informed 
by critical analysis of the issue at hand. To do so, the prioritization of narrative methods 
as a means to understand and explore relationship between context, phenomena under 
study, and participant interpretations and perceptions is crucial. Without justice-based 
interventions that analyze the role of structures that impede or promote agency, and the 
contingencies impacting each of these, the public health endeavor will continue to fall 
short of its goals. In the context of perinatal and maternal OUD shifting priorities to give 
equal merit to both quantitative and qualitative methodologies is critical in order to 
literally ground the field of substance use research.   
Furthermore, is "knowing more" enough? Now that the social determinants of 
health have become standard nomenclature within the field of public health, how do we 
move forward?  Poverty and racism are known factors that directly and negatively impact 
health (Hofrichter & Bhatia, 2010; Marmot, 2006). Are we as researchers ethically 
obligated to find and enact solutions to address poverty and racism? Is finding more 
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evidence to support these claims enough? An uncomfortable reality is that the industry of 
public health is predicated on the existence of inequality. When committing to a critical 
research paradigm, what is the obligation of the researcher to do something in addition to 
contributing to the knowledge base? While one's intention may be that research findings 
eventually inform the development of dignity and justice-based programs and policies, if 
research findings highlight larger systemic issues that cannot be addressed solely though 
those programs and policies, has the researcher failed in achieving the ethical principles 
of the field? There is never one simple answer to ethical conundrums. Continually 
questioning oneself, colleagues, peers, and the field-at-large is an important commitment 
to make when seeking to respond to some of these questions.  
To conclude, I propose that we reflect on new possibilities via “spaces of the 
otherwise” (Povinelli, 2011) that exist within the context of dignity-based care for 
pregnant women and mothers with OUD. Spaces of the otherwise encompass “obligation 
and care, or endurance or exhaustion, or refusal and persistence” (Povinelli & 
DiFruschia, 2012, p. 89). As a starting point, what might it look like to consider pregnant 
women and mothers with opioid use disorders as more than their categorical definition 
(i.e. master narrative)? As an example and for consideration, I close with what I 
identified as resistance narratives elicited from this research. It is these resistance 
narratives shared by women that are illustrative of the tender negotiations of women who, 
like all mothers, were doing their best. Speaking about leaving her daughter and home 
while she was actively using, Tammy told me, “I'm not gonna see my child when I'm 
sticking a needle in my arm, you know, out there working the streets.” What is important 
in Tammy’s claim is the conscious choice she made in those moments to protect her 
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daughter and leave her in the care of family when she was not able to do so. Similarly, 
Sarah, Nickia, and Marguerite all spoke of the care they did provide for their children. As 
Sarah told me, “I know my daughter was safe, so that's the most important thing. I've 
never hit her… Some addict parents are abusive, but no, not me.” Nickia talked about 
while she spent her days securing alcohol by visiting a succession of multiple liquor 
stores as part of her “routine” and “obsession” that was like a “full-time job,” once her 
kids got home from school, she was “mom of the year…I have a clean house, my kids are 
good, bills are paid, food's on the table every day.” Similarly, in one of the few moments 
during our interview that Marguerite shared reflections on her children, she recalled that, 
“even though we were using, we were still there for them. They weren't misabused or 
anything. [They were] fed, clothed, schooled, homework… [The] house was taken care 
of, all the bills were paid.”  
Given narratives such as these, what then might an ethic of care look like? To 
recognize our shared humanity and multidimensionality can be a place of both ending 
and beginning; a transitional point in envisioning just care. A discussion centered on the 
liminal complexities of treatment and support of pregnant and parenting women with 
OUD is crucial to a broadened understanding of maternal OUD. Deep pondering of the 
quandaries held in these liminal spaces may then allow us to envision spaces of the 
“otherwise” (Povinelli 2011), wherein the potential for intersectional notions of who has 
the right to mother and what constitutes humane approaches to the treatment of maternal 
OUD might simultaneously co-exist.  
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APPENDIX A 
 
INTERVIEW GUIDE, WOMEN 
 
 
Introduction 
 
• Thank you for agreeing to meet with me today. I appreciate your time and 
willingness to participate in this interview.  It will take no more than an hour. 
• First I want to review the informed consent form. (Show form and review) 
• Would it be okay with you if I tape record our session so that I have an accurate 
record of our discussion? 
• I want to remind you that everything you say today is confidential. If at any time 
you want to stop the interview just let me know and we will stop.  
• Do you have any questions for me before we begin?  
 
Interview Questions 
 
1. To begin, I was hoping you could talk about some of the key events or critical turning 
points in each of these chapters.  We’ll go one by one and start with 0-7.  Our main focus 
will be the present day, but we’ll briefly touch on these early chapters that lead up to 
now. 
Probe: in a few words how would you describe yourself in this/each chapter? 
Probe: Can you identify a key positive event for this/each chapter? 
Probe for 7-21: Can you talk a bit about your experience with school? 
 
2. Can you talk about key relationships- family, friends, and romantic partners? 
 
3. Can you tell me about your history with substances- opioids, etc. 
Probe: what is your experience with methadone or suboxone? 
Probe: can you talk about getting into treatment? Forced or by choice? 
 
4. Can you talk about your experience with pregnancy, childbirth, and parenting? 
  Probe: interactions with the health care system, DCF, etc. 
 
5. What does recovery mean to you? 
Probe: Can you talk about your experience of being a mom in recovery?  
Probe: What this is about and what it is like 
 
6. What are the things that help you stay in recovery?  
Probe: What supports do you think people need?  
Probe: Are there any you wished you had but didn’t get? 
 
7. Can you talk about relapsing? 
 Probe: what was happening before that happened? 
 Probe: what led you to stop using or get into treatment 
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8. What do you think causes or contributes to addiction? 
Probe: Why do you think some people become addicted and some don’t? 
Probe: Do you think anyone could have intervened and some point?  
 In what way? 
 
9. People say that one of the things that are important to staying in recovery is a “sense of 
purpose” or “having meaning” in your life.  What do you think about that? What does 
that mean to you? 
 
10. What do you see or envision for your future? 
Probe: what makes you feel uneasy? 
Probe: what gives you hope? 
 
11. Is there anything else you think I should know?  
 Probe: anything you wanted me to ask that I didn’t? 
 
THANK YOU! 
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APPENDIX B 
 
INTERVIEW GUIDE, PROFESSIONAL STAKEHOLDERS 
 
Introduction 
 
• Thank you for agreeing to meet with me today. I appreciate your time and 
willingness to participate in this interview.  It will take no more than an hour. 
• I want to learn from you about addiction and recovery among pregnant/parenting 
women. 
• First I want to review the informed consent form. (Show form and review) 
• Would it be okay with you if I tape record our session so that I have an accurate 
record of our discussion? 
• I want to remind you that everything you say today is confidential. If at any time 
you want to stop the interview just let me know and we will stop.  
• Do you have any questions for me before we begin?  
 
Interview Questions 
 
1. Can you tell me about your role, how long you’ve been here, what this program is  
about 
 Probe: How did you get into this work? How long have you been here?  
 --- What changes have you seen in the field of addiction and treatment? 
 
2. What are your overall observations of pregnant/parenting women with SUD and in 
recovery? 
 Probe: barriers specific to this population? Things this population needs that  
 others don't? 
 
3. Can you tell me about (your observations of) medication-assisted treatment for this 
population? 
 Probe: getting into treatment, methadone versus Subutex, barriers to treatment 
 
 
4. Can you tell me about your observations of relapse among this population? 
Probe: Sign and events that precede? Things that help women transition from 
relapse back to recovery? 
Critical turning points 
Do you see the same people? 
Role of DCF? 
Other sources of stress?- housing? 
 
5. What do pregnant women and mothers need to stay in recovery? 
 Probe: what should people know to support pregnant women and mothers in  
 their recovery? What supports are needed? How should families be supported? 
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6. What do you think causes addiction 
 Probe: what do you think about addiction as a chronic illness, such as diabetes? 
 
7. What does recovery mean to you? 
Probe: what are signs that someone is ready? 
 
8. Addiction researchers say that one of the things that are important to staying in 
recovery is a “sense of purpose” or “having meaning” in one’s life.  What do you think 
about that? What does that mean to you?  
Probe: Have you seen an example(s) of that that you can describe? 
 
9. Is there anything else you think I should know?  
 Probe: anything you wanted me to ask that I didn’t? 
 
THANK YOU! 
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APPENDIX C 
 
SOCIODEMOGRAPHIC SURVEY 
 
ID: _____  
 
PARTICIPANT DETAILS  
 
Below are questions about you. Please circle and/or write in responses 
 
How old are you? _____________ 
 
What is your marital status? 
1. Married 
2. Living with a partner 
3. Widowed 
4. Divorced 
5. Separated 
6. Never married 
 
What is the highest year of education you completed? 
1. 8th grade or less 
2. Some high school, but did not graduate 
3. High school graduate, GED or HiSet, or technical/vocational training that 
doesn’t count towards college degree 
4. Some college/2-year degree 
5. 4-year college graduate 
6. More than 4-year college degree 
7. Other (Specify) ____________________ 
 
Which describes your race/ethnicity? (You can select more than one). 
1. White 
2. Black/African-American 
3. American Indian/Alaska Native 
4. Asian/Asian-American 
5. Hawaiian/Pacific Islander 
6. Latina (Specify ethnicity) _________________________ 
7. Other (Specify race/ethnicity) ______________________ 
 
What is your employment status? 
 
1. Work full time  
2. Work part time 
3. What is your current job? _________________________ 
4. Unemployed 
5. Disabled? 
  250 
Last year, approximately how much was your combined family income? 
1. Less than $10,000 
2. $10,001-$20,000 
3.  $20,001-$30,000 
4.  $30,001-$40,000 
5.  $40,001-$50,000 
6. $50,001-$75,000 
7. $75,000 and greater 
 
What kind of health insurance do you have? 
1.Public insurance (ex. Health NE, BMC, etc.) 
 Company: ___________ 
 2.Private insurance 
Company: ___________ 
    3. No insurance 
 
Describe your housing situation 
1. Own 
2. Rent 
a. Pay monthly 
b. Pay weekly 
 
3. Homeless or couch surfing 
4. Shelter 
5. Other (specify): ______________ 
 
Who lives with you in your current residence? Circle all that apply. 
1. I live on my own 
2. One parent 
3. Two parents 
4. Intimate partner (boyfriend/girlfriend, husband/wife) 
5. Child/ren that live with you (circle gender, fill in age) 
 Child 1: Male   Female  Age:____ 
 Child 2: Male   Female  Age:____ 
 Child 3: Male   Female  Age:____ 
 Child 4: Male   Female  Age:____ 
6. Children that don’t live with you (circle gender, fill in age) 
Child 1: Male   Female  Age:____ 
 Child 2: Male   Female  Age:____ 
 Child 3: Male   Female  Age:____ 
 Child 4: Male   Female  Age:____ 
7. Other (Specify) __________________  
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APPENDIX D 
 
CODES 
Codes for Interview and Field Note Analysis 
 
1. Using Trajectories (Lived experience) 
When women are describing their lived experience of their using trajectories 
1. 0 Formative factors 
  1.0.1. Childhood and adolescence 
  1.0.2. Descriptions of self 
  1.0.3. Mental health issues/diagnoses 
1.1. Initiation to non-opioids 
1.1.0. Context 
1.2. Initiation to, and/or first misuse of, opioids 
1.2.0. Prescription 
1.2.1. Social networks 
1.2.2. Critical turning points 
1.2.3. Confluence of factors 
1.3. Transition to/and chaotic use (“spiraling” “kind of a daze”) 
1.3.0. Context  
1.3.1. Critical turning points 
1.3.2. Confluence of factors 
1.4. Treatment/stopping use 
1.4.0. Context 
1.4.1. Critical turning points 
1.4.2. Confluence of factors 
1.4.3. Leaving treatment  
1.5. Relapse 
1.5.0. Signs of 
1.5.1. Critical turning points 
1.5.2. Confluence of factors 
1.6. Recovery 
1.6.0. Context 
1.6.1. Supports needed  
1.6.2. Reasons for staying in recovery 
1.6.3. Future goals, hopes and dreams 
1.6.4. Stages of (*moved from values and ways- fits better 
here) 
1.6.5. What does recovery mean (women’s answers to 
interview question) 
2. Managing Addiction 
2.0. Staff backgrounds 
2.1. Medical 
 2.1.1. Medication (MOUD) 
 2.1.2. Medical treatment/ settings (NAS, SENS, birth, etc.) 
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 2.1.3. Mental health care and overlaps  
2.2. Social services 
2.3. System overlaps 
2.4. Legal/criminal 
2.5. DCF  
 2.5.1 Policies 
 2.5.2. Staff 
 2.5.3. Foster care (experiences as youth, and foster care parents) 
 2.5.4. Communication 
 2.5.6. Context 
2.6. Custody and maternal status   
2.7. Sectioning and mandated treatment 
2.8. Informal support systems and systems of care  
 
3. Barriers and access to care 
3.1.Fear, silencing, and secrets 
3.2. Active use and abstinence focus 
3.3. Program design  
3.4. Mothering and gendered expectations 
3.5. Access to information 
3.6. Structural vulnerability  
3.7. Program location (i.e. far from home and family) 
3.8. Recovery community (as support and link to relapse) 
3.9. Providers and staff (good and bad) 
 
 
4. Medical Models of Addiction (Scientific literature and staff responses) 
4.1. Brain disease model of addiction (BDMA) 
4.2. Pain 
4.3. Trauma 
 4.3.1. Adverse Childhood Experiences (<18) 
 4.3.2. Adverse Lifetime Experiences (>19)  
4.4. Individual and social factors  
  4.5. What does recovery mean? (Staff responses to this interview question) 
 
5.          Relationships and Social Networks 
5.1. Parents and family  
 5.1.1. Qualities 
 5.1.2 Communication 
5.2. Mothering  
 5.2.1. Qualities 
5.2.2. Communication 
5.2.3. Internalized shame 
5.3. Siblings 
 5.1.1. Qualities 
 5.1.2 Communication 
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5.4. Social networks and recovery community 
 5.1.2 Communication 
5.5. Partners 
 5.1.1. Qualities 
 5.1.2 Communication 
5.6. Co-parenting (if not partnered anymore) 
5.7. Home  
 
6.  Values and Ways/Addiction Discourse (Lived experience of women) 
6.1. Feelings of using 
6.2. Reasons for using 
6.4. Stratified addiction/recovery 
6.5. Resisting dominant narratives 
6.6. Institutional speak 
6.7. Why do people become addicted? (Answer to interview question)  
  
 
Codes for Media Analysis 
 
1. Mediatized Identities 
1.1. Mother as monster (criminal, negligent, sex work) 
1.2. “Good girl gone bad” 
1.3. Redemption and potential 
1.4. Anthropomorphized drug 
1.5. Racialized motherhood 
2. Managing Addiction 
2.1. Social services 
2.2. Treatment facilities 
2.3. Legal/criminal 
2.4. Public/health care 
2.5. Informal systems of resiliency 
3. Critical Turning Points 
3.1. Uptake 
3.2. Treatment/recovery 
3.3. Relapse 
3.4. Maintaining recovery 
4. Origins 
4.1. Medicine 
4.2. “Other” 
5. Effects 
5.1. Family/social networks 
5.2. Internalized shame 
5.3 Economics and society 
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